,descriptor,terms
0,characteristic_level,"< nmbr yr-white-former never diabetes-nmbr yr-nmbr - nmbr mg / dl ""-< nmbr mg / dl-nmbr mg / dl-nmbr - nmbr mg / dl-> nmbr mg / dl-no-< nmbr . nmbr mg / dl-nonwhite-nmbr mg / dl ldl cholesterol | |-nmbr . nmbr mg / dl triglycerides^-yes-no beta - blocker use-current"
2,measures,". event / total . { % )-%-% """
3,characteristic_level,"diabetic patients-non - diabetic patients-non - diabetic patients """
4,outcomes,"tvr-death ""-total-death-death , large mi-large mi"
6,characteristic_name,"smoker ( % )-diabetes ( % )-coronary - artery bypass grafting-percutaneous coronary revascularization-cerebrovascular accident-hypertension ( % )-male sex ( % )-restenotic vessel-bypass graft-l eft anterior descending coronary artery-left circumflex artery ""-myocardial infarction-r ight coronar artery-left circumflex artery-weight ( kg )-age ( yr )"
7,arms,"tirofiban ( n = nmbr )-abciximab ( n = nmbr ) ""-abciximab ( n = nmbr )"
8,characteristic_name,"location treatment center-age-clopidogrel given procedure-diabetes-indication stent-sex-indication stent """
10,characteristic_level,"history high cholesterol ( ) nmbr-monthly-weekly-infarction age nmbr ( )-past-never ""-daily-rarely-never-current"
11,characteristic_name,"use hormone replacement therapy ( )-alcohol intake ( )-age , years-history hypertension ( ) c-history diabetes ( )-exercise least weekly ( )-use hormone replacement therapy ( ) ""-smoking ( )-randomized active yitamin e-body mass index ( kg / mnmbr ) * '-post - menopausal ( )"
12,characteristic_level,"hormonal status-pre - menopausal hormone replacement-therapy ( asa nmbr / placebo nmbr )-all randomized women-post - menopausal without hormone replacement-pre - menopausal without hormone replacement-post - menopausal hormone replacement ""-post - menopausal hormone replacement-therapy ( asa nmbr , nmbr / placebo nmbr )"
13,measures,"number ( % ) reporting migraine nmbr - month questionnaire-number ( % ) reporting migraine nmbr - month questionnaire """
14,characteristic_name,"unstable angina , n ( % )-diabetes , n ( % )-platelet count , x nmbr mmnmbr-systemic arterial hypertension , n ( % )-age , years-previous myocardial infarction , n ( % )-diabetes , n ( % ) ""-smoking habit , n ( % )-previous balloon angioplasty , n ( % )-previous bypass surgery , n ( % )-hypercholesterolemia , n ( % )-women , n ( % )"
16,arms,"simvastatin ( n = nmbr )-simvastatin ( n = nmbr ) ""-placebo ( n = nmbr )"
17,characteristic_level,"aldl cholesterol-alathosterol ( % )-aabnmbr ( % )-a ( nmbr ( % )-anmbrs - hydroxy --acholesterol ( % )-cholesterol ( % )-aldl cholesterol """
18,characteristic_name,"serum ""-csf-serum-> < nmbr . nmbr , < nmbr . nmbr , r < mmse = mini - mental ;"
19,characteristic_level,"mmse nmbr - nmbr-mmse nmbr - nmbr """
20,arms,"simvastatin ""-simvastatin-placebo"
21,other,"( n = nmbr )-( n = nmbr ) """
22,characteristic_name,"lipids , mean ( sd ) , mg / dlt-blood pressure , mean ( sd ) , mm hg-medication use-lipids , mean ( sd ) , mg / dlt "" ; na"
23,characteristic_level,"cabg-ace inhibitor-hypertension-triglycerides-race , % nonwhite-alcohol , % > nmbr drink / d-aspirin-age , mean ( sd ) , y-p - blocker-total cholesterol-waist circumference , mean ( sd ) , in-digoxin-ldl - c-hdl - c-ptca-ptca ""-bmi , mean ( sd )-prior stroke-diastolic-systolic-ptca / cabg-anyantianginal agent-smoking , % current-fpi , mean ( sd ) , pu / mlt-fpg , mean ( sd ) , mg / dlt-prior myocardial infarction-calcium channel blocker-congestive heart failure"
24,characteristic_level,"undiagnosed diabetes ( n = nmbr )-diagnosed diabetes ( n = nmbr )-normal fasting glucose level ( n = nmbr )-impaired fasting glucose level ( n = nmbr )-diagnosed diabetes ( n = nmbr ) ""-p value"
25,characteristic_name,"> nmbr previous venous thromboembolisms ( % )-factor v leiden ( % )-prothrombin mutation ( % )-female sex ( % )-race ethnic group ( % )-duration full - dose warfarin therapy enrollment ( mo )-time cessation full - dose warfarin therapy enrollment ( mo )-body - mass index *-body - mass index * ""-family history venous thromboembolism ( % )-age ( yr )-history diabetes ( % )"
26,characteristic_level,"median-other-non - hispanic white-non - hispanic black-interquartile range-median ""-hispanic"
28,characteristic_name,"time since cessation full - dose warfarin therapy-age-sex-factor v leiden prothrombin mutation-no . previous venous thromboembolic events ""-time since randomization-no . previous venous thromboembolic events"
29,characteristic_level,"< nmbr yr-present-female-male-nmbr - nmbr yr-nmbr-> nmbr yr-> nmbr ""-< nmbr mo-absent-> nmbr mo-> nmbr"
31,measures,". / nmbr person - yr-no . events-no . events """
32,characteristic_name,"race ( % )-race ( % ) "" ; na"
33,arms,"placebo ""-rsg nmbr mg / day-placebo"
34,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
35,outcomes,"fpg ( mg / dl ) ""-hbanmbrc ( % )-fpg ( mg / dl )"
36,measures,"comparison baseline-baseline ( mean , sd )-( mean difference , nmbr % ci )-( mean change , nmbr % ci )-comparison placebo-week nmbr ( mean , sd )-patients ( n )-week nmbr ( mean , sd ) """
37,arms,"placebo ""-rsg nmbr mg / day-placebo"
38,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
39,measures,"comparison baseline-baseline ( mean , sd )-comparison placebo-( mean % difference , nmbr % ci )-week nmbr ( mean , sd )-patients ( n ) ""-patients ( n )-( mean % change , nmbr % ci )"
40,arms,"rsg nmbr mg / day-rsg nmbr mg / day ""-placebo"
41,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
42,measures,"% change , nmbr % ci )-% difference , nmbr % ci )-comparison placebo ( mean-comparison baseline ( mean-patients ( n ) ""-week nmbr ( geometric mean , cv )-patients ( n )-baseline ( geometric mean , cv )"
43,arms,"rsg nmbr mg / day-rsg nmbr mg / day ""-placebo"
44,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
45,measures,"comparison baseline-baseline ( mean , sd )-comparison placebo-( mean % difference , nmbr % ci )-week nmbr ( mean , sd )-patients ( n ) ""-patients ( n )-( mean % change , nmbr % ci )"
46,arms,"rsg nmbr mg / day-rsg nmbr mg / day ""-placebo"
47,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
48,characteristic_level,"thrombolytic therapy-ace inhibitors ""-previous ml-hypertension-cardiac catheterization-marital status , married-chf history-previous cabg surgery-aspirin-cabg surgery-age , mean ( sd ) , y-race , nonwhite-severe dysfunction-education , high school higher-low perceived social support only-hypercholesterolemia-body mass index , mean ( sd ) t-depressed only-peripheral vascular disease-depressed low perceived social support-anterior-lipid - lowering drugs-cerebrovascular disease-renal insufficiency-diabetes-non - q wave-killip class lll - iv-ace inhibitors-mild dysfunction normal-moderate dysfunction-anticoagulants-comorbidity score , mean ( sd ) t-systolic blood pressure , mean ( sd ) , mm hg-indeterminate unknown-sex , female-inferior-smoking history-previous ptca-q wave-ptca < nmbr h-p - blockers"
49,characteristic_name,"current prescribed medications ""-medical characteristics-current prescribed medications-characteristics index ml-treatment index ml-psychosocial risk factors-ejection fraction category"
50,arms,"intervention ( n = nmbr ) ""-intervention ( n = nmbr )-usual care ( n = nmbr )"
51,characteristic_name,". coronary vessels > nmbr % diameter stenosis-entry criteria-no . coronary vessels > nmbr % diameter stenosis "" ; na"
52,characteristic_level,"arterial hypertension-serum cholesterol , median ( iqr ) , mg / dl-st - segment depression-previous balloon angioplasty-women-insulin - dependent-previous myocardial infarction-age , median ( iqr ) , y-active smoker-nmbr-cardiac troponin level > nmbr . nmbr pg / l-none-left ventricular ejection fraction , median ( iqr ) , %-previous cabg surgery-insulin - dependent ""-cardiac troponin level , median ( iqr ) , pg / l-diabetes mellitus"
53,measures,". ( % )-no . ( % ) """
54,arms,"nmbr early intervention ( n = nmbr )-nmbr prolonged antithrombotic pretreatment ( n = nmbr )-nmbr early intervention ( n = nmbr ) """
55,characteristic_name,"diabetesf-other nsaids-abnormal angiogram-myocardial infarction-renal impairmentt-hormone replacement ! !-age , mean ( sd ) , y-aspirin antiplatelet agent-heart failure ( class l - lll )-hypercholesterolemiat-antidiabetic medication | |-arrhythmia-any lipid - lowering agent-peripheral vascular disease-prior ml abnormal angiogram-potassium supplement-pci > nmbr month ago-unstable angina > nmbr mo ago-cabg pci-cabg > nmbr month ago-stroke-bmi , mean ( sd ) , kg / mnmbr ""-race / ethnicity white-bmi , mean ( sd ) , kg / mnmbr-angina pectoris-left ventricular hypertrophy"
56,arms,"non - calcium antagonist strategy ( n = nmbr nmbr )-non - calcium antagonist strategy ( n = nmbr nmbr ) ""-calcium antagonist strategy ( n = nmbr nmbr )"
57,characteristic_name,"age , y-revascularization-us resident-race / ethnicity-diabetes-sex ""-myocardial infarction-sex-hypercholesterolemia-left ventricular hypertrophy-congestive heart failure"
58,characteristic_level,"hispanic-white-other-< nmbr-male-female-no-black-female ""-yes-> nmbr"
60,arms,"placebo ( n = nmbr ) ""-abciximab ( n = nmbr )-placebo ( n = nmbr )"
61,characteristic_level,"< nmbr yr-female-male-no-> nmbr yr-female ""-yes"
62,characteristic_name,"angina class iii iv prior-age-diabetes-sex ""-intervention complex lesions-sex"
63,arms,"abciximab . / total ( % )-placebo . / total ( % )-placebo . / total ( % ) """
64,outcomes,"death ( cause )-nonfatal ml-cardiovascular hospitalization-nonfatal stroke-cardiovascular hospitalization ""-cardiovascular death !-primary outcome !"
65,measures,"strategy-hr-nmbr % cl-strategy """
66,arms,"atenolol n = nmbr-verapamil sr n = nmbr-verapamil sr n = nmbr """
67,measures,". ( % )-rate *-rate * """
68,other,"placebo treatment ""-or placebo treatment"
69,characteristic_level,"ii-iii-iv ""-iv"
71,characteristic_name,"medical history-mean age , yrs-health habits ""-health habits"
72,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-beta - carotene ( n = nmbr , nmbr )"
73,characteristic_level,"nmbr +-total-nmbr - nmbr ""-nmbr - nmbr"
75,characteristic_level,"nmbr +-total-nmbr - nmbr ""-nmbr - nmbr"
77,outcomes,"total cataract extraction-total cataract-total cataract extraction """
78,characteristic_level,"current non - smoker-current smoker-current non - smoker """
80,characteristic_name,"baseline lipid / lipoprotem values ""-baseline lipid / lipoprotem values-pace , . ( nmbr )-sex , . ( % )"
81,characteristic_level,"white-hdl - c , mean ( sd ) , mg / dl-plp - c , mean ( sd ) , mg / dl-apo b , mean ( sd ) , mg / dl-other-non - hdl - c , mean ( sd ) , rng / dl-b lack-ldl - c , mean ( sd ) , mg / dl-tg , median ( sdy rng / cjl-male-female-ldl - cihdl - c , mean ( sd )-crp median ( se ) , rng / l-tchdl - c , mean ( sd ) ""-tc , mean ( sd ) , rrig / dl-hispanic-apo - nmbr , mean ( sd ) , mg / dl-tchdl - c , mean ( sd )"
82,arms,"eze-placebo-pooled simva-pooled eze / simva-pooled eze / simva """
83,measures,"( n = nmbr )-( n = nmbr ) ""-( ri = nmbr )-( n = ms )"
84,arms,"amiodarone ( n = nmbr )-icd therapy ( n =-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
85,characteristic_level,"diabetes-age < nmbr yr-nmbr - nmbr ft-no beta - blocker-qrs > nmbr msec nmbr - min walk test-age > nmbr yr-white race-qrs < nmbr msec-> nmbr ft-beta - blocker-diabetes-male sex-nonwhite race-lvef > nmbr %-< nmbr ft-female sex-no beta - blocker ""-lvef < nmbr %"
86,measures,"icd therapy vs . placebo . hazard ratio ( nmbr . nmbr % cl ) ""-icd therapy vs . placebo . hazard ratio ( nmbr . nmbr % cl )-amiodarone vs . placebo . hazard ratio ( nmbr . nmbr % cl )"
87,arms,"placebo ( n = nmbr , nmbr )-total ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-aspirin ( n = nmbr , nmbr )"
88,characteristic_level,"premenopausal-postmenopausal , hrt-nmbr - nmbr / nmbr - nmbr mm hg-nmbr . nmbr nmbr . nmbr-postmenopausal , current hrt-no-nmbr - nmbr yr-> nmbr yr-< nmbr / < nmbr mm hg-past never-> nmbr / > nmbr mm hg-nmbr - nmbr / nmbr - nmbr mm hg ""-> nmbr . nmbr-yes-uncertain-< nmbr . nmbr-current"
89,characteristic_name,"body - mass indexf-blood pressure-blood pressure ""-age-hypertension !-menopause hrt-smoking status"
90,outcomes,"major cv event ""-ischemic stroke-stroke-myocardial infarction-major cv event-total ."
92,arms,"placebo ( n = nmbr ) ""-clopidogrel ( n = nmbr )-placebo ( n = nmbr )"
93,characteristic_name,"types fibrinolytic agent-age-types fibrinolytic agent ""-predominant type heparin-sex-infarct location"
94,characteristic_level,"overall-< nmbr yr-anterior-low - molecular - weight-fibrin - specific-nonanterior-characteristic-fibrin - specific ""-non - fibrin - specific-male-female-> nmbr yr-none-unfractionated"
96,characteristic_name,"diabetes ( % )-men ( % )-hdl - c ( mmol / l )-bmi ( kg / mnmbr )-ldl - c ( mmol / l )-apo - l ( g / l )-non - hdl - c ( mmol / l )-tg ( mmol / l ) c-hscrp ( mg / l ) c-fibrinogen ( pmol / l ) c-apo b ( g / l )-metabolic syndrome ( % ) b-age ( years )-weight ( kg )-tc ( mmol / l )-hscrp ( mg / l ) c """
97,arms,"feno nmbr mg / eze nmbr mg ( n = nmbr ) ""-feno nmbr mg / eze nmbr mg ( n = nmbr )-placebo ( n = nmbr )-feno nmbr mg ( n = nmbr )-eze nmbr mg ( n = nmbr )"
98,characteristic_level,"tg > nmbr . nmbr-tg > nmbr . nmbr ""-tg < = nmbr . nmbr"
99,arms,"eze-feno-placebo-feno + eze-feno + eze """
100,arms,"ezetimibe nmbr mg ( n = nmbr ) ""-ezetimibe nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
101,characteristic_name,"treatment stratum^ :-age :-diabetes mellitus :-baseline ldl - c :-age : ""-body mass index :"
102,measures,"mean baseline ldl - c ( mmol / l )-mean baseline ldl - c ( mmol / l ) """
104,characteristic_name,"age , y-randomized receive beta carotene-alcohol use , drinks / wk-randomized receive vitamin e-physical activity , kcal / wk-bmi-menopausal status use ht-family history cancerf-smoking status-bmi """
105,characteristic_level,"mean ( sd )-nmbr < nmbr-premenopausal-postmenopausal current ht-past-< nmbr-postmenopausal ht-no-nmbr - nmbr-< nmbr ""-never-yes-> nmbr-uncertain-current"
109,outcomes,"itherchdt ""-itherchdt-noneh-other vasculars-ml c"
110,characteristic_name,"previous disease : ""-diastolic blood pressure ( mm hg ) :-triglycerides ( mmol / l ) :-history diabetes :-treated hypertension :-hdl cholesterol ( mmol / l ) :-total cholesterol ( mmol / l ) :-previous disease :-ldl cholesterol ( mmol / l ) :-sex :-age ( years ) :"
112,characteristic_name,"previous disease : ""-diastolic blood pressure ( mm hg ) :-triglycerides ( mmol / l ) :-history diabetes :-treated hypertension :-hdl cholesterol ( mmol / l ) :-total cholesterol ( mmol / l ) :-previous disease :-ldl cholesterol ( mmol / l ) :-sex :-age ( years ) :"
114,arms,"eze / simva nmbr / nmbr mg ( n = nmbr )-atvnmbr mg ( n = nmbr )-atvnmbr mg ( n = nmbr ) """
115,arms,"glucosamine ( n = nmbr )-celecoxib ( n = nmbr ) ""-celecoxib ( n = nmbr )-placebo ( n = nmbr )-chondroitin sulfate ( n = nmbr )-glucosamine + chondroitin sulfate ( n = nmbr )"
116,characteristic_name,"complex lesions^-left ventricular ejection fraction , mean ( sd ) , %-hours clopidogrel loading , mean ( sd )-age , mean ( sd ) , y-vessel size , mean ( sd ) , mm-elevated troponin ( > nmbr . nmbr pg / l )-women-left circumflex artery-hypercholesterolemia *-calcium antagonists-bare - metal stent-body mass index , mean ( sd ) t-nitrates-lesion length , mean ( sd ) , mm-diameter stenosis , mean ( sd ) , %-statins-left circumflex artery ""-insulin - treated diabetes-ace inhibitors-current smoking *-prior aortocoronary bypass surgery-elevated creatine kinase mb ( > nmbr u / l )-prior myocardial infarction-multivessel disease-arterial hypertension *-diabetes *-p - blockers"
117,characteristic_level,"nmbr ( nmbr . nmbr ) ""-nmbr ( nmbr . nmbr )-nmbr . nmbr ( nmbr . nmbr )"
118,measures,"p value ""-p value"
119,arms,"placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
120,characteristic_name,"clopidogrel pretreatment duration-troponin level-troponin level ""-diabetes"
121,characteristic_level,"< nmbr . nmbr l - g / l-< nmbr h-> nmbr . nmbr - g / l-no-all participants-> nmbr . nmbr - g / l ""-> nmbr h-yes"
122,measures,"primary end point , . events / total . ( % )-primary end point , . events / total . ( % ) """
123,arms,"placebo ""-abciximab-placebo"
124,characteristic_level,"yes ""-male-yes-female"
125,characteristic_name,"hemoglobin ( gm / dl )-serum creatinine ( mg / dl )-weight ( kg ) "" ; na-proteinurianmbr ( g / day )-bmi ( kg / mnmbr )-gender-sbp ( mmhg )-smoking-cholesterol ( mg / dl )-hbanmbrc ( % )-age ( years )-albuminuria ( g / g )-weight ( kg )-dbp ( mmhg )"
126,measures,"mean ( . . )-n-range ""-n ( % )-range-( gm )-w"
128,characteristic_level,"white-black ""-asian-black-hispanic"
130,measures,"n event ( rate )-w event ( rate ) ""-w event ( rate )"
131,characteristic_level,"entire cohort-age-gender-race ""-race-chd status-baseline ldl - c"
132,characteristic_name,"gender , n ( % )-bmi ( kg / mnmbr )-lipid lipoprotein values ( mg / dl )-hs - crp ( mg / l )-age , years , mean ( range )-diagnoses / risk factors , n ( % ) ""-race , n ( % )-diagnoses / risk factors , n ( % )"
133,characteristic_name,"age "" ; na-age-race"
134,characteristic_level,"caucasian-non - caucasian-no chd-< nmbr mg / dl-entire cohort gender-> nmbr years baseline ldl - c-male-chd-female-male ""-> nmbrmg / dl chd status-< nmbr years"
135,arms,"simva-eze / simva ""-eze / simva"
136,arms,"nmbr / nmbr mg-nmbr / nmbr mg ""-nmbr mg"
137,characteristic_name,"entire cohort ""-entire cohort-age-race-chd status"
138,characteristic_level,"male eze / simva-non - caucasian eze / simva-< nmbr mg / dl simva-caucasian eze / simva-simva-female simva-caucasian simva-chd simva-male simva-chd eze / simva-no chd simva-< nmbr years eze / simva-female eze / simva-> nmbr mg / dl eze / simva-< nmbr mg / dl eze / simva-eze / simva gender-> nmbr years eze / simva baseline ldl - c-no chd eze / simva-eze / simva gender ""-< nmbr years simva-> nmbr years simva-non - caucasian simva-> nmbr mg / dl simva"
139,other,"select lipids lipoproteins ""-select lipids lipoproteins"
140,outcomes,"non - hdl - c-tc-hdl - c-tg +-apo - i-apo b-tg + """
141,outcomes,"laboratory ae , n ( % } ""-laboratory ae , n ( % }-clinical ae , n ( % }"
142,outcomes,"drug - related ae *-alt / ast > nmbr times uln consecutive #-deaths-myopathyt-cpk > nmbr times uln ""-discontinuations due ae-cpk > nmbr times uln-any clinical ae-serious ae"
143,characteristic_name,"type vessel involved-additional investigations-blood pressure ( mm hg )-history-randomisation scheme-dose aspirin-demographics-time longest event randomisation-rankin grade-history ""-antithrombotic drug use time event-qualifying event"
144,characteristic_level,"nmbr = restrictions ; help needed-nmbr = symptoms-hypertension-< nmbr week-myocardial infarction-stenosis > nmbr %-aspirin-intermittent claudication-diabetes mellitus-large vessel-nmbr mg-nmbr week nmbr month-systolic ( mean , sd )-age ( years ) ( mean , sd )-minor ischaemic stroke-nmbr = help needed ; still independent-current cigarette smoking ""-nmbr = minor symptoms ; limitations-any relevant infarct-oral anticoagulants-three arm-nmbr - nmbr months-vascular intervention-transient monocular blindness-current cigarette smoking-transient ischaemic attack-none-small vessel-ct mr scan brain *-unspecified-diastolic ( mean , sd )-other-ultrasound carotid arteries-any infarct-stroke-male-hyperlipidaemia-two arm-angina pectoris"
145,arms,"aspirin + dipyridamole ( n = nmbr )-aspirin alone ( n = nmbr )-aspirin alone ( n = nmbr ) """
146,characteristic_name,"systolic blood pressure ( mm hg )-lipid - lowering agents ( % )-age ( years )-diastolic blood pressure ( mm hg ) medications-antiplatelet agents ( % )-diabetes ( % )-pci ( % )-p blockers ( % )-female ( % )-cabg ( % )-diuretics ( % )-previous myocardial infarction ( % )-hypertension ( % )-current smokers ( % )-calcium - channel blockers ( % )-serum cholesterol ( mg / l ) *-previous stroke ortransient ischaemic attack ( % )-peripheral - artery disease ( % )-current smokers ( % ) """
147,other,"peace ( n = nmbr )-hope ( n = nmbr )-hope patients coronary - artery disease ( n = nmbr )-europa ( n = nmbrlnmbr )-peace ( n = nmbr ) """
148,characteristic_level,"revascularisation-all above-revascularisation + antiplatelets + lipid - lowering agents + p blockers-without p blockers-with antiplatelets-with p blockers-without revascularsation-one above-with lipid - lowering agents-two above-without lipid - lowering agents-none above-revascularisation antiplatelets , lipid - lowering agents , p blockers-with revascularisation ""-without antiplatelets"
150,characteristic_name,"ace inhibitors / arb-men-systolic blood pressure ( mm hg )-hdl cholesterol ( mmol / l )-aspirin-women-calcium - channel blockers-body - mass index ( kg / mnmbr )-medications antihypertensive drugs-medications antihypertensive drugs ""-ldl cholesterol ( mmol / l )-current / past smoker-p blockers-demographics age ( years )-lipid concentrations total cholesterol ( mmol / l )-triglyceride ( mmol / l ) t-diuretics-hypertension *-diabetes *-diastolic blood pressure ( mm hg )-lipoprotein ( ) ( mmol / l )"
151,arms,"diet plus pravastatin group ( n = nmbr )-diet plus pravastatin group ( n = nmbr ) ""-diet group ( n = nmbr )"
152,characteristic_name,"body - mass index ""-total cholesterol-body - mass index-smoker-age-ldl cholesterol-diabetes-hypertension-triglycerides-current / past-sex-hdlcholesterol"
153,characteristic_level,"nmbr - nmbr mmol / l-nmbr years-< nmbr kg / mnmbr ""-female-male-no-nmbr kg / mnmbr-yes-< nmbr years-< nmbr - nmbr mmol / l-< nmbr kg / mnmbr"
155,characteristic_name,"race , n ( % ) ""-race , n ( % )-metabolic syndrome characteristics , n ( % )"
156,characteristic_level,"nmbr . nmbr + nmbr . nmbr-nmbr ( nmbr . nmbr )-nmbr ( nmbr . nmbr ) ""-blood pressure ; pbo patients diabe teristics ( ncep atp i-n = nmbr"
157,characteristic_level,"metabolic syndrome * n = nmbr ""-metabolic syndrome * n = nmbr-neither n = nmbr , nmbr"
158,arms,"pbo + statin n = nmbr-eze + statin n = nmbr-eze + statin n = nmbr """
159,measures,"treatment difference-treatment difference "" ; na"
160,measures,"six weeks-% change-baseline-( % , nmbr % cl )-baseline """
161,outcomes,"non - hdl - c ( mmol / l , mean )-hdl - c ( mmol / l , mean )-tg ( mmol / l , median )-ldl - c ( mmol / l , mean )-apo b / apo - l ratio ( mean )-hs - crp ( mg / l , median )-ldl - c ( mmol / l , mean ) ""-key : tc = triglyceride ; hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose ; ncep atp * category include ar > _ nmbr indicated char least - square means , except tc note : treatment subgroup-total c ( mmol / l , mean )"
163,arms,"eze + statin ""-pbo + statin nmbr-ze + statin-eze + statin-pbo + statin"
164,characteristic_level,"statins-, nmbr - blockers-statins "" ; na-aspirin-ace inhibitors"
165,characteristic_name,"arterial hypertension-age , y-body mass index , kg / mnmbr-elevated troponin ( > nmbr . nmbr / xg / l )-prior myocardial infarction-women-interval clopidogrel loading , h-current smoking-elevated creatine kinase - mb ( > nmbr u / l )-diabetes-prior pci-elevated creatine kinase - mb ( > nmbr u / l ) ""-serum creatinine , mg / dl-therapy discharge-prior coronary artery bypass surgery-hypercholesterolemia ( > nmbr mg / dl )"
166,characteristic_level,"age > nmbr ( n = nmbr )-age ' nmbr ( n nmbr ) ""-age ' nmbr ( n nmbr )"
168,outcomes,"major bleeding-target - vessel revascularization-death-major bleeding ""-mace-myocardial infarction-blood transfusion-mild thrombocytopenia ( < nmbrx nmbr / l )-minor bleeding-moderate thrombocytopenia ( < nmbrxnmbr / l )-hemorrhagic stroke-death myocardial infarction-profound thrombocytopenia ( < nmbrxnmbr / l )"
169,characteristic_level,"age > nmbr ( n = nmbr )-age ' nmbr ( n nmbr ) ""-age ' nmbr ( n nmbr )"
171,characteristic_name,"dissatisfied / stopped $ nmbr prior systemic therapy side effects-prior use biologic agents ""-prior use biologic agents-prior use $ nmbr systemic therapies-baseline pasi score-dissatisfied / stopped $ nmbr prior systemic therapies side effects-baseline % bsa involvement"
172,characteristic_level,"$ nmbr-\nmbr %-no ""-$ nmbr %-no-\nmbr-yes"
173,characteristic_name,"disease-established ascvd-age-disease ""-diabetes-low - dose aspirin use baseline-established ascvd > nmbr cv risk factors-sex-etoricoxib dose"
174,characteristic_level,"nmbr-nmbr - nmbr ""-nmbr - nmbr"
176,measures,"n / pyr-rate *-rate * """
177,arms,"metformin ( n = nmbr ) ""-glyburide ( n = nmbr )-rosiglitazone ( n = nmbr )-metformin ( n = nmbr )"
178,characteristic_name,"time symptoms treatment-to randomization ""-to randomization-baseline characteristic-medical treatment"
179,characteristic_level,"median-single - vessel disease , n ( % )-evidence thombus , n ( % )-non - stenotic vessels , n ( % )-systolic blood pressure ( mm hg )-family history , n ( % )-left anterior descending , n ( % )-interval randomization angiography-number vessels disease-age ( year )-infarct related artery location-previous myocardial infarction , n ( % )-previous angioplasty , n ( % )-degree stenosis , % diameter-double - vessel disease , n ( % )-male sex , n ( % )-heart rates ( beats / minutes )-left circumflex , n ( % )-rca , n ( % )-previous angina , n ( % )-hypertension , n ( % )-cholesterol , ( . nmbr . nmbr mmol / l ) , n ( % )-angiographic features-ace - inhibitors , n ( % )-beta - blockers , n ( % )-median ""-current smoking , n ( % )-diabetes , n ( % )-aspirin , n ( % )-calcium antagonists , n ( % )-interval onset symptoms-triple - vessel disease , n ( % )-interquartile range"
181,arms,"diclofenac group ( n = nmbr nmbr )-etoricoxib group ( n = nmbr nmbr )-diclofenac group ( n = nmbr nmbr ) """
182,characteristic_name,"patients complicated events-patients uncomplicated events ""-patients uncomplicated events-patients clinical event"
183,characteristic_level,"ppi use ( p = nmbr - nmbrt ) ""-ppi use ( p = nmbr - nmbrt )-aspirin use ( p = nmbr - nmbrt )"
184,characteristic_level,"""-yes-no"
186,measures,"n / n ( % ) ""-n / n ( % )-rate *"
187,characteristic_name,"medications , n ( % )-health - related quality life-disease characteristics-extent disease , n ( % )-demographics-extent disease , n ( % ) """
188,arms,"infliximab ""-infliximab"
189,arms,"combined ( n = nmbr )-nmbr mg / kg ( n = nmbr ) ""-nmbr mg / kg ( n = nmbr )"
190,characteristic_name,"risk factors ""-risk factors-hmgcoa rl-medication use"
191,characteristic_level,"hypertension serum lipid values-other antihypertensive agents-myocardial infarction-age ( years )-systolic ( mm hg )-total cholesterol ( mmol / l )-hypertension serum lipid values ""-smoking-triglyceride ( mmol / l ) * blood pressure-hypoglycaemic agents-angina-calcium antagonist-simvastatin-diabetes-other statin-antiplatelet agent-nitrate-p blocker-bmi ( kg / mnmbr ) cardiovascular history-cabgorptca-diastolic ( mm hg )-male-ldl - cholesterol ( mmol / l )-hdl - cholesterol ( mmol / l )-pravastatin"
192,arms,"controls ( n = nmbr )-epa treatment ( n = nmbr )-epa treatment ( n = nmbr ) """
193,characteristic_name,"ldl - cholesterol (-triglyceride ( mm-total cholesterol ( mmol / l )-diabetes-smoking-bmi-sex-age ( years )-total cholesterol ( mmol / l ) ""-hdl - cholesterol-previous cad"
194,characteristic_level,"non - smoker-smoker-present-hypertension absent-< nmbr - nmbr-> nmbr - nmbr-< nmbr-male-female-> nmbr ""-absent-> nmbr"
197,arms,"ranolazine ( n = nmbr ) ""-ranolazine ( n = nmbr )-placebo ( n = nmbr )"
198,characteristic_name,"comorbid diseasesa diabetesb-cardiovascular risk factors , . ( % )-race , . ( % ) ""-recurrent infections ( > nmbr per year )-demographic characteristics-race , . ( % )"
199,characteristic_level,"coronary artery disease-hypertension-myocardial infarction-congestive heart failure ( definite )-female , ( % )-urinary tract infection-white-arrhythmia-comorbidities diabetes-hispanic-oral hypoglycaemics only-pneumonia past year-sinusitis-at least two cardiovascular risk factors-chronic pulmonary disease-asian-bronchitis-black-age , mean ( min - max ) ( yrs )-hispanic ""-other-insulin dependentc-native american-duration ra , mean ( min - max ) ( yrs )"
200,arms,"etanercept ( n = nmbr )-etanercept ( n = nmbr ) ""-placebo ( n = nmbr )"
201,characteristic_name,"intestinal area involved , n ( % ) $ ""-concomitant medication , n ( % )-antibodies infliximab , n ( % ) * *-intestinal area involved , n ( % ) $"
202,arms,"adalimumab group ( n = nmbr ) ""-adalimumab group ( n = nmbr ) t-placebo group ( n = nmbr )"
203,other,"atorvastatin factorial study-pooled simvastatin factorial studies-pooled simvastatin factorial studies """
204,arms,"simvastatin monotherapy ( n = nmbr , nmbr * )-ezetimibe + simvastatin ( n = nmbr * )-ezetimibe nmbr mg ( n = nmbr * ) ""-ezetimibe nmbr mg ( n = nmbr * )-placebo ( n = nmbr * )-ezetimibe + simvastatin ( n = nmbr , nmbr * )-atorvastatin monotherapy ( n = nmbr * )"
206,characteristic_name,"major risk factors-blood pressure control ""-previous vascular disease-blood pressure control"
207,characteristic_level,"serum creatinine ( pmol / l ) , mean ( sd )-history currently treated hypertension , n ( % )-history macroalbuminuriat , n ( % )-serum hdl cholesterol ( mmol / l ) , mean ( sd )-current smokers , n ( % )-serum total cholesterol ( mmol / l ) , mean ( sd )-diastolic blood pressure ( mm hg ) , mean ( sd )-urinary albumin : creatinine ratio ( pg / mg ) , median ( iqr )-history microvascular eye disease < u + nmbrc > , n ( % )-history myocardial infarction , n ( % )-history major macrovascular disease , n ( % )-microalbuminuria , n ( % )-body - mass index ( kg / mnmbr ) , mean ( sd )-history stroke , n ( % )-systolic blood pressure ( mm hg ) , mean ( sd )-serum haemoglobin anmbrc concentration ( % ) , mean ( sd )-diastolic blood pressure ( mm hg ) , mean ( sd ) ""-history major microvascular disease , n ( % )"
208,other,"randomised treatment-randomised treatment """
209,arms,"placebo ( n = nmbr ) ""-active ( n = nmbr )-placebo ( n = nmbr )"
210,characteristic_name,"treatment anti - platelet drugs-sbp ( mm hg )-treatment statins-history hypertension *-treatment open - label perindopril ""-treatment bp lowering drugs-history macrovascular disease-hbanmbrc ( % )-sex-age ( years )-treatment open - label perindopril-history microvascular disease"
211,characteristic_level,"^nmbr - nmbr-men-women-> nmbr - nmbr-< nmbr-no-yes ""-yes-> nmbr-combined macro + micro"
212,measures,"relative risk reduction ( nmbr % cl )-number ( % ) patients event ""-number ( % ) patients event"
213,arms,"placebo ( n = nmbr ) ""-pctindopnl - indapamide ( n = nmbr )-placebo ( n = nmbr )"
214,arms,"rosuvastatin ""-rosuvastatin-placebo"
215,measures,"( n = nmbr )-( n = nmbr ) """
216,characteristic_name,"anticoagulants-age-previous myocardial infarction-bmi-previous hypertension-cardiac rhythm-cardiac rhythm ""-systolic blood pressure"
217,characteristic_level,"atrial fibrillation ldl cholesterol level-> nmbr mm hg-< nmbr-> nmbr . nmbr pmol / liter hscrp level-no-> nmbr . nmbr mmol / liter-> nmbr . nmbr mmol / liter ""-< nmbr . nmbr mmol / liter triglyceride level-male nyha class-< nmbr . nmbr bpm-> nmbr yr sex-< nmbr . nmbr mg / liter-iii iv ejection fraction-> nmbr . nmbr mg / liter antiplatelet agents-> nmbr . nmbr mm hg-> nmbr-< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp-< nmbr . nmbr mmol / liter estimated gfr-> nmbr . nmbr hdl cholesterol level-> nmbr ml / min / nmbr . nmbr mnmbr-female-< nmbr . nmbr mm hg diastolic blood pressure-all patients-> nmbr . nmbr bpm current smoker-no diabetes-yes-ii-< nmbr yr-< nmbr mm hg heart rate-sinus rhythm-< nmbr . nmbr mmol / liter apob : apoa - l ratio-> nmbr . nmbr-yes previous revascularization-< nmbr . nmbr-< nmbr . nmbr pmol / liter"
218,arms,"placebo . events / .-rosuvastatin patients ( rate ) ""-rosuvastatin patients ( rate )"
219,characteristic_name,"race ethnicity , n ( % )-race ethnicity , n ( % ) """
220,characteristic_level,"phosphorus , mmol nmbr nmbr-systolic bp , mm hg-white-triglycerides , mmoltnmbr ( gm * )-age , years-egfr , ml min nmbr nmbr . nmbr nmbr-serum creatinine , limo nmbr nmbr-hispanic-female , n ( % )-other ""-uacr , mgg nmbr ( gm )-asian-black-calcium , mmol nmbr nmbr-hemoglobin , g nmbr nmbr-serum albumin , g nmbr nmbr-other-diastolic bp , mm hg-male , n ( % )"
221,characteristic_level,"baseline hb < nmbr g nmbr nmbr n = nmbr ""-baseline hb nmbrg nmbr n = nmbr-combined n = nmbr-baseline hb < nmbr g nmbr nmbr n = nmbr"
222,arms,"losartan n = nmbr-nmbr placebo n = nmbr-placebo n = nmbr-nmbr placebo n = nmbr """
223,outcomes,"esrd ""-esrd-esrd death"
224,characteristic_level,"cox bsl onlyc-cox bsl + yr nmbr hbd ""-cox bsl + yr nmbr hbd"
226,measures,"k ( rate )-n ""-n"
227,characteristic_name,"age-age """
228,characteristic_level,"tg , median ( interquartile range )-mean ( sd ) , y-bmi indicates body mass index ; sbp , systolic blood pressure ; dbp , lipoprotein ( ) . ldl - c calculated friedewald formula . ' hypertension diabetes based physician diagnosis . ! smoker includes current past smokers .-smoker , ! n ( % )-tc , mean ( sd )-< nmbr , n ( % )-hdl - c , mean ( sd )-ldl - c , mean ( sd ) ""-diabetes , * n ( % )-lp ( ) , mean ( sd )-dbp , mean ( sd ) , mm hg-hypertension , * n ( % )-drinking , n ( % ) lipid values , mmol / l-bmi , mean ( sd ) , kg / mnmbr-> nmbr , n ( % )-ldl - c , mean ( sd )-sbp , mean ( sd ) , mm hg"
229,characteristic_level,"men , total ( n = nmbr ) ""-men , total ( n = nmbr )-women"
230,arms,"diet ( n = nmbr )-total ( n = nmbr ) ""-diet - - pravastatin ( n = nmbr )-total ( n = nmbr )"
231,outcomes,"total mortality-chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr )-stroke-total mortality """
232,characteristic_level,"nmbr / nmbr ( nmbr . nmbr )-nmbr / nmbr ( nmbr . nmbr ) """
234,outcomes,"total mortality-chd + cerebral infarction-stroke ""-stroke"
235,characteristic_level,"""-all-> nmbr years-> nmbr years nmbr / nmbr ( nmbr . nmbr )"
236,measures,"incidence rate . ( / nmbrperson - years ) ""-p value f-hazard ratiof ( nmbr % ci )-incidence rate . ( / nmbrperson - years )"
237,arms,"diet-diet ""-diet + pravastatin"
238,characteristic_name,"serum cholesterol , mg / dld-blood pressure , mmhg-sex , . ( % )-laboratory variables-race ethnic group , . ( % ) ""-known duration diabetes , yr-medical history , . ( % )-race ethnic group , . ( % )"
239,characteristic_level,"glomerular filtration rate , nmbr ml / min / nmbr . nmbr mnmbr-urinary albumin / creatinine ratio , median mg / g ( range )-serum triglycerides , mg / dle-hemoglobin , g / dlf-myocardial infarction-lipid disorder-white-total-neuropathy-diastolic-hispanic-systolic-serum creatinine , mg / dlb-retinopathy-amputation-hdl-asian-female-black-serum albumin , g / dl-use antihypertensive drugs-hispanic ""-age , yr-< nmbr yr-coronary revascularization procedure-glycosylated hemoglobin , %-other-current smoking-stroke-male-ldl-> nmbr yr-angina pectoris-not available-body mass indexnmbr"
241,arms,"ii ( n = nmbr )-id ( n = nmbr )-id ( n = nmbr ) ""-dd ( n = nmbr )"
242,outcomes,"death ""-death-esrd-doubling serum creatinine-esrd death"
243,characteristic_level,"dd-ii-id ""-id-composite endpoint doubling serum creatinine , esrd ,"
245,characteristic_name,"time since diagnosis diabetes-time since diagnosis diabetes """
246,characteristic_level,"> nmbr years-bmi ( kg / mnmbr )-calcium supplements-age ( years )-fasting plasma glucose ( mg / dl )-n-fasting plasma glucose ( mg / dl ) ""-thiazide diuretics-glucocorticoids *-anmbrc ( % )-waist circumference ( cm )-systolic blood pressure ( mmhg )-fasting insulin ( pmol / l )-diastolic blood pressure ( mmhg )-< nmbr year-bisphosphonates-waist - - hip ratio-loop diuretics-postmenopausal-estrogen - containing hormones-nmbr - nmbr years"
247,characteristic_level,"women ""-men-women"
248,arms,"metformin-rosiglitazone-glyburide-metformin """
249,outcomes,"tibia fracture-fractures ( site specified )-radius fracture-lower limb fractures-number patients fractures-spinal fractures-skull , facial bone fractures-lower limb fracture-fibula fracture-upper limb fracture-foot fracture-ankle fracture-humerus fracture-hand fracture-wrist fracture-thoracic cage fractures-others ""-others-clavicle fracture-femur fracture-upper limb fractures-patella fracture-hip fracture"
250,arms,"metformin-rosiglitazone-glyburide-metformin """
251,measures,"( n = nmbr ,-( n = nmbr , """
252,measures,"py = nmbr . nmbr )-py = nmbr . nmbr ) """
253,measures,"py *-n ""-%-n"
254,outcomes,"tibia fracture-fractures ( site specified )-radius fracture-lower limb fractures-number patients fractures-forearm fracture-wrist fracture ""-spinal fractures-skull , facial bone fractures-lower limb fracture-fibula fracture-upper limb fracture-foot fracture-ankle fracture-humerus fracture-hand fracture-wrist fracture-thoracic cage fractures-pelvic fractures-others-clavicle fracture-femur fracture-upper limb fractures-patella fracture-hip fracture"
255,arms,"metformin-rosiglitazone-glyburide-metformin """
256,measures,"( n = nmbr ,-( n = nmbr , """
257,measures,"py = nmbr . nmbr )-py = nmbr ) ""-py = nmbr )"
258,measures,"py *-%-n-% """
259,characteristic_name,"severity hypertensionb-age category-diabetic status-prior treatment ""-sex-race-prior treatment"
260,characteristic_level,"diuretic-sitting pulse , bpma-white-p - blocker-diabetic-acei-< nmbr y-> nmbr y-ccb-less severe-female-arb-black-more severe-other-nondiabetic-msdbp , mm hga-diuretic ""-male-age , ya-mssbp , mm hga"
262,characteristic_name,"alcohol consumption ( % )-postmenopausal hormone use-smoking status ( % )-exercise ( % )-exercise ( % ) """
263,characteristic_level,"current ( nmbr + cigs / day )-bmi > nmbr kg / mnmbr ( % )-nmbr - nmbr / month-history hypertension ( % )-past-current ( , nmbr cigs / day )-> nmbr / day-current-nmbr - nmbr / week-mean ( sd ) age ( years )-postmenopausal-> nmbr / week-mean ( sd ) bmi ( kg / mnmbr )-, nmbr / week ""-rarely-, nmbr / week-never-history diabetes ( % )"
265,characteristic_level,"exercise ""-exercise-postmenopausal hormone use-bmi ( kg / mnmbr )-vitamin e-age ( years )-smoking status"
266,characteristic_name,"stratified analyses-stratified analyses """
268,characteristic_level,"prior mi-prior mi-prior mi """
269,measures,"n-death-non - fatal mi ""-non - fatal stroke-non - fatal mi-adverse outcome"
272,characteristic_name,"femoral neck-total body ( without head )-trochanter-one - third radius "" ; na-one - third radius-total hip-lumbar spine"
273,characteristic_level,"< nmbr yr since menopause-overall-> nmbr yr since menopause-> nmbr yr since menopause "" ; na"
274,arms,"denosumab ""-denosumab-placebo"
275,measures,"difference baselinea-difference placeboa-difference baselinea """
276,measures,"( ci ) b-ls mean-( ci ) b ""-p value c"
277,characteristic_name,"aspirin use ( > nmbr mg )-cardiac-diabetes therapy-cholesterol ( mg / dl )-carotid-cardiac "" ; na"
278,characteristic_level,"imt ( mm )-lv mass-insulin plus oral-lv ejection fraction "" ; na-lv ejection fraction-systolic blood pressure ( mm hg )-crp ( mg / dl ) * *-former-age ( years )-never-total-ale-egfr-gender , women n , % )-smoking-lifestyle-hdl-triglycerides ( mg / dl ) * *-plaque score ( nmbr - nmbr )-plaque ( n , % )-yes-oral hypoglycemics-lv mass index ( g / mnmbr - nmbr )-arterial area ( mmnmbr )-body mass index ( bmi ) , kg / mnmbr-ldl-waist ( cm )-non - hdl-insulin-diastolic blood pressure ( mm hg )-current"
280,measures,"group dif . ( nmbr )-group dif . ( nmbr ) ""-lvmi ( nmbr-imt ( nmbr )-aggressive ( nmbr )-p - val . ( nmbr )-standard ( nmbr )"
281,measures,"mean ( sd ) ""-mean ( sd )-n-inter ."
282,characteristic_level,"cerebral hemorrhage-unknown-unknown "" ; na-subarachnoid hemorrhage-cerebral thrombosis-cerebral embolism-tia"
283,characteristic_name,"sbp , mm hg-coronary artery disease-hdl cholesterol , mmol / l-hypertension-epa / aa ratio-aa , mol %-antihypertensive agents-smoker-age , y-dbp , mm hg-diabetes-antiplatelet agents-ldl cholesterol , mmol / l-stroke ""-stroke-male-triglyceride , mmol / l-total cholesterol , mmol / l-bmi , kg / mnmbr-epa , mol %-sbp indicates systolic blood pressure ; dbp , diastolic blood pressure ; aa , arachidonic acid ; epa , eicosapentaenoic acid . values age , bmi , total cholesterol , ldl cholesterol , hdl cholesterol , sbp , dbp , aa , epa , epa / aa ratio represent mean values represent median ( interquartile range ) . p values differences epa epa groups ."
284,characteristic_level,"secondary prevention subgroup-secondary prevention subgroup ""-primary prevention subgroup"
286,characteristic_name,"secondary prevention subgroup-secondary prevention subgroup ""-primary prevention subgroup"
288,characteristic_name,"cardiovascular risk factors-anaesthesia / analgesia ""-surgery-anaesthesia / analgesia-pre - operative cardiac medications *"
289,characteristic_level,"diuretic-general andthoracic epidural-statin-preoperative heart rate ( beats per minute )-coronary artery disease-intraperitoneal-current smoker-age ( years )-aspirin-vascular-preoperative serum creatinine > nmbr pmol / l-general-three seven risk factors-history hypertension-low - molecular weight heparin intravenous unfractionated heparin-lumbar epidural ""-ace inhibitor arb-intrathoracic intraperitoneal surgery-regional anaesthesia-sex ( female )-preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria-general lumbar epidural-hospitalisation chf within nmbr years randomisation-diabetes currently oral hypoglycaemic agent orinsulin-lumbar epidural-age > nmbr years-other-spinal-peripheral arterial disease-any history congestive heart failure-orthopaedic-calcium channel blocker-history transient ischaemic attack-undergoing major vascular surgery-emergent / urgent surgery-stroke thought due atherothrombotic disease"
291,characteristic_name,"< nmbr-aspirin-never-white-overweight ( nmbr < nmbr kg / mnmbr )-obese ( > nmbr kg / mnmbr )-past-lean ( < nmbr kg / mnmbr )-hispanic-diastolic-> nmbr-systolic-statins-female-black-oral contraceptives-other-male-hormone therapy-systolic ""-current"
292,measures,"blood pressure , mean ( sd ) , mm hg-body mass index category , . ( % ) l-age , median ( interquartile range ) , y-smoking status , . ( % )-age group , . ( % ) , y-sex , . ( % )-blood pressure , mean ( sd ) , mm hg ""-diabetes , . ( % )-hctz = hydrochlorothiazide . * based wilcoxon nmbr - sample rank - sum tests age body mass index , tests systolic diastolic blood ' / nmbr tests categorical variables . data missing patients .-race , . ( % )-weight , median ( interquartile range ) , kg-concomitant therapy , . ( % )"
294,characteristic_level,"men-white-women-overweight ( nmbr < nmbr kg / mnmbr )-obese ( > nmbr kg / mnmbr )-obese ( > nmbr kg / mnmbr ) ""-< nmbr-current nonsmokers-black-current smokers-> nmbr-lean ( < nmbr kg / mnmbr )-hispanic"
295,characteristic_name,"body mass index +-age , y-race-body mass index + ""-sex-smoking status"
297,characteristic_level,"men-white-diabetic-women-overweight ( nmbr < nmbr kg / mnmbr )-obese ( > nmbr kg / mnmbr )-nondiabetic-< nmbr-black-current nonsmoker-current smoker ""-current smoker-> nmbr-lean ( < nmbr kg / mnmbr )-hispanic"
298,characteristic_name,"age , y-race-smoking status ""-diabetes status-body mass index *-sex-smoking status"
301,characteristic_name,"treatment antiplatelet drugs-treatment statins-body - mass index-age-glycated hemoglobin-history macrovascular disease-sex-lowering drugs-history microvascular disease-lowering drugs ""-blood glucose-systolic blood pressure"
302,characteristic_level,"overall-< nmbr yr-< nmbr . nmbr mmol / liter-> nmbr mm hg-< nmbr-male-female-no-yes ""-< nmbr mm hg-> nmbr yr-> nmbr . nmbr mmol / liter-< nmbr . nmbr %-yes-> nmbr-> nmbr . nmbr %"
304,characteristic_name,"> nmbr years-diabetes mellitus-white-mean age , years ( sd )-serum creatinine , mean ( sd ) , pmol / l-mssbp , mmhg ( sd )-pacific islander ""-< nmbr years-mean bmi , kg / mnmbr ( sd )-female-asian-black-no . patients-msdbp , mmhg ( sd )-mean weight , kg ( sd )-pacific islander-other-male-native american"
305,arms,"valsartan , n ( % ) ""-v alsartan / hctz , n ( % )-valsartan , n ( % )"
306,characteristic_name,"severity-age-age ""-race"
307,characteristic_name,"blood pressure-race / ethnicity , . ( % )-medications , . ( % )-medical history , . ( % ) ""-medical history , . ( % )-demographic"
308,arms,"atenolol strategy ( n = nmbr , nmbr )-verapamil sr strategy ( n = nmbr , nmbr )-verapamil sr strategy ( n = nmbr , nmbr ) """
309,outcomes,"- cause mortality "" ; na-nonfatal ml-nonfatal stroke-all - cause mortality-primary outcome"
310,characteristic_level,"nmbr-nmbr """
311,arms,"verapamil sr-verapamil sr ""-atenolol *"
312,measures,"hazard ratio ( nmbr % confidence interval ) *-p-incidence * ""-incidence *"
313,arms,"rerapamil - sr strategy ( n = nmbr )-p-v total ( n = nmbr )-atenolol strategy ( n = nmbr )-v total ( n = nmbr ) """
314,outcomes,"death-nonfatal stroke-fatal nonfatal stroke-primary outcome-nonfatal stroke ""-fatal nonfatal ml-cv death-nontatal ml"
316,characteristic_name,"exercise category ( % )-region ( % )-tobacco use ( % )-toast classification qualifying stroke ( % )-baseline nihss score ( % ) #-alcohol use ( % )-ethnic group ( % )-score modified rankin scale ( ' % / ' ""-score modified rankin scale ( ' % / '-time qualifying stroke randomization"
317,arms,"clopidogrel ( n = nmbr , nmbr ) ""-aspirin - erdp ( n = nmbr , nmbr )-clopidogrel ( n = nmbr , nmbr )"
318,characteristic_name,"time onset qualifying stroke randomization-obesity-age-ace - inhibitor use-alcohol use-statin use-prespecified analysis-ethnic group-medical history-medical history hypertension-baseline systolic blood pressure-sex-toast classification qualifying stroke-obesity ""-stroke risk score-randomization placebo telmisartan-diabetes mellitus"
319,characteristic_level,"white / european-> nmbr mm hg-nmbr - nmbr drinks / wk-native latin-no-previous stroke tia-undetermined , , cardioembolism-slo days-placebo-no ""-any recurrent stroke-> nmbr days-< nmbr mm hg-> nmbr - nmbr ( moderate risk )-african-> nmbr ( high risk )-> nmbr < nmbr yr-large - artery atherosclerosis-nmbr - nmbr ( low risk )-telmisartan-south asian-female-neither-nmbr drinks / wk-chinese-yes-> nmbr drinks / wk-< nmbr yr-other asian-> nmbr < nmbr mm hg-male-small - artery occlusion-other atherosclerotic event-> nmbr yr"
321,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-telmisartan ( n = nmbr , nmbr )"
322,characteristic_name,"heart disease risk factors-physical examinations-heart failure cause-nyha class-patients ' characteristics-medical history-medical treatment-heart disease risk factors ""-ecg findings"
323,characteristic_level,"cabg-admission hf previous year-bmi ( kg / mnmbr )-current smoking ""-ace inhibitors / arbs-third heart sound-atrial fibrillation-age ( years )-ischaemic-aspirin-other antiplatelet agents-oral anticoagulant drugs-hypertensive-women-heart rate ( beats per min )-calcium - channel blockers-non - detectable / unknown-digitalis-spironolactone-iv-history hypertension-qrs > nmbr ms *-aortic stenosis-pulmonary rales-p blockers-peripheral vascular disease-nitrates-sbp ( mm hg )-previous ami-pacemaker-neoplasia-icd-diabetes-lvef > nmbr %-arbs-ace inhibitors-amiodarone-dbp ( mm hg )-ii-iii-pci-history atrial fibrillation-dilatative-age > nmbr years-mitral insufficiency-lvef ( % )-current smoking-diuretic drugs-other cause-copd-pathological q waves-left ventricular hypertrophy-previous stroke"
324,arms,"placebo ( n = nmbr ) ""-rosuvastatin ( n = nmbr )-placebo ( n = nmbr )"
325,characteristic_level,"total cholesterol > nmbr ' nmbr mmol / lt-nyha iii iv-total cholesterol < nmbr nmbr mmol / lt-nyha ii-ischaemic cause-diabetes-age < nmbr years ( median )-lvef > nmbr %-total cholesterol < nmbr nmbr mmol / lt ""-no diabetes-non - ischaemic cause-age > nmbr years ( median )-lvef < nmbr %"
327,characteristic_name,"heart disease risk factors-nyha class-physical examination-patients ' characteristics-medical history-medical treatment-patients ' characteristics ""-ecg findings-cause heart failure"
328,characteristic_level,"cabg-admission hf previous year-ace inhibitors / arbs-third heart sound-atrial fibrillation-statin ( open )-age ( years )-ischaemic-aspirin-other antiplatelet agents-diabetes mellitus-oral anticoagulant drugs-hypertensive-women-heart rate ( beats per min )-calcium - channel blockers-non - detectable / unknown-digitalis-spironolactone-iv-history hypertension-qrs > nmbr ms *-aortic stenosis-bmi ( kg / rrr )-women ""-pulmonary rales-p blockers-peripheral vascular disease-nitrates-sbp ( mm hg )-previous ami-pacemaker-neoplasia-icd-lvef > nmbr %-arbs-ace inhibitors-amiodarone-left ventricular hypertrophy-dilatative-ii-iii-pci-history atrial fibrillation-mitral insufficiency-age > nmbr years-other-lvef ( % )-current smoking-diuretic drugs-copd-pathological q waves-dbp ( mmhg )-previous stroke"
329,arms,"placebo ( n = nmbrl )-n - nmbr pufa ( n = nmbr )-placebo ( n = nmbrl ) """
330,characteristic_level,"total cholesterol < nmbr - nmbr mmol / lt-total cholesterol > nmbr - nmbr mmol / lt-nyhaiiioriv-ischaemic cause-nyhaii-diabetes-age < nmbr years ( median )-lvef > nmbr %-total cholesterol < nmbr - nmbr mmol / lt ""-no diabetes-non - ischaemic cause-age > nmbr years ( median )-lvef < nmbr %"
332,characteristic_level,"< nmbr-prior lower gi clinical event-cox - nmbr selective nsaid use-> nmbr < nmbr-> nmbr < nmbr ""-prior upper gi clinical event-> nmbr-systemic corticosteroid use-established atherosclerotic cardiovascular disease"
333,characteristic_name,"mean ( sd )-methotrexate use-smoker-women-low - dose aspirin use-other dmard use-mean ( sd ) ""-diabetes-traditional nsaid use-osteoarthritis-rheumatoid arthritis-proton pump inhibitor use"
334,arms,"diclofenac ( n = nmbr , nmbr )-etoricoxib ( n = nmbr , nmbr )-diclofenac ( n = nmbr , nmbr ) """
335,characteristic_level,"femaleb-corticosteroid-< nmbr-no prior ugi event-ascvd-no aspirin-aspirin-rheumatoid arthritis-no prior lgi event-> nmbr-cigarette smoker-nonsmoker-cigarette smoker ""-> nmbr - nmbr-prior ugi event-no corticosteroid-osteoarthritis-no ascvd-male-prior lgi event"
336,measures,"rates per nmbr patient - years ""-hazard ratio ( nmbr % ci )-rates per nmbr patient - years"
337,arms,"etoricoxib-diclofenac ""-diclofenac"
338,characteristic_name,"age category ( % )-bmi category ( % ) ""-bmi category ( % )-ethnicity ( % )"
339,characteristic_level,"postmenopausal ( % )-> nmbr years-history hypertension ( % )-nmbr . nmbr - nmbr . nmbr kg / mnmbr-hdl cholesterol ( mmol / l )-exercise > weekly-american indian alaskan native-hscrp ( mg / l )-african american-> nmbr . nmbr kg / mnmbr-total cholesterol - - hdl cholesterol ratio-total cholesterol ( mmol / l )-> nmbr . nmbr kg / mnmbr ""-baseline use hormone therapy ( % )-hispanic-ldl cholesterol ( mmol / l )-anmbrc ( % )-alcohol consumption > weekly-white hispanic origin-< nmbr . nmbr kg / mnmbr-current smoker ( % )-non - hdl cholesterol ( mmol / l )-total population n-family history diabetes ( % ) *-asian pacific islander-history hyperlipidemia ( % )-unknown ( none )-nmbr - nmbr years-available baseline blood specimen n"
340,arms,"placebo ""-aspirin-placebo"
341,characteristic_name,"hyperlipidemia-hdl choleslerol-anmbrc-hyperlension-tolal choleslerol-hscrp-age-family history ol diabetes ?-ldl choleslerol-exercise > weekly ?-bmi-tolal choleslerol - lo - hdl choleslerol ralio-non - hdl choleslerol-menopause ht-ldl choleslerol """
342,characteristic_level,"> nmbr years-> nmbr . nmbr mmol / l-no-nmbr . nmbr - nmbr . nmbr mmol / l ""-< nmbr . nmbrmg / l-nmbr . nmbr - nmbr . nmbr mg / l-nmbr . nmbr - nmbr . nmbr-nmbr - nmbr . nmbr kg / mnmbr-< nmbr . nmbr kg / mnmbr-poslmenopausal , ht-yes-poslmenopausal , ht-> nmbr . nmbr %-premenopausal-nmbr . nmbr - nmbr . nmbr mmol / l-> nmbr kg / mnmbr-uncerlain-< nmbr . nmbr mmol / l-> nmbr . nmbr mg / l-nmbr - nmbr years-< nmbr . nmbr %-> nmbr . nmbr-< nmbr . nmbr"
344,measures,"evenls per nmbr , nmbr palienl - years-evenls per nmbr , nmbr palienl - years ""-no . evenls"
345,arms,"tiotropium ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
346,characteristic_name,"reversibility *-race-region-reversibility * ""-gender-bmi-age ( years )-smoking status-gold stage"
347,characteristic_level,"< nmbr-no-laba-i / ii-former-full cohort-laba + ics-white-iv-> nmbr-usa-> nmbr , < nmbr-asia-female-asian-yes ""-black-yes-iii-ics-latin america-w . europe-male-e . europe-anticholinergic-current"
348,arms,"irbesartan ( n = nmbr )-irbesartan ( n = nmbr ) ""-placebo ( n = nmbr )"
349,characteristic_name,"use beta - blocker-geographic region-age-ejection fraction-diabetes-hospitalization heart failure within nmbr mo-sex-ejection fraction ""-use ace inhibitor"
350,characteristic_level,"< nmbr yr-> nmbr %-> nmbr % ""-other-north america-europe-female-male-nmbr - nmbr yr-no-> nmbr yr-< nmbr %-all patients-yes"
352,characteristic_name,"visit nmbr ldl cholesterol strata-mean body mass index ( kg / mnmbr ) *-race ""-race-ncep atp iii risk factors"
353,arms,"atorvastatin nmbr mg ( n = nmbr ) ""-atorvastatin nmbr mg ( n = nmbr )-atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr )"
354,characteristic_name,"duration type nmbr diabetes mellitus ( years ) ""-naive antihyperglycemic agent therapy-duration type nmbr diabetes mellitus ( years )-hbanmbrc ( % )-nationality"
355,characteristic_level,"chinese ""-indian-weight ( range ) ( kg )-korean-sex , female-fpg ( range ) ( mmol / l )-all randomized patients ( range )-body mass index ( range ) ( kg / mnmbr )-all randomized patients-age ( range ) ( years )-chinese"
356,measures,"number patients ( % ) mean < u + nmbreb > sd ""-number patients ( % ) mean < u + nmbreb > sd"
357,arms,"sitagliptin ( n = nmbr ) ""-sitagliptin ( n = nmbr )-placebo ( n = nmbr )"
359,arms,"nmbr-nmbr """
360,measures,"ls - mean change baseline ( nmbr % ci )-ls - mean change baseline ( nmbr % ci ) ""-ls - mean - group difference ( nmbr % ci )-week nmbr mean < u + nmbreb > sd-baseline mean < u + nmbreb > sd"
361,characteristic_name,"body mass index , kg / mnmbr-pacific islander-race , n ( % ) ""-diabetes duration ( years )-glyburide dose duringthe study ( mg )-alaska native-baseline hbanmbrc , n ( % )-sex , n ( % )-age group , n ( % )-age ( years )-race , n ( % )"
362,characteristic_level,"mean ( . . )-native hawaiian / other-white-> nmbr years-median-other-patients < nmbr %-female-male-asian-range-patients > nmbr %-native hawaiian / ""-american indian /-black / african american-median ( range )-< nmbr years"
363,other,"glyburide-glyburide """
364,arms,"alogliptin nmbr . nmbr mg ( n nmbr nmbr ) ""-with placebo ( n nmbr nmbr )-with alogliptin nmbr . nmbr mg ( n nmbr nmbr )-with alogliptin nmbr mg ( n nmbr nmbr )"
366,measures,"baseline mssbp / msdbp , mm hg-msdbp-mssbp-change bp , mm hg-change bp , mm hg """
367,arms,"hydrochlorothiazide-aliskiren-aliskiren """
368,characteristic_level,"> nmbr ( n = nmbr )-< nmbr ( n = nmbr )-> nmbr ( n = nmbr ) """
369,arms,"placebo + statin ( n = nmbr , nmbr )-ezetimibe nmbr mg + statin ( n = nmbr , nmbr ) ""-ezetimibe nmbr mg + statin ( n = nmbr , nmbr )"
370,characteristic_name,"populations :-race / ethnicity n ( % )-severity n ( % ) ""-severity n ( % )-mean blood pressure , mmhg ( . . j-sex , n ( % )"
371,arms,"amlodipine / vaisartan ( n = nmbr )-amlodipine ( n = nmbr ) ""-amlodipine ( n = nmbr )"
372,characteristic_name,"previous tnf antagonist exposure , n ( % )-nmbr - mercaptopurine-mean ( sd )-methotrexate-baseline cdai score , mean ( sd ) ""-male , ( % )-baseline cdai score , mean ( sd )-current smoker , ( % )-any glucocorticoid *-prednisone-budesonide-nmbr - aminosalicylates {-median ( range )-any immunosuppressive agent-age years , mean ( sd )-azathioprine-crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l ) , n ( % )"
373,other,"patients fistulas baseline-patients fistulas baseline """
374,arms,"adalimumab ( n = nmbr )-adalimumab ( n = nmbr ) ""-all patients fistulas ( n = nmbr )-placebo ( n = nmbr )"
375,characteristic_name,"arterial blood pressure , mm hg-patient characteristics ""-infarct characteristics-patient characteristics"
376,characteristic_level,"killip class , n ( % ) i-body mass index , kg / mnmbr-heart rate , bpm-diabetes mellitus , n ( % ) ""-diabetes mellitus , n ( % )-history cabg surgery , n ( % )-iv-peak creatine kinase - mb , u / l-arterial hypertension , n ( % )-history mi , n ( % )-diastolic-systolic-age , y-anterior-insulin - requiring-ii-iii-lateral-infarct localization , n ( % )-current smoker , n ( % )-inferior-hypercholesterolemia , n ( % )-women , n ( % )"
378,characteristic_name,"interval study drug pci-age-infarct localization-diabetes-history mi-interval clopidogrel pci ""-interval pain onset admission-sex-interval clopidogrel pci"
379,characteristic_level,"> nmbr min ""-> nmbr . nmbr yrs-all-non - anterior-male-no-> nmbr min"
381,arms,"placebo ""-placebo"
382,characteristic_level,"diabetes mellitus-diabetes mellitus ""-diabetes mellitus"
384,arms,"placebo ( n = nmbr ) ""-valsartan ( n = nmbr )-placebo ( n = nmbr )"
385,characteristic_name,"af alone-use beta - blockers-age-use beta - blockers ""-use antiarrhythmic agent-hf , lvd , both-use ace inhibitor"
386,characteristic_level,"< nmbr yr-other-no ""-no-> nmbr yr-none-all patients-amiodarone-yes"
388,characteristic_name,"ccsc nmbr month enrollment-risk factors atherosclerosis-ccsc nmbr month enrollment ""-cardiac history-cardiac medications index hospital stay / discharge"
389,characteristic_level,"nmbr / nmbr , nmbr ( nmbr . nmbr ) ""-nmbr , nmbr / nmbr , nmbr ( nmbr . nmbr )-nmbr / nmbr ( nmbr . nmbr )-nmbr ( nmbr , nmbr )-nmbr / nmbr , nmbr ( nmbr . nmbr )"
390,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) """
391,characteristic_name,"smoking status "" ; na-sex-smoking status"
392,characteristic_level,"reversibility %-baseline fevnmbr #-female-male-patients n-former-patients n ""-age yrs-total pack - yrs-current"
394,characteristic_name,"blood pressure-lipid profile-fatty acid profile-clinical history-lipid profile ""-glucose metabolism"
395,characteristic_level,"diastolic ( mmhg )-coronary artery disease ( % )-smoker ( % )-ldl - cholesterol ( mg / dl )-hdl - cholesterol ( mg / dl )-hypertension ( % )-hdl - cholesterol ( mg / dl ) ""-total cholesterol ( mg / dl )-triglyceride ( median ; mg / dl ) - nmbr [nmbr - nmbr percentile |-systolic ( mmhg )-drinker ( % )-male ( % )-hba , c ( % )-bmi > nmbr ( % )-epa ( mol % )-fpg ( mg / dl )-average age ( year )"
396,characteristic_level,"lgm ( n = nmbr ) ""-ng ( n = nmbr , nmbr )-lgm ( n = nmbr )"
397,arms,"non - epa ( n = nmbr )-epa ( n = nmbr )-epa ( n = nmbr ) """
398,outcomes,"blood pressure-lipid profile-blood pressure ""-fatty acid profile-glucose metabolism"
400,characteristic_level,"igm ( n = nmbr )-ng ( n = nmbr , nmbr )-igm ( n = nmbr ) """
401,arms,"non - epa ( n = nmbr )-epa ( n = nmbr )-epa ( n = nmbr ) """
402,characteristic_level,"igm ""-igm-ng"
404,characteristic_name,"chadsnmbr score *-chadsnmbr score * ""-atrial fibrillation pattern-race / ethnicity-characteristics-atrial fibrillation onset"
405,characteristic_level,"unknown-persistent-previous transient ischaemic attack / ischaemic stroke previous warfarin use-no estimate-left ventricular ejection-nmbr-age ( years )-paroxysmal-age nmbr years more-white-nmbr year more-less nmbr year ""-history hypertension-less nmbr year-hawaiian / pacific islander-fraction ( % )-black / african - american-asian-diabetes-hispanic / latin american-permanent-other-male-congestive heart failure"
406,arms,"intervention group ( n = nmbr )-control group ( n = nmbr )-control group ( n = nmbr ) """
407,characteristic_name,"bmi ( kg / mnmbr )-past smoker , n ( % )-macroalbuminuria , n ( % )-age ( years )-history major cardiovascular disease , n ( % )-serum creatinine , ^mol / l-estimated gfr , ml min - nmbr nmbr . nmbr - nmbr ( sd ) a-systolic bp , mmhg ( sd )-history hypertension , n ( % )-diastolic bp , mmhg ( sd )-major diabetic eye disease , n ( % )-serum creatinine , ^mol / l ""-estimated gfr , < nmbr ml min - nmbr nmbr . nmbr - nmbr , n ( % ) a-female , n ( % )-serum total cholesterol , mmol / l ( sd )-duration diabetes ( years )-uacr , mg / mmol ( interquartile range ) b-history major microvascular disease , n ( % )-current alcohol use , n ( % )-age completion highest education , years ( sd )-hbanmbrc , % ( sd )-current smoker , n ( % )-myocardial infarction , n ( % )-stroke , n ( % )"
409,characteristic_level,"< nmbr ( n = nmbr )-nmbr - nmbr ( n = nmbr , nmbr )-< nmbr ( n = nmbr ) """
410,outcomes,"- cause death-cardiovascular death-cardiovascular death ""-major cardiovascular events"
412,arms,"placebo ""-placebo-perindopril"
413,characteristic_name,"fevnmbr ( l ) ""-fevnmbr ( l )-fevnmbr ( % predicted )-smoking status"
414,characteristic_level,"prebronchodilator-prebronchodilator ""-sgrq total score * ( units )-male-body - mass index ( kg / mnmbr )-smoking history ( pack - years )-current smoker-age ( years )-postbronchodilator-duration copd ( years )"
415,characteristic_level,"gold stage ii-gold stage iii-gold stage iv-gold stage ii """
416,arms,"control ( n = nmbr )-tiotropium ( n = nmbr )-control ( n = nmbr ) """
417,outcomes,"one copd exacerbations ( n / n [ % ] )-median time first exacerbation ( months [nmbr % ci] )-mean number exacerbations ( per patient - year [nmbr % ci] ) ""-mean number exacerbations ( per patient - year [nmbr % ci] )"
418,characteristic_level,"gold stage ii-gold stage iii ""-gold stage iii-gold stage iv"
419,characteristic_name,"lipid profile-physical examinations-heart failure cause-laboratory examination-medical treatment "" ; na-medical history-medical treatment-ecg findings"
420,arms,"placebo ( n = nmbr ) ""-rosuvastatin ( n = nmbr )-placebo ( n = nmbr )"
422,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-fluvastatin ( n = nmbr )"
423,characteristic_name,"baseline high - sensitivity crp-cardiac risk-temporary discontinuation study drug-baseline ldl cholesterol ""-baseline ldl cholesterol-baseline total cholesterol-type surgery"
424,characteristic_level,"open-< nmbr yr-high-endovascular-> nmbr . nmbr mg / liter-< nmbr . nmbr mmol / liter ""-< nmbr . nmbr mmol / liter-all-yes-no-< nmbr . nmbr mg / liter-> nmbr yr-> nmbr . nmbr mmol / liter-intermediate-low"
426,measures,". events / . patients-no . events / . patients """
427,arms,"amlodipine / valsartan nmbr / nmbr mg / v = nmbr-amlodipine nmbrmg / v = nmbr-amlodipine nmbrmg / v = nmbr """
428,characteristic_level,"age < nmbr years ""-age < nmbr years-age > = nmbr years"
429,characteristic_name,"prior ms treatment ifn - beta or-tnmbr lesion volume , mmnmbr-edss stratification , . ( % )-brain volume , cmnmbr-total gadolinium - enhancing lesion count , . ( % ) ""-ethnicity , . ( % )-disease duration , mean yr ( sd )-total gadolinium - enhancing lesion count , . ( % )-edss score-gender , . ( % )"
430,characteristic_level,"= nmbr-minimum - maximum-white-mean ( sd )-median-ended > nmbr days trial entry-other-since diagnosis-age , mean yr ( sd )-since onset-female-male-no prior ms therapies-msfc timed nmbr - foot walk test , median seconds-= nmbr ""-> nmbr . nmbr-> nmbr-median ( min , max )"
431,arms,"total , n = nmbr-rituximab , n = nmbr-placebo , n = nmbr-total , n = nmbr """
432,characteristic_name,"location infarction "" ; na-location infarction-cigarette smoker"
434,characteristic_name,"geographic location-sites-enrollment lmwh-previous ml ""-baseline killip class-previous ml-time symptom onset randomization ( hrs )-gender-age ( yrs )-high risk-history diabetes mellitus-time qualifying ecg balloon inflation ( hrs )-time symptom onset balloon inflation ( hrs )-infarct location-pci delay due low risk"
435,characteristic_level,"= nmbr-no / unknown-no / unknown ""-anterior-hub-not anterior-north america-tertile nmbr index pci performed-< nmbr-rest world-male-female-no-all subjects-tertile nmbr-yes-> nmbr-spoke"
436,measures,"% nmbr ""-n .-i % nmbr-n"
437,characteristic_name,"geographic location-sites-enrollment lmwh-previous ml ""-previous ml-time symptom onset randomization ( hrs )-gender-age ( yrs )-high risk-history diabetes mellitus-time qualifying ecg balloon inflation ( hrs )-time symptom onset balloon inflation ( hrs )-index pci performed-infarct location-pci delay due low risk"
438,characteristic_level,"= nmbr-no / unknown-no / unknown ""-anterior-hub-not anterior-north america-< nmbr-rest world-male-female-no-all subjects-tertile nmbr-> nmbr-yes-< nmbr baseline killip class-spoke"
439,measures,"ni-nmbr % nmbr ""-nmbr % nmbr-n_"
440,characteristic_name,"smoking status *-time treatment ( min ) t-smoking status * """
441,characteristic_level,"men-never smoked ""-ex - smoker-atrial flutter / fibrillation-diabetes-systolic blood pressure ( mm hg )-baseline nihss-median ( iqr )-history stroke-hypertension-age ( years )-never smoked-current smoker-nmbr - nmbr-previous use antiplatelet drugs-weight ( kg )-time treatment initiation ( min ;-diastolic blood pressure ( mm hg )"
442,arms,"placebo ( n = nmbr ) ""-alteplase ( n = nmbr )-placebo ( n = nmbr )"
443,characteristic_name,"previous chronic use antiplatelet drugs-nihss baseline-time treatment initiation ( min )-hypertension-previous diabetes ""-history stroke-arial flutter fibrillation-sex-age ( years )-smoking history-previous diabetes"
444,characteristic_level,"non - smoker-no ""-ex - smoker-< nmbr-itt population-female-male-no-nmbr - nmbr-current smoker-yes-> nmbr"
445,characteristic_level,"intention - - treat st - segment - elevation myocardial infarction-intention - - treat without st - segment - elevation myocardial infarction-intention - - treat st - segment - elevation myocardial infarction ""-intention - - treat"
446,arms,"cangrelor ( n = nmbr )-clopidogrel ( n = nmbr )-clopidogrel ( n = nmbr ) """
447,outcomes,"primary endpointnmbr-coronary eventsnmbr-all - cause mortality-all - cause mortality """
448,characteristic_level,"hs - crp mg / l-hs - crp _ = nmbr . nmbr mg / l-hs - crp jnmbr . nmbr mg / l-hs - crp < nmbr . nmbr nlg l-hs - crp jnmbr . nmbrmg / l-all randomized-hs - crp jnmbr . nmbr mg / l ""-all cause mortality hosp . worsening hf hs - crp < nmbr . nmbr mg / l-hs - crp < nmbr . nmbr mg / l"
450,characteristic_level,"hs - crp < nmbr . nmbr g / l-hs - crp < nmbr . nmbr g / l ""-hs - crp > nmbr . nmbr mg / l-hs - crp < nmbr . nmbr mg / l"
451,measures,"hospitalizations , n-patients , n-hospitalizations , n """
452,outcomes,"noncardiovascular-noncardiovascular ""-all - cause-cardiovascular-worsening heart failure"
454,characteristic_level,"hs - crp > nmbr . nmbr mg / l-hs - crp < nmbr . nmbr mg / l-hs - crp < nmbr . nmbr mg / l """
455,outcomes,"hdl cholesterol , mmol / l *-triglycerides , mmol / lf-hs - crp , mg / l-ldl cholesterol , mmol / l *-triglycerides , mmol / lf """
456,arms,"rosuvastatin ""-rosuvastatin-placebo"
457,measures,"nmbr - month follow - median ( iq range )-p , net difference-baseline median ( iq range )-baseline median ( iq range ) ""-difference , % median"
458,characteristic_level,"neither tnmbrdm mets-metabolic syndrome w / tnmbrdm-tnmbrdm-neither tnmbrdm mets """
459,arms,"anmbr + eznmbr-anmbr ""-anmbr"
460,characteristic_name,"non - hdl - c-total cholesterol-hs - crp-non - hdl - c / hdl - c ""-ldl - c-ldl - c / hdl - c-hdl - c-apolipoprotein b^-apolipoprotein - *-triglycerides-total cholesterol / hdl - c-apo b / apo - l-non - hdl - c / hdl - c"
461,characteristic_level,"treatment difference ( nmbr % ci ) ""-treatment difference ( nmbr % ci )-treatment difference ( nmbr % cl )"
462,characteristic_level,"neither tnmbrdm mets-tnmbrdm-mets w / tnmbrdm-mets w / tnmbrdm """
463,arms,"anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr )-anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr )-anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ) """
464,arms,"anmbr / nmbr ( n = nmbr )-anmbr / nmbr ( n = nmbr ) ""-anmbr + enmbr ( n = nmbr )"
465,characteristic_name,"antidiabetes drug usage [ % ( n ) ]-antidiabetes drug usage [ % ( n ) ] "" ; na"
466,characteristic_level,"bmi ( kg / mnmbr ) [median ( nmbrth nmbrth percentile ) ] ""-biguanide ( metformin )-three drugs-age ( years ) [median ( nmbrth nmbrth percentile ) ]-n-sulfonylurea-a - glucosidase inhibitor-thiazolidinedione-dual therapy-hypertension ( % )-monotherapy-no antidiabetic drug-bmi ( kg / mnmbr ) [median ( nmbrth nmbrth percentile ) ]-current smoker ( % )-meglitinide-weight ( kg / mnmbr ) [median ( nmbrth nmbrth percentile ) ]-female sex ( % )-hyperlipidemia ( % )-insulin"
467,arms,"ranolazine-ranolazine ""-placebo"
468,characteristic_level,"men ""-men-women"
469,outcomes,"myocardial infarction-myocardial infarction ""-cardiovascular death-primary endpoint-recurrent ischemia"
470,measures,"hr ( nmbr % cl ) ""-hr ( nmbr % cl )-p nmbr interaction women vs men"
472,characteristic_name,"fvc ( l )-smoking status-( b ) concomitant respiratory medications [n ( % ) ]-fevnmbr ( l )-fvc ( % predicted ) ""-fvc ( % predicted )-fevnmbr ( % predicted )-( ) demographics-gold stage [n ( % ) ]"
473,characteristic_level,"women ""-men-women"
474,arms,"control ( nznmbr )-tiotropium ( nznmbr )-control ( nznmbr ) """
475,outcomes,"fevnmbr pre - bronchodilator-fevnmbr post - bronchodilator ""-fvc post - bronchodilator-fevnmbr post - bronchodilator-fvc pre - bronchodilator"
476,characteristic_level,"women ""-men-women"
479,measures,"n ""-n-% pred-ml"
480,characteristic_name,"albuterol use ( sd ) , puffs / day ""-mean age ( sd ) , years-symptom score ( sd )-female ( % )-fevnmbr percent predicted ( sd )-pm pef ( sd ) , l / min-asthma duration ( sd ) , years-am pef ( sd ) , l / min-number subjects-albuterol use ( sd ) , puffs / day"
481,characteristic_name,"bmi category ""-bmi category"
482,characteristic_level,"nmbr-nmbr - nmbr . nmbr ""-> nmbr-nmbr - nmbr . nmbr"
483,characteristic_name,"n-reversibility ( bnmbr - agonist ) , % , mean ( sd ) nmbr-reversibility ( anticholinergic ) , % , mean ( sd ) $-age , yr , mean ( sd ) ""-bmi , mean ( sd )-ics users , n ( % )-male sex , n ( % )-fevi , l , mean ( sd ) nmbr-fevi , % predicted , mean ( sd ) nmbr-fevnmbr / fvc , % , mean ( sd ) nmbr-smoking history , pack - years , mean ( sd )-age , yr , mean ( sd )"
484,arms,"placebo ""-indacaterol nmbr mg-tiotropium-placebo"
485,characteristic_level,"female ""-female-male"
486,arms,"ami nmbr mg-aml / val nmbr / nmbr mg-aml / val nmbr / nmbr mg """
487,characteristic_level,"pad baseline ""-no pad baseline-pad baseline"
488,arms,"epa-control-epa "" ; na"
490,characteristic_name,"fasting lipid levels , mmol / l-diabetes-cardiovascular disease-cardiovascular disease ""-race , n ( % )"
491,characteristic_level,"caucasian-total cholesterol-mean nmbr - year cvd risk * ""-other-current cvd / diabetes , n ( % )-ldl - c-hdl - c-age , years-type nmbr , n ( % )-asian-current smoker , n ( % )-black-high - risk cvd , n ( % )-triglycerides , median ( range )-mean nmbr - year cvd risk *-> nmbr years , n ( % )-male , n ( % )"
492,arms,"atorvastatin nmbr mg ( n = nmbr ) ""-atorvastatin nmbr mg ( n = nmbr )-rosuvastatin nmbr - nmbr mg ( n = nmbr )-ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr )"
493,characteristic_level,"ldl - c < nmbr . nmbr mmol / l-nice primary prevention onlyb-nice secondary prevention onlyb-baseline ldl - c nmbr . nmbr < nmbr . nmbr mmol / lc-jbs - nmbr primary prevention onlynmbr-baseline ldl - c > nmbr . nmbr < nmbr . nmbr mmol / lc-jbs - nmbr secondary prevention onlynmbr-nice primary prevention onlyb """
494,measures,"percentage patients reaching target ""-percentage patients reaching target"
495,arms,"atorvastatin-rosuvastatin-exetimibe / simvastatin-atorvastatin """
496,characteristic_name,"medications baseline , n ( % ) ""-location crohn ' disease , %-medications baseline , n ( % )"
497,characteristic_level,"mean duration disease , years-no corticosteroids immunosuppressants-upper gastrointestinal-ileocolon-corticosteroids immunosuppressants-resection performed , %-mean cdai score-geometric mean crp concentration ( mg / l )-corticosteroids-no corticosteroids immunosuppressants ""-penetrating disease , %-colon-male , %-immunosuppressants-terminal ileum-mean ( . . ) age , years"
498,arms,"infliximab - naive ( n = nmbr )-infliximab - experienced ( n = nmbr )-infliximab - experienced ( n = nmbr ) """
499,characteristic_level,"nmbr . nmbr yrs-anterior-> nmbr . nmbr yrs-non - anterior-male-female-no-nmbr min-yes ""-< nmbr min-> nmbr . nmbr min-> nmbr min-yes-nmbr . nmbr min-nmbr - nmbr min"
500,characteristic_name,"diabetes ""-interval study drug pci-age-infarct localization-diabetes-history mi-interval pain onset admission-sex-interval clopidogrel pci"
502,characteristic_name,"blood pressure-elevated blood pressure-increased waist circumference-prevalence metabolic syndrome criterion-diastolic-waist circumference-low hdl cholesterol ""-fasting blood glucose-low hdl cholesterol-elevated tg-elevated fasting glucose-changes ( ) metabolic syndrome parameters hdl cholesterol-systolic"
503,arms,"low - dose statin-fenofibric acid + low - dose statin-high - dose statin-moderate - dose statin-low - dose statin ""-fenofibric acid-fenofibric acid + moderate - dose statin"
504,characteristic_name,"screening visit ""-screening visit-randomisation visit ( baseline )"
505,characteristic_level,"pre - bronchodilator fevnmbr ( l )-age ( years )-any medication-men : women ( % )-post - bronchodilator fevnmbr ( l ) a-oral corticosteroids-post - bronchodilator fvc ( l ) a-time since copd diagnosis ( yrs )-smoking history ( pack - years )-pre - bronchodilator fvc ( l )-pre - bronchodilator fevnmbr / fvc ( % )-mucolytics-fevnmbr ( l )-current smoker : ex - smoker ( % )-long - acting bnmbr - agonists-pre - bronchodilator fvc ( l ) ""-fevnmbr ( % predicted normal )-xanthines-fvc ( l ) proportion taking pulmonary medications ( % ) b-pre - bronchodilator fevnmbr ( % predicted normal )-post - bronchodilator fevnmbr ( % predicted normal ) a-supplementary oxygen-reversibility fevnmbr ( % )-inhaled corticosteroids-short - acting anticholinergics-short - acting bnmbr - agonists-post - bronchodilator fevnmbr / fvc ( % )"
506,characteristic_name,"pre - bronchodilator fevnmbr ( l )-age ( years )-any medication-men : women ( % )-post - bronchodilator fevnmbr ( l ) a-oral corticosteroids-post - bronchodilator fvc ( l ) a-time since copd diagnosis ( yrs )-short - acting anticholinergics ""-smoking history ( pack - years )-pre - bronchodilator fvc ( l )-pre - bronchodilator fevnmbr / fvc ( % )-mucolytics-fevnmbr ( l )-current smoker : ex - smoker ( % )-long - acting bnmbr - agonists-fevnmbr ( % predicted normal )-xanthines-tiotropiumc-pre - bronchodilator fevnmbr ( % predicted normal )-fvc ( l )-post - bronchodilator fevnmbr ( % predicted normal ) a-supplementary oxygen-reversibility fevnmbr ( % )-inhaled corticosteroids-short - acting anticholinergics-short - acting bnmbr - agonists-post - bronchodilator fevnmbr / fvc ( % )"
507,characteristic_level,"laba users-laba non - users ""-laba non - users"
508,characteristic_name,"primary enrollment diagnoses , n ( % )-race ethnicity , n ( % ) ""-risk factors immobility level , n ( % )-previous medications , n ( % )-region enrollment , n ( % ) +-race ethnicity , n ( % )"
509,measures,"postamendment-preamendment-total population-preamendment """
510,arms,"extended - duration enoxaparin ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
511,outcomes,"major bleeding events *-vte day nmbr + ""-vte day nmbr +"
512,characteristic_name,"age > nmbr y-age < nmbr ""-age < nmbr"
513,characteristic_level,"level nmbr-level nmbr ""-men-women"
515,characteristic_name,"geographical region , n ( % )-previous copd treatment , n ( % ) *-previous copd treatment , n ( % ) * """
516,characteristic_level,"$ nmbr % , n ( % )-body mass index , kg / mnmbr-nmbre < nmbr % , n ( % )-< nmbr % , n ( % )-nmbr-neither ics laba-western europe-ics alone-laba alone-age enrolment , years-asia pacific-$ nmbr-nmbr ""-usa-ics + laba-pack - years smoked-baseline short - acting anticholinergics , n ( % )-other-previous mi , n ( % )-eastern europe-postbronchodilator fevnmbr , % predicted-current smoker , n ( % )-male gender , n ( % )-baseline cv treatment , n ( % )"
517,arms,"salmeterol ( n [nmbr )-placebo ( n[nmbr )-fp ( n [nmbr )-sfc ( n [nmbr ) ""-sfc ( n [nmbr )"
518,characteristic_name,"prior mi-smoking status-age-sex ""-sex-baseline fevnmbr-baseline short - acting anticholinergics-baseline cv treatment"
519,characteristic_level,"$ nmbr-nmbre < nmbr %-$ nmbr %-< nmbr-male-female-no-female ""-former-nmbrenmbr-< nmbr %-yes-current"
521,characteristic_name,"demographic characteristics-medical history duration heart failure ( years ) primary cause heart failure-demographic characteristics ""-nyha class"
522,characteristic_level,"ace inhibitor-class iv-hypertension-antialdosterone agents-heart rate ( bpm )-myocardial infarction-age ( years )-non - ischaemic-ischaemic-bmi ( kg / mnmbr ) cardiac parameters-white-sex ( male ) ethnic origin-egfr ( ml / min per nmbr - nmbr mnmbr ) ""-diuretic drugs ( excluding antialdosterone )-sbp ( mm hg )-egfr ( ml / min per nmbr - nmbr mnmbr )-icd-asian-diabetes-arb-class iii-devices-crt-history atrial fibrillation flutter treatment randomisation-p blocker-other-lvef ( % )-current smoking-class ii-cardiac glycosides-dbp ( mmhg )-previous stroke"
523,arms,"placebo group ( n = nmbr ) ""-placebo group ( n = nmbr )-ivabradine group ( n = nmbr )"
524,characteristic_name,"baseline heart rate-age-nyha class-diabetes-hypertension-sex-cause heart failure ""-cause heart failure-p blockers"
525,characteristic_level,"age < nmbr years ( n = nmbr )-non - ischaemic ( n = nmbronmbr )-nyha class iii iv ( n = nmbr )-ischaemic ( n = nmbrlnmbr )-history hypertension ( n = nmbr )-female ( n = nmbr )-history diabetes ( n = nmbr )-= nmbr bpm ( n = nmbr )-p - blocker intake randomisation ( n = nmbro )-no p - blocker intake randomisation ( n = nmbr )-> = nmbr years ( n = nmbr )-no history hypertension ( n = nmbr )-< nmbr bpm ( n = nmbr )-non - ischaemic ( n = nmbronmbr ) ""-nyha class ii ( n = nmbrlnmbr )-male ( n - nmbr )-no history diabetes ( n = nmbr )"
527,characteristic_name,"medication , n ( % ) ""-medical history , n ( % )-laboratory measurements-demographics-medication , n ( % )"
530,characteristic_name,"medical history ( % ) ""-treatment admission-blood pressure ( mm hg )-medications day nmbr-treatment admission ( % )-medications discharge day nmbr , earlier ( % )-measurements-demographic characteristics-medical history ( % )"
532,characteristic_name,"age , y-medical history , n ( % )-race , n ( % )-medical history , n ( % ) ""-ethnicity , n ( % )"
533,arms,"fenofibric acid nmbr = nmbr-rosuvastatin n = nmbr-fenofibric acid nmbr = nmbr ""-rosuvastain + fenofibric acid nmbr = nmbr"
534,outcomes,"tg-hdl - c-hdl - c "" ; na-ldl - c"
535,measures,"% ( se )-final mean , mg / dl ""-mean change ,-baseline mean , mg / dl-final mean , mg / dl"
536,arms,"treatment group-treatment group """
537,arms,"acid-fenofibric acid ""-fenofibric acid"
538,characteristic_level,"non - diabetic ""-diabeticb-non - diabetic"
539,other,"study end concentration-study end concentration """
540,characteristic_name,"hdlnmbr - c ""-ldu - c-apo b *-triglyceride-ldl , - c-total ldl - c *-non - hdl - c *-ldlnmbr - c-hdlnmbr - c"
541,characteristic_level,"baseline trig > nmbr millycerides g / dl-overall population-baseline triglycerides < nmbr mg / dl-overall population """
542,arms,"anmbr + ez n = nmbr-anmbr + ez n = nmbr anmbr n = nmbr-anmbr n = nmbr ""-anmbr n = nmbr"
543,other,"acute dvt study-continued treatment study ""-continued treatment study"
544,arms,"standard therapyy ( n = nmbr )-placebo ( n = nmbr ) ""-rivaroxaban ( n = nmbr )-placebo ( n = nmbr )"
545,characteristic_name,"known ' rc - iitoji cccndilon-renal fmclicn : creatntoe clearance-intended durat - sm antccagubficn-redon-wegu ""-cardiac disease-age-rarertd antocagibtcn andorrtzafon-locafon index dvt-wegu-mafcaiancy randorrtzaton-miami k antagonist received-sex-kheeatne index dvt-modmy al randcnxzaton-pre ' rtous eptscde ( } dvt / pe"
546,arms,"enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr )-riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ) ""-riva roxa ban n / n { % ) nmbr ( nmbr . nmbr )"
547,characteristic_name,"intended duration anticoagulation-renal function : creatinine clearance-age-race ""-parenteral anticoagulalion randomization-malignancy randomization-race-weight"
548,arms,"rivaroxaban-enoxaparin / vka ""-enoxaparin / vka"
549,measures,"( % ) ( nmbr . nmbr )-( % ) ( nmbr - nmbr ) ""-( % ) ( nmbr - nmbr )-n / n nmbr / nmbr"
550,characteristic_name,"comorbidities , n ( % ) a-mean lipid values , mg / dl-body weight ( kg ) , n ( % )-race , n ( % ) ""-sex , n ( % )-dm medication , n ( % ) c-age ( years )-race , n ( % )"
551,arms,"fa nmbr mg-r nmbr mg-r nmbr mg + fa ""-r nmbr mg + fa"
552,characteristic_name,"concomitant medication , n ( % )-concomitant medication , n ( % ) "" ; na-disease location ( % ) *"
553,characteristic_level,"endoscopy subscore-left - sided colitisz-aminosalicylates * *-corticosteroid + imm-no corticosteroid , imm-male ( % ) ""-mayo score , mean ( sd )-crp , mg / l : median ( range )-age , years : median ( range )-disease duration , years : median ( range )-male ( % )-extensive colitisy-corticosteroid ( without imm )-weight , kg : mean ( sd )-otherx-pga subscore-imm ( without corticosteroid )-stool frequency subscore-rectal bleeding subscore {"
554,arms,"placebo ( n[nmbr )-ada nmbr / nmbr ( n[nmbr ) ""-ada nmbr / nmbr ( n[nmbr )"
556,arms,"ada nmbr / nmbr n[nmbr ""-ada nmbr / nmbr n[nmbr-placebo n[nmbr"
557,characteristic_name,"caucasian-body mass index , kg / mnmbr-n-fevnmbr , % predicteda-ex - smoker / smoker , %-other-patients treated > nmbr weeks ( % )-age , years-asian-ex - smoker / smoker , % ""-black-ics use yes / , %-fevnmbr , la-treatment duration , days-history current cardiac disorders , %-age > nmbr , %-male / female , %"
558,arms,"salmeterol nmbr gg bid-placebo-indacaterol nmbr gg qd-formoterol nmbr gg bid-tiotropium nmbr gg qd-formoterol nmbr gg bid """
559,characteristic_name,"renal impairment , n ( % )-duration tnmbrdm ( years )-gender , n ( % )-hbanmbrc category , n ( % )-hbanmbrc category , n ( % ) ""-race , n ( % )-age category ( years ) , n ( % )"
560,characteristic_level,"mean ( . . )-men-esrd-< nmbr-body mass index ( kg / mnmbr ) ,-sulphonylurea-white-> nmbr . nmbrto < nmbr . nmbr %-women-weight ( kg ) , mean ( . . )-> nmbr , n ( % )-a - glucosidase inhibitor-oral blood glucose - lowering drug nmbr ( nmbr . nmbr )-> nmbr-thiazolidinedione-moderate-diabetes therapy , n ( % ) ""-age ( years ) , mean ( . . )-oral blood glucose - lowering-> nmbr . nmbr %-severe-diabetes therapy , n ( % )-fpg ( mmol / l )-glinide-crcb - ( ml / min ) , mean ( . e . )-hbanmbrc ( % )-< nmbr . nmbr %-insulin"
561,arms,"saxa nmbr . nmbr mg ( n = nmbr )-pbo ( n = nmbr ) ""-pbo ( n = nmbr )"
562,characteristic_level,"baseline hbanmbrc , mean ( . e . )-adjusted change baseline mean ( . e . ) ""-esrd-moderate renal impairment-adjusted change baseline mean ( . e . )-week nmbr hbanmbrc , mean ( . e . )-severe renal impairment-difference vs . pbof mean ( . e . )"
563,arms,"pbo-saxa nmbr . nmbr mg ""-saxa nmbr . nmbr mg"
564,measures,"n = nmbr ""-n = nmbr"
565,characteristic_level,"pbo ( n = nmbr )-esrd saxa nmbr . nmbr mg ( n = nmbr )-severe renal impairment ""-moderate renal impairment-severe renal impairment"
566,arms,"saxa nmbr . nmbr mg ( n = nmbr )-saxa nmbr . nmbr mg ( n = nmbr ) ""-pbo ( n = nmbr )"
567,characteristic_name,"clinical presentation-medical therapy-antithrombotic therapy ""-treated vessel-antithrombotic therapy"
568,characteristic_level,"left anterior descending-glycoprotein llb / llla inhibitors-left circumflex-enoxaparin ""-chronic stable angina-multivessel pci-enoxaparin-lesions bnmbr / c-ace inhibitors / sartans-multivessel disease-acs-saphenous vein graft-left main-right coronary-unfractionated heparin-bivalirudin-/ nmbr - blockers"
569,arms,"controls ( n = nmbr )-high - dose statin pretreatment ( n = nmbr )-controls ( n = nmbr ) """
570,arms,"placebo ( n - nmbr ) ""-placebo ( n - nmbr )-bosentan ( n = nmbr )"
571,characteristic_name,"baseline fvc , l-baseline fvc , l ""-location-age , years-smoking history"
573,characteristic_name,"baseline low - density lipoprotein cholesterol ( mg / dl )-risk group-baseline low - density lipoprotein cholesterol ( mg / dl ) ""-race"
574,characteristic_level,"american indian alaska-white-body mass index ( kg / nr )-men-nmbr - < nmbr-high risk atherosclerotic vascular disease *-women-moderately high risk without atherosclerotic vascular disease *-< nmbr-asian-high risk without atherosclerotic vascular disease +-> nmbr ""-multiracial-nmbr - nmbr-age ( years )-black african american-> nmbr"
575,other,"stratum ii ""-stratum i-stratum ii"
576,arms,"rnmbr + ezio ( n = nmbr )-rnmbr ( n = nmbr )-rnmbr ( n = nmbr ) """
577,characteristic_name,"geographical region ( % )-geographical region ( % ) "" ; na"
578,characteristic_level,"pack - years smoked-male gender ( % )-usa-bmi ( kg / mnmbr )-other-eastern europe-reversibility ( % predicted fevnmbr ) *-age enrollment ( years )-male gender ( % ) ""-post - bronchodilator fevnmbr ( % predicted * )-current smoker ( % )-baseline sgrq total score-pre - bronchodilator fevnmbr / fvc ratio *-western europe-asia - pacific-post - bronchodilator fevnmbr ( l ) *"
580,characteristic_name,"concomitant medication , n ( % )-location disease , n ( % )-hrqol "" ; na-hrqol-diagnosis ( ) , mean ( sd )"
581,characteristic_level,"ileocolon-corticosteroid immunosuppressant-immunosuppressant ( without corticosteroid )-inflammatory-stricturing-corticosteroid immunosuppressant-nmbr-ibdq score , mean ( sd )-colon-ibdq score , mean ( sd ) "" ; na-geometric mean baseline-neither corticosteroid immunosuppressant-terminal ileum-> nmbr-corticosteroid ( without immunosuppressants )-mean body mass index ( kg / mnmbr )"
582,arms,"certolizumab pegol ( n = nmbr )-certolizumab pegol ( n = nmbr ) ""-placebo ( n = nmbr )"
583,characteristic_name,"age ( yrs ) nmbr - nmbr-stricturing-< nmbr-nmbr-nmbr yrs-previous current use im cs : no-smoker-im use : no-cs use : no-> nmbr-penetrating-im cs use : no-nonsmoker-disease location / type : terminal ileum-caucasian-im cs use : no-bmi ( kg / mnmbr ) < nmbr-prior surgery : no-previous current use im cs : no-female-disease duration : < baseline mean-inflammatory-yes-previous current im use : no-previous current cs use : no-nmbrbaseline mean-cdai score < nmbr-< nmbr yr-lleocolon-nmbr - nmbr yrs-noncaucasian-crp ( mg / l ) : < nmbr-male-colon-nonsmoker """
584,characteristic_name,"country ""-country"
585,characteristic_level,"hungary-estonia-czech republic-rest world-poland-latvia-germany-new zealand ""-austria-romania-canada-australia-belgium-new zealand-ukraine-brazil-united states-italy-europe ( zone nmbr )-russia-north america-israel"
586,characteristic_name,"crohn ' disease - related medication baseline , n ( % )-c - reactive protein ( mg / dl_ )-crohn ' disease - related medication baseline , n ( % ) "" ; na-involved intestinal area , n ( % )"
587,characteristic_level,"mean ( . . )-ileum-age ( years ) , mean ( . . ) ""-body weight ( kg ) , mean ( . . )-other-immunosuppressants-male patients , n ( % )-baseline cdai score , mean ( . . )-age ( years ) , mean ( . . )-previous tnf - antagonist use , n ( % )-current smoker , n ( % )-gastroduodenum-colon-aminosalicylates-draining cutaneous fistula baseline , n ( % )-median ( range )"
588,characteristic_name,"baseline corticosteroids * ""-no baseline corticosteroids-baseline corticosteroids *"
589,arms,"nmbr mg eow n = nmbr ""-nmbr mg eow n = nmbr-nmbr mg ew n = nmbr-placebo n = nmbr"
590,characteristic_name,"body mass index , %-smoking , %-body mass index , % """
591,characteristic_level,"nmbr - nmbr . nmbr kg / mnmbr-> nmbr kg / mnmbr-nmbr - nmbr . nmbr kg / mnmbr ""-past-current-never-< nmbr kg / mnmbr"
592,characteristic_level,"migraine aura-migraine without aura-prior migraine *-migraine aura """
593,arms,"placebo nmbr-placebo nmbr ""-aspirin nmbr"
594,outcomes,"ischemic stroke-coronary revascularization ""-stroke-coronary revascularization-no .-myocardial infarction-cvd death-hemorrhagic stroke-tia-major cvd /"
595,characteristic_level,"prior migraine-no history migraine-no history migraine ""-migraine aura-migraine without aura-p *"
597,characteristic_name,"alcohol consumption-gender , n ( % )-tobacco use-history medical conditions , n ( % )-fracture history ( predefined ) , n ( % )-maternal history , n ( % )-tobacco use ""-history bone disease ( predefined ) , n ( % )-paternal history , n ( % )-risk factor ( predefined ) falling screening , n ( % )-race , n ( % )"
598,characteristic_level,"current ( predefined ) medical conditions-priorother ( predefined ) medical conditions-years , mean ( sd )-priorbone disease-hbalc ( % ) , mean ( sd ) ^-former , n ( % )-years , mean ( sd ) ""-bmi ( kg / mnmbr ) , mean ( sd )-past-current bone disease-african america-weight ( kg ) , mean ( sd )-currentother ( notpredefined ) medical conditions-osteoporosis-age ( years ) , mean ( sd )-caucasian-priorother ( predefined ) medical conditions-fpg ( mmol / l ) , mean ( sd ) < u + nmbr >-yes , n ( % )-any condition-asian-female-current , n ( % )-other-male-units per week , mean ( sd )-duration diabetes-hip fracture-current"
599,arms,"met ( n = nmbr )-avm ( n = nmbr ) ""-avm ( n = nmbr )"
600,other,"lumbar spine ""-femoral neck-total body-distal one - third radius-total hip-lumbar spine"
601,measures,"treatment difference-avm % < u + nmbrbnmbr > ( se )-met % < u + nmbrbnmbr > ( se )-treatment difference """
602,characteristic_level,"overall-premenopausal-female-male-postmenopausal-overall """
603,arms,"apixaban ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
604,characteristic_name,"heart failure-apixaban dose ( matching placebo )-acs treatment-geographic region-age-history stroke ""-bmi-history stroke-acs type-sex-race-level renal impairment-diabetes mellitus"
605,outcomes,"cv death , ml , ischemic stroke ""-cv death , ml , ischemic stroke"
606,measures,"hr ( nmbr % cl )-n / n-interaction p value-n / n """
607,characteristic_name,"age , y-weight , kg ""-weight , kg"
610,characteristic_name,"severity copd , ( gold nmbr ) , % ""-severity copd , ( gold nmbr ) , %-race , %"
611,characteristic_level,"duration copd , y-sex , male / female , %-smoking history , pack - years-severe severe-white-fevnmbr , pre - albuterol , l-fevnmbr / fvc , post - albuterol , %-baseline sgrq score-fevnmbr % predicted , post - albuterol , %-age , y-ics use , yes / , %-ex - smoker / smoker , %-moderate-asian-fevnmbr reversibility , pre - / post - albuterol , %-fevnmbr , post - albuterol , l-ex - smoker / smoker , % ""-black-other-use rescue albuterol , puffs / day *-days without albuterol use , * %"
612,other,"study nmbr ""-study nmbr"
613,arms,"placebo group ( n = nmbr ) ""-placebo group ( n = nmbr )-all patients ( n = nmbr )-indacaterol group ( n = nmbr )"
614,characteristic_name,"age , y-copd severity ( gold nmbr ) ""-bmi , kg / mnmbr-copd severity ( gold nmbr )-albuterol reversibility , %-smoking history-sex-use ics-waist - hip ratio"
615,characteristic_level,"nmbr / nmbr-nmbr / nmbr """
616,other,"study nmbr ""-study nmbr"
617,measures,"treatment difference , ml-treatment difference , ml ""-no . patients ( indacaterol / placebo )"
618,characteristic_name,"diabetes duration ( known ) , % patients ""-egfr using cg / mdrd formulae , % patients-gender , % patients-cv risk factors , % patients-framingham nmbr - year cv risk score-cv medication , % patients-diabetes duration ( known ) , % patients-race , % patients-previous oral glucose - lowering agents , % patients"
619,characteristic_level,"moderately impaired-antihypertensive-> nmbr years-ex - / current smoker-coronary artery disease-hbanmbrc , %-hypertension-nmbr-severely impaired-white-age , years-score > nmbr % , % patients-> nmbr-< nmbr years-hbanmbrc , mmol / mol-any above-cerebrovascular disease-acetyl - salicylic acid-asian-fpg , mmol / l-lipid - lowering therapy-black-none-peripheral artery disease-mildly impaired-male / female-> nmbr years ""-bmi , kg / mnmbr-normal-nmbr - nmbr years-score , %-metabolic syndrome *"
620,arms,"total comparators ( n = nmbr ) ""-total comparators ( n = nmbr )-linagliptin ( n = nmbr )"
621,characteristic_name,"use rescue medication-gender-framingham nmbr - year cv risk score-investigator - reported hypoglycaemia *-race-age ( years ) *-gender """
622,characteristic_level,"white-> nmbr %-< nmbr-female-male-asian-no-black-female ""-< nmbr %-yes-> nmbr"
624,characteristic_name,"age category >-duration tnmbrdm-bmi ( kg / mnmbr )-nmbr - h ppg ( mmol / l ) * ""-fpg ( mmol / l )-nmbr - h ppg ( mmol / l ) *-hbanmbrc ( % )-body weight-age ( years )-female , n ( % )"
625,arms,"vildagliptin nmbr mg qd n = nmbr-vildagliptin nmbr mg qd n = nmbr ""-vildagliptin nmbr mg bid n = nmbr-placebo n = nmbr"
626,characteristic_name,"duration metformin therapy ( months )-gender-hbanmbrc baseline , %-duration diabetes ( months )-bmi baseline ( kg / mnmbr )-hbanmbrc baseline , % ""-age ( years )"
627,characteristic_level,"< nmbr-female-male-> nmbr ""-> nmbr"
628,arms,"vildagliptin nmbr mg bid-vildagliptin nmbr mg qd ""-vildagliptin nmbr mg qd-placebo"
629,measures,"n-baseline-baseline ""-am < u + nmbrbnmbr > < u + nmbreb > . e .-ama < u + nmbreb > . e ."
630,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-vorapaxar ( n = nmbr , nmbr )"
631,characteristic_name,"aspirin enrollment-age-region-diabetes-egfr ( mumin / nmbr . nmbr mnmbr )-history stroke-body weight-sex-current smoker-qualifying atherosclerosis-thienopyridine enrollment-region """
632,characteristic_level,"europe ii-australia / nz-men-> = nmbr-mi-pad-women-asia-north america-latin america-< nmbr-stroke-no-< nmbrkg-europe i-> = nmbrkg-yes-north america """
634,other,"nmbr . nmbr ""-nmbr . nmbr"
635,characteristic_name,"diabetes ""-aspirin enrollment-age-region-diabetes-history stroke-body weight-sex-current smoker-qualifying atherosclerosis-thienopyridine enrollment-estimated glomerular filtration"
636,characteristic_level,"> = nmbr-women-no ""-< nmbr-stroke-no-< nmbrkg-overall nmbr-yes"
638,measures,"hazard ratio ( nmbr % cl ) ""-hazard ratio ( nmbr % cl )"
639,characteristic_name,"inadequate response / intolerance prior therapy , % ""-inadequate response / intolerance prior therapy , %-extent disease , %"
640,characteristic_level,"mean disease duration , ( sd )-immunosuppressant use , % ""-anti - tnf agent ( )-mean age , ( sd )-prednisone use , %-mean weight , kg ( sd )-mean cdai score ( sd )-immunosuppressant use , %-corticosteroidsa-immunosuppressants-mean mayo score ( sd )-left - sided disease only-mean hscrp , mg / l ( sd )-sex , % female-oral aminosalicylates-extensive disease"
641,characteristic_level,"crohn ' disease-ulcerative colitis-ulcerative colitis """
642,characteristic_name,"severity copd , n ( % ) *-race , %-severity copd , n ( % ) * """
643,characteristic_level,"fevnmbr , litres ( post - salbutamol ) , mean ( sd )-ics use , yes / %-fevnmbr reversibilityz ( pre / post salbutamol ) , %-sex , men / women , %-duration copd ( years ) , mean ( sd )-severe severe-fevnmbr , litres ( post ipratropium ) , mean ( sd )-pack - years , mean ( sd )-moderatey-fevnmbr reversibilityz ( pre / post ipratropium ) , %-fevnmbr , litres ( pre salbutamol ) , mean ( sd )-age ( years ) , mean ( sd )-caucasian-ex - smoker / smoker , %-fevnmbr % predicted ( post salbutamol )-asian-black-fevnmbr / fvc ( post salbutamol )-moderatey ""-other-fevnmbr , litres ( pre ipratropium ) , mean ( sd )-native american"
644,other,"study nmbr ""-study nmbr"
645,arms,"tiotropium + placeb ( n[nmbr )-tiotropium + placebo ( n[nmbr )-tiotropium + placeb ( n[nmbr ) ""-indacaterol + tiotropium ( n[nmbr )"
646,characteristic_name,"women , %-tc , mmol / l ( mg / dl )-diabetes , n ( % )-sbp , mm hg-hdl - c , mmol / l ( mg / dl )-tg , mmol / l [mg / dl]-dbp , mm hg-hypertension , n ( % )-age , years-age > nmbr years , %-bmi , mean ( sd ) , kg / mnmbr-ldl - c , mmol / l ( mg / dl )-fpg , mmol / l ( mg / dl )-current smoker , %-hdl - c , mmol / l ( mg / dl ) ""-obesity ( bmi > nmbr kg / mnmbr ) , %"
649,outcomes,"apo b : apo - ratio-total cholesterol , mg / dl-total cholesterohhdl cholesterol ratio ""-total cholesterohhdl cholesterol ratio-triglycerides , mg / dl-hdl cholesterol , mg / dl-apo - , mg / dl-ldl cholesterohhdl cholesterol ratio-apo b , mg / dl-ldl cholesterol , mg / dl"
650,characteristic_level,"patients without ra , , psa ( n = nmbr , nmbr )-patients ra , , psa ( n = nmbr )-patients without ra , , psa ( n = nmbr , nmbr ) """
652,arms,"standard care-insulin glargine-standard care """
653,characteristic_name,"anmbrc < nmbr . nmbr % ( median )-age > = nmbr yrs-prior dm-placebo allocation-new dm-overall-bmi < = nmbr-metformin-ifg / igt-no metformin-female-statin use-prior cv event-omega nmbr allocation-ace - / arb-male-no ace - / arb-bmi > nmbr-anmbr = nmbr . nmbr % ( median )-placebo allocation ""-age < nmbr yrs-no statin use-no prior cv event"
655,characteristic_name,"mean *-baseline crp ( mg / dl )-smoking status , n ( % )-baseline crp ( mg / dl ) """
656,characteristic_level,"baseline cdai ,-white , n ( % )-fistula baseline , n ( % )-mean-prior-age ( yrs ) , mean *-> nmbr . nmbr , n ( % )-women , n ( % ) *-baseline ibdq total score , mean-> nmbr . nmbr , n ( % ) ""-never-current"
657,outcomes,"disease duration nmbr bnmbr years ( n = nmbr ) ""-disease duration b nmbr years ( n = nmbr )-disease duration nmbr bnmbr years ( n = nmbr )-disease duration > nmbr years ( n = nmbr )"
658,characteristic_name,"clinical history , . ( % )-exercise-antihypertensive medication , open - label , . ( % )-smoker-age group , . ( % )-toast classification qualifying stroke , . ( % ) ""-ethnicity , . ( % )-demographics-clinical details-toast classification qualifying stroke , . ( % )-regular alcohol consumption per week , . ( % )"
659,characteristic_level,"hyperlipidemia-diuretic-ace inhibitor-other determined etiology-hypertension-nmbr drinks-atrial fibrillation-former-nmbr - nmbr drinks-tia-never-diabetes mellitus-white-> nmbr drinks-sex , male , . ( % )-undetermined etiology-other determined etiology ""-alpha receptor antagonist-< nmbr y-baseline nihss score , median ( range )-systolic blood pressure , mm hg , mean ( sd )-diastolic blood pressure , mm hg , mean ( sd )-> nmbr y-large - artery atherosclerosis-intense-beta receptor antagonist-asian-body mass index , kg / mnmbr , mean ( sd )-sedentary-black-age , , mean ( sd )-other-small - artery occlusion-hypertension , treated-calcium channel blocker-some-cardioembolism-current"
660,arms,"telmisartan ( n = nmbr )-placebo ( n = nmbr ) ""-mri substudy ( n = nmbr )-placebo ( n = nmbr )"
661,characteristic_name,"wml load baseline mri-total periventricular wml score , mean ( sd )-subcortical wml load diameter , mm , mean ( sd ) ""-wml load follow - mri-subcortical wml load diameter , mm , mean ( sd )"
662,characteristic_level,"none ""-total periventricular wml score , mean ( sd )-severe-subcortical wml load diameter , mm , , mean ( sd )-none-subcortical wml load diameter , mm , mean ( sd )-mild moderate"
663,arms,"placebo group ( n = nmbr ) ""-placebo group ( n = nmbr )-telmisartan group ( n = nmbr )"
664,measures,"percent patients ""-percent patients"
665,characteristic_name,"diabetes status , . ( % ) ""-eos serum k + , meq / l-diabetes status , . ( % )-baseline serum k + , meq / l"
667,other,"serum k + level drug treatment-serum k + level drug treatment """
668,characteristic_level,"baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l-baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr < nmbr . nmbr meq / l-baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l-baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l """
669,arms,"aml / hctz ( n = nmbr )-val / hctz ( n = nmbr )-aml / hctz ( n = nmbr ) """
670,outcomes,"sedbp ""-sedbp-sesbp"
671,arms,"om nmbr mg / hctz nmbr mg-om nmbr mg / aml nmbr mg / hctz nmbr mg ""-om nmbr mg / aml nmbr mg / hctz nmbr mg-aml nmbr mg / hctz nmbr mg-om nmbr mg / aml nmbr mg"
672,characteristic_level,"non - black ""-non - black-black"
673,measures,"n = nmbr ""-n = nmbr"
674,arms,"tofacitinib , nmbr mg ( n = nmbr ) ""-tofacitinib , nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
676,outcomes,"low - density lipoprotein cholesterol , % ""-nmbr - year framingham chd risk , %-low - density lipoprotein cholesterol , %-diastolic blood pressure , mm hg-total cholesterol , %-systolic blood pressure , mm hg"
677,characteristic_level,"diabetes-with diabetes ""-without diabetes"
678,measures,"difference ls meannmbr ( nmbr % cl ) ""-difference ls meannmbr ( nmbr % cl )"
679,characteristic_name,"concomitant drugs-time qualifying myocardial infarction "" ; na-time qualifying myocardial infarction"
680,characteristic_level,"weight < nmbr kg ""-hypertension-current smoker-aspirin-angiotensin - converting enzyme inhibitor angiotensin receptor blocker-white ethnic origin-diabetes mellitus-median age ( iqr ; years )-women-previous coronary revascularisation-< nmbr months-p blockers-nmbr - nmbr months-any peripheral arterial disease-weight < nmbr kg-thienopyridine-lipid - lowering drug-age > nmbr years-previous cerebrovascular event-hyperlipidaemia-> nmbr months"
681,arms,"placebo group ( n = nmbr ) ""-vorapaxar group ( n = nmbr )-placebo group ( n = nmbr )"
682,characteristic_name,"prior stent-planned thienopyridine enrollment-age-region-diabetes-egfr ( ml / min / nmbr . nmbrmnmbr )-age ""-sex-prior stroke tia-weight-qualifying myocardial infarction"
683,characteristic_level,"unknown-< nmbr yr ""-< nmbr-no-> = nmbr kg-> = nmbr yr-overall-> = nmbr-< nmbr kg-nstemi-stemi-asia-female-yes-< nmbr yr-australia / nz-europe nmbr-north america-latin america-male"
686,other,"study nmbr ""-study nmbr"
687,arms,"placebo n = nmbr ""-indacaterol n = nmbr-placebo n = nmbr"
689,other,"study nmbr ""-study nmbr"
690,characteristic_level,"gold iii - iv ""-gold ii-gold iii - iv"
691,arms,"placebo ""-indacaterol nmbr pg-placebo"
693,characteristic_level,"moderate copdb [n z nmbr]-severe copdc [n z nmbr]-moderate copdb [n z nmbr] """
694,arms,"indacaterol nmbr mg[n z nmbr] ""-indacaterol nmbr mg[n z nmbr]-placebo [n z nmbr]"
695,measures,"percent change "" ; na-absolute change-percent change"
696,outcomes,"tc / hdl - c-non - hdl - c-ldl - c-apob-total c-apob ""-triglyceride"
697,other,"baseline sitosterol ""-baseline sitosterol"
698,outcomes,"teaes *-muscle spasms-headache "" ; na-hvookalemia-discontinuations teaes-bronchitis-edema , peripheral-headache-drug - related teaes *-teaes ( > nmbr % treatment group ) *"
699,characteristic_name,"ckd ""-ckd-chronic cvd-diabetes"
700,arms,"om nmbr / aml nmbr /-om nmbr /-om nmbr / ""-aml nmbr /"
701,arms,"hctz ""-aml-hctz"
702,arms,"nmbr mg ""-nmbr mg"
703,arms,"conventional treatment ( n = nmbr )-monitoring ( n = nmbr )-monitoring ( n = nmbr ) """
704,characteristic_name,"n diabetes-no smo king-number ste "" "" > nmbr-men-age > nmbr-no acs-women-age > nmbr ""-bm < nmbr-age < nmbr-full po pulatio n-diabetes-smoking-acs-bmi > nmbr-number stent = nmbr"
706,characteristic_name,"n diabetes-no smo king-number ste "" "" > nmbr-men-age > nmbr-no acs-women-bm < nmbr-age < nmbr-full po pulatio n-diabetes-smoking-acs-bmi > nmbr-number stent = nmbr-bmi > nmbr """
708,other,"%-n-% """
709,characteristic_level,"ii-iii-not available-other-ventricular tachycardia fibrillation-others-warfarin-other cardiac surgery , n ( % )-iv-clopidogrel-heparin-atrial fibrillation-iii ""-ticlopidine-valve surgery , n ( % )-aspirin-coronary bypass , n ( % )-other supraventricular tachycardia"
710,characteristic_level,"italy ( n = nmbr )-nmbr ( n = nmbr )-usa ( n = nmbr )-female ( n = nmbr )-> nmbr . nmbrmmol / l ( n = nmbr )-> l : nmbrhrs : min ( n = nmbr )-> nmbr : nmbr hrs : min ( n = nmbr )-> nmbr servings / wk ( n = nmbr )-> nmbr mm ( n = nmbr )-yes ( n = nmbr )-> nmbr % ( n = nmbr )-yes ( n = nmbr ) ""-> nmbr years ( n = nmbr )"
712,measures,"pfor-events ( % ) ""-odds ratio-events ( % )"
714,characteristic_name,"blood pressure , mm-geographic site , %-geographic site , % "" ; na"
715,characteristic_level,"body mass index , kg / mnmbr-female , %-hbanmbrc , %-europe-glucose , mmol / l-fibrinogen , g / l-insulin , pmol / l-duration diabetes mellitus , y-americas-ldl - c , mmol / l-previous metformin use , %-diastolic-metformin dose , mg-systolic-age , y-asia-hdl - c , mmol / l-female , % ""-non - hdl - c , mmol / l-hscrp , mg / l-triglyceride , mmol / l-il - nmbr , ng / l-homa - ir-current smoker , %"
716,arms,"total group ( n = nmbr )-canakinumab dose ( per mo )-canakinumab dose ( per mo ) ""-placebo ( n = nmbr )"
717,arms,"nmbrmg ( n = nmbr )-nmbr mg ( n = nmbr )-nmbr mg ( n = nmbr ) """
718,outcomes,"fibrinogen-il - nmbr-crp ""-crp"
720,arms,"placebo ""-nmbrmg-canakinumab dose ( per month )-placebo"
721,arms,"nmbrmg-nmbrmg """
722,arms,"apixaban , nmbr mg ( n = nmbr ) ""-apixaban , nmbr . nmbr mg ( n = nmbr )-apixaban , nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
723,characteristic_level,"pe ( without dvt )-< nmbr yr-severe moderate-normal renal function-< nmbr kg ""-dvt only-nmbr < nmbr yr-female-male-> nmbr kg-> nmbr yr-mild-< nmbr kg"
724,arms,"apixaban , nmbr mg-apixaban , nmbr . nmbr mg ""-apixaban , nmbr . nmbr mg-placebo"
725,characteristic_name,"overall-weight ""-age-sex-level renal impairment-index event-weight"
726,arms,"apixaban-apixaban ""-placebo"
727,measures,". patients-no . events-no . patients """
728,characteristic_name,"pah origin / cause-pah origin / cause ""-race"
729,characteristic_level,"age , y-white-not provided-who functional class ii / iii-nmbrmwd , m-cvd ""-ipah / hpah-years since pah diagnosis-asian *-female-cvd-hiv-black-native american-repaired chd"
730,other,"mitt population-itt population-mitt population """
731,arms,"placebo ( n = nmbr ) ""-oral treprostinil ( n = nmbr )-placebo ( n = nmbr )"
732,characteristic_level,"missing-white-other-female-male-black-missing ""-> nmbr mg / g-nmbr - nmbr mg / g-< nmbr mg / g"
733,characteristic_name,"msdbp , mm hg ""-nmbr - hour madbp , mm hg-bmi , kg / mnmbr uac , . ( % )-mssbp , mm hg-msdbp , mm hg-nmbr - hour masbp , mm hg-race , . ( % )-age , sex , . ( % )"
734,arms,"valsartan ( n = nmbr ) ""-valsartan ( n = nmbr )-aliskiren / valsartan ( n = nmbr )"
735,characteristic_name,"serum potassium , meq / l-bun , mg / dl-egfr , ml / min / nmbr . nmbr mnmbr-serum creatinine , mg / dl-serum potassium , meq / l """
737,characteristic_name,"uac nmbr - nmbr mg / g-overall-uac =-uac > nmbr mg / g-nmbr mg / g-uac > nmbr mg / g """
738,arms,"/ v ( n = nmbr ) v ( n = nmbr )-a / v ( n = nmbr )-v ( n = nmbr )-a / v ( n = nmbr ) v ( n = nmbr ) """
739,characteristic_name,"mean dlqi score ( nmbr % ci )-mean dlqi score ( nmbr % ci ) ""-characteristic-mean sfnmbr score ( nmbr % ci )"
740,characteristic_level,"symptoms feelings-physical role-mean bmi ( nmbr % ci )-work school-physical component summary-mean involved bsa , % ( nmbr % ci )-mean pasi score ( nmbr % ci )-mental health-mental component summary-treatment satisfaction-total score-general health-personal relationships-physical functioning-daily activities-mean age , years ( nmbr % ci )-emotional role-social functioning-caucasian , n ( % )-mean eq - nmbrd response ( nmbr % ci )-vitality-bodily pain-mean ham - score ( nmbr % ci )-work school ""-leisure-male , n ( % )"
741,arms,"psa ( n = nmbr )-psa ( n = nmbr ) ""-no psa ( n = nmbr )"
742,characteristic_name,"race , n ( % ) ""-race , n ( % )-concomitant asthma medications , n ( % )-sex , n ( % )"
743,characteristic_level,"mean ( sd ) total asthma symptom scores-white-mean eosinophil count , per ml-mean ( sd ) feno , ppb-mean prebronchodilator fevnmbr ( sd ) , % predicted-female-mean ( sd ) age , yr-hospitalized asthma , n ( % ) *-mean ( sd ) periostin , ng / ml-mean total serum ige ( sd ) , iu / ml-mean prebronchodilator fevnmbr ( sd ) , % predicted ""-mean ( sd ) number albuterol per day , puff-mnmbr subgroup-mean body weight ( sd ) , kg-mean ( sd ) aqlq-mean ( sd ) number exacerbations *"
744,characteristic_name,"low feno subgroup ( , nmbr . nmbr ppb ) ( n = nmbr )-high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr )-low periostin subgroup ( , nmbr ng / ml ) ( n = nmbr )-high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr )-low eosinophil subgroup ( , nmbr / ml ) ( n = nmbr )-high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr ) ""-high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr )"
745,outcomes,"change baseline % predicted fevnmbr ""-change baseline % predicted fevnmbr-total asthma symptom score-aqlq score-albuterol use"
746,characteristic_name,"high subgroup ""-high subgroup-low subgroup"
747,arms,"cangrelor ( n = nmbr )-clopidogrel ( n = nmbr )-clopidogrel ( n = nmbr ) """
749,characteristic_name,"killip class-age-time randomization-place randomization-hypertension-diabetes-weight-timi risk score-sex ""-time randomization-sex-infarct location-systolic blood pressure"
750,characteristic_level,"amendment-> nmbr mm hg-< nmbr-no-> nmbr kg-after amendment-nmbr < nmbr hr-< nmbr mm hg-community hospital-> nmbr-< nmbr kg-nmbr < nmbr kg-anterior-female-male ""-ii - iv-yes-i-< nmbr yr-overall event rate-ambulance-other-male-inferior-> nmbr yr-> nmbr hr-nmbr < nmbr mm hg"
752,characteristic_name,"antianginal medications-antianginal medications """
753,characteristic_level,"men-ace - l / arbs-hypertension-prior angioplasty-antidiabetic medication-white-age , yrs-calcium - channel blockers-baseline systolic blood pressure ( mm hg )-beta - blockers ""-baseline diastolic blood pressure ( mm hg )-prior bypass graft surgery-long - acting nitrates-hbalc , %-statins-beta - blockers-baseline heart rate ( beats / min )-antiplatelet agents-prior myocardial infarction-dyslipidemia-current smoking-insulin-duration diabetes , yrs-on nmbr"
754,arms,"ranolazine ( n = nmbr ) placebo ( n = nmbr ) ""-ranolazine ( n = nmbr ) placebo ( n = nmbr )"
755,characteristic_name,"islander-experience-chads score-experience ""-mellitus"
756,characteristic_level,"hispanic / latino-no-nmbr-history diabetes ""-> nmbr yr warfarin experience-age , yrs-race / ethnicity-history hypertension-height , inches-black / african american-history cad-caucasian-warfarin naive-female-asian-sex-hawaiian / pacific-yes-chads score-weight , lbs-> nmbr days warfarin-other-male-history diabetes"
758,characteristic_level,"australia-north america-europe-south america-australia ""-india"
759,characteristic_name,"hyperlipidemia-microalbuminuria macroalbuminuria-statin-average maximum far wall cimt ( mm )-hypertension-average maximum common carotid cimt ( mm )-triglycerides ( mmol / l )-serum creatinine ( gmol / )-ankle / brachial index-total cholesterol ( mmol / l )-sulfonylurea-anticoagulant-metformin-other oral hypoglycemic drug ( )-glycated hemoglobin ( % )-prior new diabetes-geographic distribution - . ( % )-diastolic blood pressure-average maximum common bifurcation cimt ( mm )-body mass index ( kg / mnmbr )-urinary albumin : creatinine ratio *-heart rate ( beats per minute )-fasting plasma glucose ( mmol / l )-ace inhibitor arb-mean age ( years )-systolic blood pressure ( mmhg )-geographic distribution - . ( % ) ""-calcium channel blocker-impaired glucose tolerance impaired fasting glucose-beta - blocker-asa antiplatelet agent-average maximum cimt ( mm )-estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr )-current smoking-thiazide diuretic-dietary epa - dha intake ( mg / day ) *-hdl - cholesterol ( mmol / l )-prior cardiovascular event "" "" ' "" ""-ldl - cholesterol ( mmol / )-women - . ( % )"
760,arms,"insulin glargine ( n = nmbr )-n - nmbr fatty acids ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) ""-standard care ( n = nmbr )"
761,characteristic_name,"fascng plasma glucose medan-ageadj-age < nmbr-no previous cv event-stalin-no statin-overall-previous cv event-tnglycendes < median-maximum cimt med an-fastng plasma glucose < median-diabetes ""-female-diabetes-hbalc < medan-maximum cimt < median-no diabetes-tngtycendes median-ace - / arb-male-no ace - / arb-hbalca median"
762,characteristic_name,"dabetes-age nmbr-age < nmbr-no previous cv event-tngtycerides median-hbalc < median-overall-previous cv event-maximum cimt med an-no ststm-female-tngtycerides < median-maximum cimt < median-no diabetes-fasting plasma glucose < median-fasting plasma glucose nmbr medan-llv wlalil nmbr statin-dabetes ""-ace - / arb-male-no ace - / arb-hbalca median"
763,characteristic_name,"urine acr ( mg / g )-waist - - hip , male-statin-hypertension-nmbr - h pg ( mmol / l )-current smoker-age ( years )-> nmbr years education-randomized-ldl ( mmol / l )-total cholesterol-depression-p - blocker-waist - - hip , female-omega - nmbr fa-bmnmbr ( kg / mnmbr )-sbp ( mmhg )-females-hdl ( mmol / l )-tg ( mmol / l )-weight ( kg )-abi < nmbr . nmbr-anmbrc ( % )-egfr ( ml / min )-thiazide-alt ( units / l )-anmbrc ( mmol / mol )-prior cv event-fpg ( mmol / l ) ""-ace - / arb-fpg ( mmol / l )-dbp ( mmhg )-grip strength ( kg )-> nmbr drinks / week"
764,arms,"overall-standard therapy-standard therapy ""-glargine"
766,characteristic_name,"gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr )-frailty status ""-frailty status-race"
767,characteristic_level,"duration type nmbr diabetes ( years )-missing-men-white-fasting plasma glucose ( mmol / l )-moderate ( > nmbr < nmbr )-other-normal ( > nmbr )-mild ( > nmbr < nmbr )-no-systolic blood pressure ( mm hg )-body - mass index ( kg / mnmbr )-range-missing ""-hbanmbrc ( % )-age ( years )-yes-diastolic blood pressure ( mm hg )"
768,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-vildagliptin ( n = nmbr )"
769,characteristic_name,"hbanmbrc levels ""-hbanmbrc levels-frailty status-age ( years )"
770,characteristic_level,"snmbr %-> nmbr %-non - frail-frail-< nmbr-> nmbr % ""-> nmbr"
771,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-vildagliptin ( n = nmbr )"
772,characteristic_name,"post - bronchodilator-concomitant medications , %-concomitant medications , % ""-smoking status-gold stage , %-pre - bronchodilator"
773,characteristic_level,"fevnmbr / fvc-saaca-sabaa-male , %-fevnmbr , % predicted-labaa-history , pack - years-labaa ""-iv-sgrq total score , units-theophylline compound-icsa-age , y-current smokers , %-laaca-fevnmbr , l-ii-iii-ocs-bmi , kg / mnmbr-copd duration , y-fvc , l"
774,arms,"control ( n z nmbr )-tiotropium ( n z nmbr )-control ( n z nmbr ) """
775,characteristic_level,"< nmbr ( n z nmbr )-< nmbr ( n = nmbr )-nmbr < nmbr ( n = nmbr )-iorii ( n z nmbr )-western europe ( n = nmbr )-latin america ( n = nmbr )-control ( n z nmbr )-male ( n z nmbr )-iv ( n z nmbr )-< nmbr ( n z nmbr ) ""-usa ( n = nmbr )-> nmbr ( n = nmbr )-eastern europe ( n = nmbr )-iii ( n z nmbr )-current smoker ( n z nmbr )-nmbr < nmbr ( n z nmbr )-tiotropium ( n z nmbr )-female ( n z nmbr )-ex - smoker ( n z nmbr )-asia ( n = nmbr )"
776,characteristic_name,"age , y-smoking status-region-copd severity ( gold stage )-bronchodilator response , ml-treatment arm-sex-age , """
777,outcomes,"mean - sd change pre - bronchodilator fevnmbr , l ""-mean - sd change pre - bronchodilator fevnmbr , l"
778,characteristic_name,"smokers , n ( % )-smokers , n ( % ) """
779,characteristic_level,"bmi ( kg / mnmbr )-former-age ( years )-map ( mmhg )-hdl cholesterol ( mg / dl )-never-sbp ( mmhg ) ""-serum creatinine ( mg / dl )-n-glucose ( mg / dl )-sbp ( mmhg )-uae ( p , g / min )-mmol / mol-diabetes duration ( years )-total cholesterol ( mg / dl )-triglycerides ( mg / dl )-hbalc ( % )-sex ( male ) , n ( % )-dbp ( mmhg )-ldl cholesterol ( mg / dl )-current"
780,characteristic_name,"pro / pro homozygotes-ala carriers-pro / pro homozygotes """
781,outcomes,"composite events-cvd events-renal events-cvd events """
782,arms,"acei vs . non - acei ""-acei vs . non - acei"
783,characteristic_name,"pro / pro homozygotes-ala carriers-pro / pro homozygotes """
784,measures,"p-hr ( nmbr % ci )-p """
785,characteristic_name,"anmbrc distribution ( % )-anmbrc distribution ( % ) "" ; na-race"
786,characteristic_level,"american indian native alaskan-white-known duration type nmbr diabetes ( years )-> nmbr . nmbr % = nmbr . nmbr %-received oral aha within nmbr weeks prior screening "" ; na-asian-= nmbr . nmbr %-multi - racial-received oral aha within nmbr weeks prior screening-black african american-native hawaiian pacific islander-> nmbr . nmbr %"
787,arms,"sita nmbr ""-sita nmbr-sita nmbr + pio nmbr-pio nmbr"
788,measures,"baseline-n-change baseline "" ; na-change baseline"
789,characteristic_level,"anmbrc baseline < nmbr . nmbr %-anmbrc baseline = nmbr . nmbr %-anmbrc baseline < nmbr . nmbr % """
790,arms,"sita / pio nmbr / nmbr-sita nmbr-pio nmbr ""-pio nmbr"
791,characteristic_name,"race ""-time since diagnosis type nmbr diabetes-sex-race"
792,characteristic_level,"american indian / alaska native-> nmbr years-bmi ( kg / mnmbr )-american indian / alaska native ""-body weight ( kg )-age ( years )-# nmbr year-number patients-white-sbp ( mmhg )-black / african american-> nmbr - nmbr years-asian-female-egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] )-mdg ( mmol / l )-male-fpg ( mmol / l )-hbanmbrc ( % )-dbp ( mmhg )"
793,arms,"pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % )-placebo-placebo ""-empagliflozin nmbr mg-o total randomized"
794,arms,"empagliflozin nmbr mg-empagliflozin nmbr mg ""-placebo"
795,arms,"total ( n = nmbr )-total ( n = nmbr ) ""-vedolizumab"
796,other,"combined ( n = nmbr )-combined ( n = nmbr ) ""-cohort nmbr ( n = nmbr ) f-cohort nmbr ( n = nmbr )"
797,characteristic_name,"duration ulcerative colitis-age-stratification variables-extent disease-prior treatment historynmbr-baseline composite mayo clinic score ""-sex-baseline composite mayo clinic score-baseline fecal caicrctectin"
798,characteristic_name,"geographic region-race ""-chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr )-race-pre - enrollment antihyperglycemic therapy"
799,characteristic_level,"urinary albumin : creatinine ratioa ( mg / g )-urinary protein : creatinine ratioa ( mg / mg )-men-europe-stage nmbrb : > = nmbr < nmbr-stage nmbra : > = nmbr < nmbr-fpg ( mg / dl )-stage nmbr : > = nmbr-age ( years )-white-african american-n-women-stage nmbr : < nmbr-bmi , xnmbr kg / mnmbr-weight ( kg )-thiazolidinedione based-patients diabetic nephropathy-sulfonylurea based-northamerica-asian-insulin based-duration diabetes ( years )-asia / pacific-other-latin america-hbanmbrc ( % )-fpg ( mg / dl ) """
800,arms,"dapagliflozin nmbrmg-dapagliflozin nmbrmg ""-dapagliflozin nmbr mg-placebo"
801,arms,"dapagliflozin nmbr mg ""-dapagliflozin nmbr mg"
802,characteristic_name,"stage nmbra : egfr > = nmbr < nmbr ml / min per nmbr . nmbr mnmbr-stage nmbrb : egfr > = nmbr < nmbr ml / min per nmbr . nmbr mnmbr ""-stage nmbrb : egfr > = nmbr < nmbr ml / min per nmbr . nmbr mnmbr"
803,outcomes,"hbanmbrc ( % ) ""-weight ( kg )-hbanmbrc ( % )-fpg ( mg / dl )"
804,measures,"n-difference placebo ""-difference placebo"
805,characteristic_name,"concomitant medication , n ( % )-comorbidites , n ( % )-disease location , % ""-disease location , %"
806,characteristic_level,"hyperlipidemia-endoscopy subscore-hypertension-uc duration , , mean ( range )-corticosteroid - azathioprine / nmbr - mercaptopurine-aminosalicylates-men , %-asthma-mayo score , mean ( sd )-gastroesophageal reflux disease-rectal bleeding subscore-weight , kg , median ( range )-corticosteroid azathioprine / nmbr - mercaptopurine-mayo score , mean ( sd ) ""-azathioprine / nmbr - mercaptopurine-age , median ( range )-diabetes-crp , nmol / l , median ( range )-prior therapy tnf antagonist , n ( % )-partial mayo score , mean ( sd )-anemia-pga subscore-oral corticosteroid-stool frequency subscore-pancolitis"
807,arms,"adalimumab ( n = nmbr )-adalimumab ( n = nmbr ) ""-placebo ( n = nmbr )"
808,characteristic_name,"clinical presentation-randomization-> nmbr ml-medications discharge-angiographic data treatment :-pci data-blockers ""-> nmbr ( ml ) additional angiography-> nmbr mg / dl-time intervals , h-medications coronary angiography-first procedure-distribution time-risk factors-blockers-laboratory variables baseline"
809,characteristic_level,"unstable angina-ecrcl , ml / min-cabg-contrast nephropathy risk score-score distribution : < nmbr-previous ml-calcium channel blockers-hypertension-ef < nmbr %-nste - mi-contrast volume ( ml )-glycemia , mg / dl-within nmbr h after-diabetes mellitus-haemoglobin , mg / dl-total cholesterol-symptom onset - --hospital stay ( days )-triglycerides , mg / dl-hdl cholesterol , mg / dl-age , yrs-active smoking-egfr , ml / min / mnmbr-ldl cholesterol , mg / dl-previous pci cabg-ck - mb , ng / ml-> nmbr-randomization - --egfr < nmbr , ml / min / mnmbr-management distribution medical treatment-ecrcl < nmbr ml / min-angiotensin receptor-contrast volume , ml-nitrates-after nmbr h-within nmbr h-beta - blockers-serum creatinine , mg / dl-ace inhibitors-contrast volume-age > nmbr yrs-ctn - l , ng / ml-diuretics-high - risk clinical features-baseline lvef , %-pci-calcium channel-multivessel pci-gp llb / llla inhibitors-bmi , kg / mnmbr-multivessel disease-male-nitrates ""-nmbr - nmbr"
811,characteristic_level,"> nmbr ml-> nmbr %-< nmbr ml / min-< nmbr ml-male-female-no-< nmbr-yes ""-< nmbr yrs-> nmbr yrs-< nmbr %-> nmbr ml / min-yes-> nmbr"
812,characteristic_name,"diabetes mellitus-ci - aki risk score-pci-age-high risk-sex-baseline ecrcl-diabetes mellitus ""-contrast volume-baseline lvef"
814,characteristic_name,"type drug - eluting stent , n ( % ) ""-clinical indication index procedure , n ( % )-discharge medication , n ( % )-type drug - eluting stent , n ( % )"
815,arms,"aspirin alone ( n = nmbr )-clopidogrel + aspirin ( n = nmbr )-clopidogrel + aspirin ( n = nmbr ) """
816,characteristic_name,"cohort-type des ""-multivessel stenting-age-ejection fraction-type des-diabetes-left main disease-acute coronary syndrome-time randomization-sex-bifurcation"
817,arms,"nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr )-nmbr . nmbr ""-nmbr . nmbr-aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr-aspirin alone ( n = nmbr ) nmbr . nmbr"
818,characteristic_name,"lung function , mean-copd severity , n ( % ) ""-smoking status , n ( % )-race , n ( % )-copd severity , n ( % )"
819,characteristic_level,"prebronchodilator fevnmbr , l-postbronchodilator fevnmbr , l-moderate ""-former-age , mean-concomitant treatment-white-moderate-asian-black-very severe-with laba , n ( % ) pretreatment-severe-other-postbronchodilator fevnmbr , % predicted-prebronchodilator fevnmbr , % predicted-mild-male , n ( % )-current"
820,characteristic_name,"geographic region-age-smoking status ""-pretreatment / concomitant treatment-smoking status-copd severity"
821,characteristic_level,"+ ics / + laba nz nmbr-very severe n z nmbr-moderate n z nmbr-severe n z nmbr-- ics / + laba n z nmbr-north america n z nmbr-< nmbr years n z nmbr-current n z nmbr-former n z nmbr ""-rest world n z nmbr-former n z nmbr-europe n z nmbr-> nmbr years n z nmbr"
822,characteristic_level,"caucasian-severe-other-moderate-ex - smoker-asian-black-current smoker ""-> nmbr exacerbations-nmbr exacerbations-current smoker-very severe"
823,characteristic_name,"ics use baseline , n ( % )-mean ( sd ) fevnmbr ( l ) post - bronchodilator-smoking history , n ( % )-gender , n ( % ) male-copd exacerbation history , n ( % )-mean ( sd ) post - bronchodilator fevnmbr reversibility , %-severity disease ( gold nmbr ) , n ( % )-mean ( sd ) body mass index , kg / mnmbr-mean ( sd ) duration smoking , pack years-mean ( sd ) post - bronchodilator fevnmbr percentage predicted-mean ( sd ) fevnmbr ( l ) post - bronchodilator ""-mean ( sd ) age , years-mean ( sd ) duration copd , years-mean ( sd ) post - bronchodilator fevnmbr / fvc , %-mean ( sd ) fevnmbr ( l ) pre - bronchodilator-ethnicity , n ( % )"
824,arms,"placebo ( n = nmbr ) ""-tiotropium nmbrmg ( n = nmbr-glycopyrronium nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
826,arms,"losartan plus lisinopril ( n = nmbr )-losartan plus placebo ( n = nmbr )-losartan plus lisinopril ( n = nmbr ) """
827,characteristic_level,"hyperlipidemia-other ""-prior myocardial infarction-other-magnetic resonance angiography-history heart failure-bilateral disease ( % ) ' j ' ' j '-smoking past yr-% stenosis , assessed investigator-global ischemia ( % ) * *-diabetes-duplex ultrasonography-black-computed tomographic angiography-angiography-% stenosis , assessed core laboratory"
828,arms,"medical therapy ( n = nmbr ) ""-stenting plus medical therapy ( n = nmbr )-medical therapy ( n = nmbr )"
829,characteristic_level,"hypertension-nmbr-triglycerides-myocardial infarction-present smokerc-aspirin-clopidogrel , ticlopidine , prasugrel-cabg surgery-unstable angina ( biomarker negative )-white-p - blocker-ldl - c-hdl - c-hypercholesterolemia-australia new zealand-nstemi-ace inhibitor arb-asia-stemi-triglycerides ""-otherb-asian-diabetes-black-western europe lebanon-metabolic syndrome-pci-peripheral arterial disease-eastern europe-north america-stroke"
830,characteristic_name,"region enrollment-concomitant atorvastatin dose , mg-age , mean ( sd ) , y-pci cabg surgery index event-cardiovascular disease history-index diagnosis-c - reactive protein , median ( iqr ) , mg / l-prior lipid - modifying therapy-race / ethnicity-c - reactive protein , median ( iqr ) , mg / l ""-cardiovascular risk factors-index event randomization , median ( iqr ) , h-medications randomization-( sd ) , mg / dl-female sex-body mass index , mean ( sd )"
831,arms,"varespladib ( n = nmbr )-varespladib ( n = nmbr ) ""-placebo ( n = nmbr )"
832,characteristic_name,"race , n ( % ) ""-race , n ( % )-country , n ( % )"
833,characteristic_level,"white-african american-russia-australia-other-ukraine-asian-germany-poland-japan-african american ""-united states-argentina-philippines-mexico-romania"
835,characteristic_level,"mdi / hfa , n-dpi ( diskus ) , n-handihaler , n-diskus , n-handihaler diskus , n-mdi / hfa , n """
836,characteristic_name,"duration disease , years-self - reported disease severity , nmbr - nmbr scale *-age , years-current inhaler + ""-current inhaler +"
837,characteristic_level,"copd population ( n = nmbr ) ""-copd population ( n = nmbr )-asthma population ( n = nmbr )"
838,characteristic_name,"race , %-age group , n ( % )-severity copd * , n ( % )-severity copd * , n ( % ) "" ; na-ethnicity , n ( % )"
839,characteristic_level,"> nmbr years-smoking history , pack - years-age , years ""-male / female , %-smokers , %-age , years-indian ( indian subcontinent )-< nmbr years-caucasian-fevi , % predicted *-moderate-asian-duration copd , years-chinese-severe-other-ics use , %-fevi , l *-fevnmbr / fvc , % *-reversibility salbutamol , %"
841,characteristic_level,"smokers ""-> nmbr %-ex - smokers-severe-moderate-no-< nmbr %-chinese-yes-smokers"
842,characteristic_name,"ethnicity-saba reversibility-theophylline use screening-ics use-smoking history-smoking history ""-copd severity"
843,arms,"indacaterol nmbr ug versus indacaterol nmbr ug ""-indacaterol nmbr ug versus indacaterol nmbr ug-indacaterol nmbr ug versus placebo-n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo )"
844,characteristic_name,"smoking history , n ( % )-severity airflow limitation ( gold nmbr ) , n ( % )-baseline copd exacerbation history , * n ( % )-ethnicity , n ( % ) ""-ethnicity , n ( % )"
845,characteristic_level,"caucasian-$ nmbr exacerbations-severe-other-moderate-ex - smoker-native american-nmbr exacerbations-current smoker-nmbr exacerbation-native american """
846,arms,"ind + pbo ( n = nmbr ) ""-ind + gly ( n = nmbr )-ind + pbo ( n = nmbr )"
848,characteristic_level,"symbol digit score-< nmbr-nmbr-age onset , y-pdqol scale-total-male sex-> nmbr-adl-age , y-duration pd , y-duration pd , ""-diagnosed , y-hoehn yahr stage-modified se - adl scale-motor-white race-mental-age diagnosis , y-modified rankin score-nmbr - nmbr"
849,characteristic_name,"continuous variables , mean ( sd ) ""-continuous variables , mean ( sd )-no . ( % ) participants"
850,measures,"treatment group-treatment group ""-pvalue"
851,arms,"coenzyme qnmbr ""-coenzyme qnmbr"
852,measures,"nmbr mg ( n = nmbr )-nmbr mg ( n = nmbr ) """
855,characteristic_name,"digit symbol substitution-sex ""-sex-education *-mini - mental state examination-ethnic origin"
856,arms,"placebo ( n = nmbro )-omega - nmbr fatty acid ( n = nmbr )-standard care ( n = nmbr )-insulin glargine ( n = nmbrll )-overall ( n = unmbr )-overall ( n = unmbr ) """
857,outcomes,"b digit symbol substitution , insulin glargine vs standard care-a mini - mental state examination , insulin glargine vs standard care-b digit symbol substitution , insulin glargine vs standard care """
860,outcomes,"b digit symbol substitution , omega - nmbr fatty acids vs placebo ""-a mini - mental state examination , omega - nmbr fatty acids vs placebo-b digit symbol substitution , omega - nmbr fatty acids vs placebo"
863,characteristic_name,"drug treatment ( % )-body weight ( kg )-age ( years )-fasting plasma glucose ( mg / dl )-hdl cholesterol ( mg / dl )-na ( mmol / l )-history peripheral arterial disease ( % )-history stroke ( % )-diastolic bp ( mm hg )-triglyceride ( mg / dl )-pulse rate ( bpm )-body mass index ( kg / mnmbr )-history myocardial infarction ( % )-k ( mmol / l )-men ( % )-total cholesterol ( mg / dl )-alcohol intake ( + ) ( % )-positive family history type nmbr diabetes ( % )-systolic bp ( mm hg )-egfr ( mumin / nmbr . nmbr mnmbr )-current smoker ( % )-body mass index ( kg / mnmbr ) ""-left ventricular hypertrophy ( % )-hbanmbrc ( % )-uric acid ( mg / dl )"
864,arms,"diuretics group ( n = nmbr )-no - diuretics group ( n = nmbr ) ""-no - diuretics group ( n = nmbr )"
866,arms,"non diuretics-non diuretics """
868,characteristic_name,"calcium - channel inhibitor-statin-hypertension-left main-current smoker-age years-coronary artery bypass graft-women-prior stroke-high - treatment platelet reactivity *-drug - eluting stent implanted-p blockers-left anterior descending-dyslipidaemia-circumflex-second - generation stent-body weight index ( kg / mnmbr )-diabetes-proton - pump inhibitors-circumflex ""-older nmbr years-ace inhibitors-right coronary artery-first - generation stentt-prior myocardial infarction-prior heart failure-prior coronary artery bypass graft-prior percutaneous coronary intervention"
869,arms,"interruption ( n = nmbr ) ""-continuation ( n = nmbr )-interruption ( n = nmbr )"
870,characteristic_level,"smoking-diabetes ""-age > nmbr-men-no acs-bmi < nmbr-aqc < nmbr-diabetes-smoking-acs-bmi > nmbr-number stent > nmbr-full population-woman-number stent = nmbr-no diabetes"
872,measures,"%-n-% """
873,characteristic_level,"smoking-age > nmbr-men-no acs-bmi < nmbr-aqc < nmbr-diabetes-smoking-acs-bmi > nmbr-number stent > nmbr-full population-woman-number stent = nmbr-aqc < nmbr ""-no diabetes"
875,characteristic_name,"place randomization-time randomization symptom onset-place randomization "" ; na-infarct location"
876,characteristic_level,"> nmbr h , n ( % )-community hospital , n ( % )-other ( n , % )-nmbr < nmbr h , n ( % )-inferior ( n , % )-anterior ( n , % )-> nmbr < nmbr h , n ( % )-ambulance , n ( % )-community hospital , n ( % ) "" ; na"
877,arms,"pharmaco - invasive ( n = nmbr )-primary pci ( n = nmbr )-pharmaco - invasive ( n = nmbr ) """
878,characteristic_level,"inferior ( % )-nmbr - < nmbr ( % )-before amendment ( % )-> = nmbr * ( % )-nmbr < nmbr ( % )-after amendment ( % )-> = nmbr ( % )-female ( % )-community hospital ( % )-no ( % )-male ( % )-ii - iv ( % )-< nmbr { % )-yes ( % )-< nmbr ( % ) ""-< nmbr ( % )-ambulance ( % )-l ( % )-anterior { % )"
879,characteristic_name,"time randomization ( interaction : p = nmbr . nmbr )-previous ml ( interaction : p = nmbr . nmbr )-infarct location ( interactsn $ : p = nmbr . nmbr ) ""-infarct location ( interactsn $ : p = nmbr . nmbr )-age [years] ( interaction : p = nmbr . nmbr )-p lace randomization ( interaction : p = nmbr . nmbr )-sex ( interaction : p = nmbr . nmbr )-systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr )-killip class ( interaction : p = nmbr . nmbr )-timi risk score ( interaction : p = nmbr . nmbr )-time randomisation [hours] ( interaction : p = nmbr . nmbr )"
880,arms,"- hospital ticagrelor ( n = nmbr )-in - hospital ticagrelor ( n = nmbr ) ""-prehospital ticagrelor ( n = nmbr )"
882,arms,"( nmbr % cl )-pre - h-in - h-or ( nmbr % cl ) """
883,arms,"ivabradine ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
884,characteristic_name,"angina class baseline-age-beta - blocker use randomization-heart rate-previous myocardial infarction-previous coronary revascularization-sex-heart rate ""-history diabetes"
885,characteristic_level,"< nmbr beats / min ""-< nmbr yr-> nmbr beats / min-class > nmbr-< nmbr beats / min-no-male-female-> nmbr yr-yes-class nmbr symptoms"
886,other,"p value ""-p value"
888,characteristic_name,"baseline pre - bronchodilator fevnmbr , l-body mass index , kg / mnmbr-non - reversible ( % )-reversible ( % )-age , years-white race , n ( % )-smoking pack - years-female sex , n ( % )-duration copd , years-baseline % predicted fevnmbr-fevnmbr % reversibility-baseline % predicted fevnmbr ""-both ( % )-emphysema ( % )-chronic bronchitis ( % )"
890,characteristic_level,"class iii aad use nmbr months enrollment-hypertension-coronary disease-age , yrs-persistent af-sinus rhythm baseline-acei arb-left atrial dimension , cm-nmbr - lead ecg heart rate , beats / min-diabetes-female-beta - blockers-left ventricular hypertrophy echo-waist circumference , cm-valvular disease-paroxysmal af-persistent af ""-bmi , kg / mnmbr-class l / heart failure-time since first af diagnosis , yrs-oral anticoagulant"
891,characteristic_name,"cardiac echocardiography parameters-concomitant medications-left ventricular ejection fraction , % af history-left ventricular ejection fraction , % af history ""-demographic medical variables"
892,arms,"placebo ( n = nmbr ) ""-fish oil ( n = nmbr )-placebo ( n = nmbr )"
893,characteristic_level,"triglycerides ( mmol / l )-apolipoprotein b ( g / l )-apolipoprotein anmbr ( g / l )-hdl cholesterol ( mmol / l )-apolipoprotein b ( g / l ) ""-> nmbr - nmbr mmol / l-< nmbr - nmbr mmol / l-lipoprotein ( ) ( nmol / l )"
894,characteristic_name,"coronary artery disease-ldl cholesterol baseline ( mmol / l ) * ldl cholesterol screening-unbound pcsknmbr ( nmol / l )-age ( years )-hscrp ( nmol / l )-female sex-other lipid parameters ""-other lipid parameters"
895,arms,"evolocumab nmbr mg every nmbrweeks ( n = nmbr )-placebo monthly ( n = nmbr )-evolocumab nmbr mg monthly ( n = nmbr )-evolocumab nmbr mg monthly ( n = nmbr ) ""-placebo every nmbr weeks ( n = nmbr )"
896,measures,"duration diabetes , years-> = nmbr % < nmbr % ( > = nmbrand < nmbr mmol / mol )-white-african american-ppg , mg / dl-fpg , mg / dl-women-other-hbanmbrc , %-< nmbr % ( nmbr mmol / mol )-fasting c - peptide , ng / ml-age , years-asian-bmi , kg / mnmbr-ppg , mg / dl ""-egfr , * ml / min / nmbr . nmbr mnmbr-> = nmbr % ( nmbr mmol / mol )-hbanmbrc , mmol / mol"
898,characteristic_level,"> nmbr % < nmbr % ( > nmbr < nmbr mmol / mol )-< nmbr % ( < nmbr mmol / mol )-> nmbr % ( > nmbr mmol / mol )-< nmbr % ( < nmbr mmol / mol ) """
899,measures,"baseline mean ( sd ) , % [mmol / mol]-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol] ""-mean ( nmbr % ci ) difference vs saxa + dapa + met-n *-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol]"
900,arms,"dapa + met n = nmbr-saxa + met n = nmbr ""-saxa + dapa + met n = nmbr-saxa + met n = nmbr"
901,characteristic_level,"< nmbr ""-> nmbr-< nmbr"
902,measures,"baseline mean ( sd ) , % [mmol / mol]-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol] ""-mean ( nmbr % ci ) difference vs saxa + dapa + met-n *-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol]"
903,arms,"dapa + met n = nmbr-saxa + met n = nmbr ""-saxa + dapa + met n = nmbr-saxa + met n = nmbr"
904,characteristic_level,"< nmbr % ( nmbr mmol / mol ) ""-> nmbr % ( > nmbr mmol / mol )-> nmbr % < nmbr % ( > nmbr nmbr mmol / mol )-< nmbr % ( nmbr mmol / mol )"
905,measures,"baseline mean ( sd ) , % [mmol / mol]-proportion ( nmbr % ci ) adjusted baseline hbanmbrc , % ""-proportion ( nmbr % ci ) adjusted baseline hbanmbrc , %-mean ( nmbr % ci ) difference vs saxa + dapa + met-x / n *"
906,arms,"dapa + met n = nmbr-saxa + met n = nmbr ""-saxa + dapa + met n = nmbr-saxa + met n = nmbr"
907,arms,"abatacept plus mtx ( n = nmbr )-total ( n = nmbr )-abatacept monotherapy ( n = nmbr )-mtx ( n = nmbr )-total ( n = nmbr ) """
908,characteristic_name,"erosion-pain ( nmbr mm vas )-symptom duration ""-dasnmbr ( crp )-synovitis-symptom duration-osteitis-haq - di , number ( % )"
909,arms,"abatacept monotherapy ( n = nmbr )-mtx ( n = nmbr )-abatacept plus mtx ( n = nmbr )-abatacept monotherapy ( n = nmbr ) """
910,characteristic_name,"race / ethnicity , . ( % )-region enrollment , . ( % )-previous warfarin use , . ( % )-previous warfarin use , . ( % ) ""-chadsnmbr scoreb-classification af , . ( % )-score , . ( % )-onsetofaf , . ( % )-blood pressure , mean ( sd ) [range] , mm hg-risk factors stroke , . ( % )"
911,characteristic_level,"unknown-persistent-age , mean ( sd ) [range] , y-no estimate-hispanic / latino-europe-nmbr-paroxysmal-mean ( sd ) [range]-body mass index , mean ( sd ) [range]a-lv ejection fraction , mean ( sd ) [range] , %-white-history hypertension-united states-black / african american-diastolic-systolic-heart rate , mean ( sd ) [range] , beats / min-previous ischemic stroke ortia-asian-diabetes-male sex , . ( % )-nmbry-permanent-other-nmbry ""-age nmbr y-< nmbry-hawaiian pacific islander-congestive heart failure"
912,arms,"device group ( n = nmbr )-warfarin group ( n = nmbr ) ""-warfarin group ( n = nmbr )"
913,characteristic_name,"age-prior years taking warfarin ""-lv ejection fraction-prior years taking warfarin-sex-laa ostium-laa length-af pattern-history tia stroke-chadsnmbr score"
914,characteristic_level,"persistent-all patients-< nmbr-male-female-< nmbr y-nmbr-no-< nmbr ""-< median-> median ( nmbr % )-permanent-paroxysmal-yes-> nmbr-> nmbr y-> median ( nmbr mm )"
916,measures,". patients-no . events-no . events """
917,characteristic_name,"treatment characteristics-region-subject characteristics-treatment characteristics ""-indication pci"
918,characteristic_level,"venous graft-number treated vessels ""-bmi ( kg / mnmbr )-sirolimus - eluting-number treated vessels-paclitaxel - eluting-europe-australia / new zealand-hypertension-< nmbr-* * positive stress test-clopidogrel-left main-prasugrel-stroke / tia-age ( years )-number stents-diabetes mellitus-prior mi-everolimus - eluting-arterial graft-weight ( kg )-> nmbr des type-> nmbr-total stent length-lad-number treated lesions-nstemi-race - non - white-stemi-circumflex-female-rca-prior pci-lesion characteristics-* * * unstable angina-native coronary-prior cabg-= nmbr-stable angina-current cigarette smoker within past year-peripheral arterial disease-other-north america-hispanic latino-modified acc / aha lesion class bnmbr cj-congestive heart failure-zotarolimus - eluting"
919,arms,"placebo n = nmbr subjects-continued thienopyridine n = nmbr subjects-placebo n = nmbr subjects """
920,characteristic_name,"aspirin dose randomization-des type-age-region-thienopyridine type-bmi-sex-race-thienopyridine type """
921,characteristic_level,"clinical lesion rfs st-australia / new zealand-no prior ml-current tobacco use-prasugrel-no prior cabg-paclitaxel-clopiodogrel-< nmbr mg-> nmbr mg-overall-white-> = nmbr years-no prior pci-prior ml-any clinical lesion rf st-non - white-< nmbr years-european union-female-diabetes-zotarolimust-prior pci-< median-no current tobacco use-no diabetes-prior cabg-everolimus-sirolimus-north america-male-> = median-clopiodogrel """
923,characteristic_name,"clinical characteristics ""-clinical characteristics-demographics-baseline medical therapy"
924,characteristic_level,"hyperlipidemia-prior stemi-thienopyridine-drug - eluting stent-age , yrs-prior myocardial infarction-aspirin thienopyridine therapy-peripheral artery disease ""-white race-female-hypertension-weight < nmbr kg-current smoker-peripheral artery disease-aspirin-crcl baseline < nmbr ml / min-coronary artery bypass grafting-diabetes mellitus"
926,outcomes,"stroke ""-all stroke-all ischemic stroke-ischemic stroke without hemorrhagic conversior-ischemic stroke hemnrrhnaic cnnversinn"
927,arms,"+ thienopyridine ""-+ thienopyridine-- thienopyridine"
928,characteristic_level,"past smoking-peri - postmenopausal-high density lipoprotein ( mg / dl )-lipid lowering medication use-age ( years )-colorectal cancer-diabetes mellitus-non - colorectal cancer-family history cancera-history dyspepsia-family history premature chd-body mass index ( kg / mnmbr )-major gastro - intestinal bleeding-hormone replacement therapy use ""-systolic blood pressure ( mmhg )-total cholesterol ( mg / dl )-caucasian ethnicity-blood pressure lowering medication use-alcohol use ( > nmbr drink / wk )-never smoking-high sensitivity c - reactive protein ( mg / l )-age > nmbr years-major cardiovascular events-current smoking-hormone replacement therapy use-randomized aspirin use"
929,characteristic_name,"> nmbr % predicted arr ( n = nmbr )-> nmbr % predicted arr ( n = nmbr ) ""-> nmbr % < nmbr % predicted arr ( n = nmbr , nmbr )-total study population ( n = nmbr , nmbr )-< nmbr % predicted arr ( n = nmbr , nmbr )"
930,outcomes,"non - colorectal cancer-major gastro - intestinal bleeding-total-major cardiovascular event-total , adjusted weight nmbr . nmbr gastrointestinal bleeding-colorectal cancer ""-colorectal cancer"
932,measures,"annt bnnh ( nmbr % ci )-arr ( nmbr % ci )-annt bnnh ( nmbr % ci ) """
933,characteristic_name,"baseline fevnmbr % predicted-age , yr mean ( sd ) ""-total pack - years mean ( sd )-age , yr mean ( sd )-post - bronchodilator reversibility fevnmbr ( % ) mean ( sd )-female sex , n ( % )-smoking status , n ( % ) former-current"
934,arms,"ff / vi nmbr mg / nmbr mg ( n = nmbr )-ff / vi nmbr mg / nmbr mg ( n = nmbr ) ""-vi nmbr mg ( n = nmbr )"
935,characteristic_name,"previous pneumonia-bmi-sex-smoking status-gold stage-bmi """
936,characteristic_level,"> nmbr kg / mnmbr-i & ii : fevnmbr > nmbr % predicted-< nmbr-male-female-no-iii : fevnmbr > nmbr % - < nmbr % predicted-former smoker-iv : fevnmbr < nmbr % predicted-current smoker-> nmbr kg / mnmbr ""-yes-> nmbr-< nmbr kg / mnmbr"
937,other,"hr ( nmbr % ci )-hr ( nmbr % ci ) """
938,characteristic_name,"laboratory variables baseline ""-time intervals , h-angiographic data-risk factors-laboratory variables baseline"
939,characteristic_level,"total cholesterol > nmbr mg / dl-ecrcl , ml / min-hs - crp , mg / l-lymphocytes , nmbr / + il-previous ml-hypertension-symptom onset randomization-monocytes , nmbr / nl-glycemia , mg / dl-diabetes mellitus-randomization angiography-age , yrs-triglycerides , mg / dl-hdl cholesterol , mg / dl-active smoking-egfr , ml / min / mnmbr-hospital stay , days-ldl cholesterol , mg / dl-previous pci cabg-neutrophils , nmbr / nl-ck - mb , ng / ml-leukocytes , nmbr / nl-hemoglobin , mg / dl-serum creatinine , mg / dl-pci revascularization-age > nmbr yrs-ctn - l , ng / ml-ci - aki risk score-high - risk clinical features-baseline lvef , %-neutrophils , nmbr / nl ""-bmi , kg / mnmbr-multivessel disease-male"
940,characteristic_name,"baseline hs - crp tertiles ( mg / i]-baseline hs - crp tertiles ( mg / i] """
941,characteristic_level,"overall-nmbrnd > nmbr . nmbr / < nmbr . nmbr-nmbr st < nmbr . nmbr-nmbrrd > nmbr . nmbr ""-nmbrrd > nmbr . nmbr"
942,outcomes,"ischemic stroke-cv death , mi , ischemic stroke , hospitalization hf , coronary revascularization , ua-mi-hospitalization hf-cv death , mi , ischemic stroke-hospitalization hf ""-cv death"
944,outcomes,"ischemic stroke-ml-any new anti - hyperglycemic rx-primary renal endpoint-primary renal endpoint death-cv death , ml , ischemic stroke , hosp . hf , cor . revasc . , ua-hosp . hf-hosp . hf ""-cv death-cv death , ml , ischemic stroke-initiation insulin"
945,characteristic_level,"egfr > nmbr-ebria-egfr < nmbr ""-egfr nmbr - nmbr-major hypoglycemia-hosji fcrhypoglycemia-egfr < nmbr"
947,arms,"s-p-p """
948,characteristic_level,"egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ) ""-egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )-egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )-egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )"
949,arms,"placebo ""-saxagliptin-placebo"
950,measures,"total-worsened-no change-improved-total ""-p value *"
951,characteristic_name,"participants n-age years-gold stage #-co - morbidities-male-post - bronchodilator screening fevnmbr ml-baseline pulmonary medication-smoking status-pre - bronchodilator screening fevnmbr ml-post - bronchodilator screening fevnmbr ml """
952,arms,"tiotropium + olodaterol nmbr / nmbr mg-olodaterol nmbr mg-tiotropium nmbr . nmbr mg-olodaterol nmbr mg ""-tiotropium + olodaterol nmbr . nmbr / nmbr mg-tiotropium nmbrmg"
953,arms,"tiotropium + olodaterol nmbr / nmbr pg-tiotropium + olodaterol nmbr . nmbr / nmbr pg-tiotropium + olodaterol nmbr . nmbr / nmbr pg """
954,arms,"versus tiotropium nmbr . nmbr pg ""-common study baseline-versus tiotropium nmbr . nmbr pg-versus tiotropium + olodaterol nmbr . nmbr / nmbr pg-versus olodaterol nmbr pg-versus tiotropium nmbr pg"
955,outcomes,"fevi aucnmbr - nmbrl-fevi aucnmbr - nmbrl ""-trough fevi l"
956,characteristic_name,"ics usage ""-ics usage"
957,characteristic_level,"yes ""-yes-no"
958,characteristic_name,"race , n ( % ) ""-race , n ( % )-concomitant medications , n ( % )"
959,characteristic_level,"type nmbr diabetes duration , mean ( sd ) , years-age , mean ( sd ) , years-white-prior history cardiovascular disease , n ( % )-thiazide diuretics-fpg , mean ( sd ) , mg / dl [mmol / l]-antihypertensives-angiotensin receptor blocker / ace-white ""-dbp , mean ( sd ) , mmhg-bmi , mean ( sd ) , kg / mnmbr-weight , mean ( sd ) , kg-sbp , mean ( sd ) , mmhg-hbanmbrc , mean ( sd ) , % [mmol / mol]-female , n ( % )"
960,arms,"dapagliflozin nmbr mg / day ( n = nmbr )-dapagliflozin nmbr mg / day ( n = nmbr ) ""-placebo ( n = nmbr )"
961,characteristic_level,"hbanmbrc patients baseline hbanmbrc > nmbr % ( > nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )-hbanmbrc patients baseline hbanmbrc < nmbr % ( < nmbr mmol / l ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se ) ""-hbanmbrc patients baseline hbanmbrc > nmbr % < nmbr % ( > nmbr < nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se )-hbanmbrc patients baseline hbanmbrc < nmbr % ( < nmbr mmol / l ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )"
962,arms,"dapagliflozin nmbr mg ( n = nmbr ) ""-dapagliflozin nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
963,characteristic_name,"age , y-fc - ldl - c , friedewald - calculated-hdl - c , mg / dl-gender-use concomitant lipid - modifying therapy-race ""-type concomitant statin-fc - ldl - c , mg / dl-race"
964,characteristic_level,"mean ( sd )-diabetes , n ( % )-< nmbr , n ( % )-simvastatin , n ( % )-rosuvastatin , n ( % )-white , n ( % )-other , n ( % )-statin + fibrate or-statin , n ( % )-black , n ( % )-statin + ezetimibe , n ( % )-> nmbr , n ( % )-terol ; hdl - c , high - density lipoprotein cholesterol ;-other , n ( % ) ""-tg mg / dl , median ( sd )-atorvastatin , n ( % )-male , n ( % )-female , n ( % )"
965,arms,"anacetrapib nmbr mg ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
966,characteristic_name,"current tobacco abuse , n ( % )-peripheral arterial disease , n ( % )-previous pci / cabg , n ( % )-baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr , n ( % )-lipid - lowering agent-body mass index > nmbr , n ( % )-median age ( nmbr % , nmbr % ) , y-history heart failure , n ( % )-hypertension , n ( % )-lifestyle modifications-noninsulin therapy-body mass index > nmbr , n ( % ) ""-acei / arb-insulin therapy-aspirin-thienopyridine-women , n ( % )-hyperlipidemia , n ( % )"
968,outcomes,"hospitalization unstable angina-death ""-death-mi-cvd , mi , stroke-cvd mi-stroke-coronary revascularization-recurrent ischemia - urgent revascularization-cvd , mi , stroke , recurrent ischemia - urgent revascularization , hospitalization unstable angina-cv death-cvd , mi , stroke , recurrent ischemia - urgent revascularization"
969,characteristic_level,"diabetes mellitus ""-no diabetes mellitus-diabetes mellitus"
971,characteristic_level,"patients treated statins ( n = nmbr ) ""-patients treated statins ( n = nmbr )-patients treated statins ( n = nmbr )"
972,outcomes,"recurrent vte ( statin use vs non - use )-recurrent vte ( statin use vs non - use ) """
973,characteristic_level,"age < nmbr years-bmi < nmbr kg / mnmbr-crcl < nmbr ml / min-age > nmbr years-enoxaparin / vka-crcl > nmbr ml / min-rivaroxaban-cardiac disease-asa use baseline ""-female-male-no asa use baseline-no cardiac disease-asa use baseline-bmi > nmbr kg / mnmbr"
975,outcomes,"major bleeding ( statin use vs non - use )-major bleeding ( statin use vs non - use ) """
976,characteristic_level,"age < nmbr years-bmi < nmbr kg / mnmbr-crcl < nmbr ml / min-age > nmbr years-enoxaparin / vka-crcl > nmbr ml / min-rivaroxaban-cardiac disease-asa use baseline ""-female-male-no asa use baseline-no cardiac disease-asa use baseline-bmi > nmbr kg / mnmbr"
978,characteristic_name,"type concomitant statin daily dose-race-use concomitant lipid - lowering treatment-baseline lipid lipoprotein values ""-baseline lipid lipoprotein values"
979,characteristic_level,"coronary heart disease-hypertension-myocardial infarction-age ( years )-pravastatin nmbr mg-apo anmbr ( g / l )-age < nmbr years-white-atorvastatin nmbr mg-hdl - c ( mmol / l )-statin only-male sex-non - white-rosuvastatin nmbr mg-body - mass index ( kg / mj ) previous diagnosis-fluvastatin nmbr mg-simvastatin nmbr mg-diabetes-apo b ( g / l )-apo anmbr ( g / l ) ""-statin ezetimibe-lp ( ) ( pmol / l )-other-non - hdl - c ( mmol / l )-triglyceride ( mmol / l )-ldl - c * ( mmol / l )"
980,arms,"anacetrapib nmbrmg ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
981,characteristic_name,"pharmacotherapy-bmi ( kg / mnmbr ) ""-bmi ( kg / mnmbr )"
982,arms,"placebo ( n = nmbr , nmbr )-saxagliptin ( n = nmbr , nmbr )-saxagliptin ( n = nmbr , nmbr ) """
983,outcomes,"heart failure-heart failure ""-unstable angina-initiation dialysis , renal transplantation , creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l )-mi-end point-cv mortality-coronary revascularization-secondary *-all - cause mortality-non - cv mortality-nonfatal ischemic stroke-primary *-hypoglycemia"
985,arms,"ticagrelor , nmbr mg ( n = nmbr ) ""-ticagrelor , nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
986,characteristic_name,"history diabetes-aspirin dose-region-time qualifying myocardial infarction-multivessel disease-non - endstage renal dysfunction *-second prior mi-sex-race-history pci-age randomization-weight-qualifying myocardial infarction-region """
987,characteristic_level,"renal dysfunction-unknown-age > nmbr-> nmbr years-age < nmbr-europe-second mi-south america ""-< nmbr mg-> nmbr mg-no prior pci-< median ( nmbr kg )-< nmbr years-> median ( nmbr kg )-caucasian-non - caucasian-nstemi-stemi-asia-female-diabetes-prior pci-renal dysfunction-all patients-no diabetes-no multivessel disease-north america-male-multivessel disease-no second mi-south america"
988,characteristic_name,"treated vessel-minimum stent diameter-thienopyridine randomization-type des index procedure-indication pci ""-indication pci-patients"
989,characteristic_level,"unstable angina-vein graft stented-more nmbr vessels stented-venous graft-in - stent restenosis-hypertension-bmi-no . treated vessels-stroke tia-< nmbr mm-clopidogrel-myocardial infarction-prasugrel-paclitaxel-age ( years )-left main-heavy calcification-diabetes mellitus-non - white race-unprotected left main stented-any risk factor stent thrombosis-> nmbr type-no . treated lesions-thrombus - containing lesion-more nmbr lesions per vessel-total stent length - mm-no . stents-arterial graft-weight ( kg )-cigarette smoker-left anterior descending-> nmbr mm-nstemi-right-stemi-renal insufficiency failure-circumflex-prior brachytherapy-female-in - stent restenosis des-prior pci-prior cabg-lesion length > nmbr mm-extreme tortuosity-stable angina-prior myocardial infarction-des-peripheral arterial disease-other-bifurcation lesion-sirolimus-zotarolimus-lesions-native coronary - artery lesions-modified acc aha lesion class bnmbr c-everolimus-stable angina ""-congestive heart failure-lvef < nmbr %"
990,characteristic_level,"myocardial infarction presentation ( n = nmbr )-no myocardial infarction presentation ( n = nmbr ) ""-no myocardial infarction presentation ( n = nmbr )"
991,arms,"placebo n = nmbr ""-thienopyridine n = nmbr-placebo n = nmbr"
992,characteristic_name,"antiplatelet therapy-selected clinical characteristics , n ( % ) ""-demographic characteristics-selected clinical characteristics , n ( % )-qualifying type atherosclerosis , n ( % )"
993,characteristic_level,"hyperlipidemia-hypertension-myocardial infarction-current smoker-any established peripheral arterial disease-aspirin-ace inhibitors arb-diabetes mellitus-age > nmbr years , n ( % )-white race , n ( % )-age ( ) , median ( nmbrth nmbrth percentiles )-any established coronary artery disease-any established peripheral arterial disease ""-female , n ( % )-estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr-prior coronary revascularization-prior pci-peripheral artery disease-thienopyridine-peripheral revascularization-prior cabg-lipid - lowering medications"
994,arms,"placebo ( n = nmbr nmbr ) ""-vorapaxar ( n = nmbr nmbr )-placebo ( n = nmbr nmbr )"
995,characteristic_level,"europe ii-europe ii ""-australia / nz-> = nmbr-asia-north america-latin america-< nmbr-female-male-no-> = nmbr kg-europe i-yes-< nmbr kg"
996,characteristic_name,"prior stent-age-region-diabetes-planned thienopyridine baseline-egfr ( ml / min / nmbr . nmbrmnmbr )-sex-weight-region """
998,characteristic_name,"qualifying cv event , n ( % )-time recent qualifying-race , n ( % ) ""-concomitant medications , * n ( % )-type treatment , n ( % )-race , n ( % )-duration hypertension , n ( % )-oads , n ( % )"
999,characteristic_level,"antihypertensive-coronary heart disease-cv event , years-bw , mean ( sd ) , kg-stroke tia-$ nmbrand , nmbr years-not reported-nmbr-oad-subjects $ nmbr years age , n ( % )-age , mean ( sd ) , years-white-subjects , nmbr years age , n ( % )-female sex , n ( % )-black / african american-seated sbp , mean ( sd ) , mmhg-oad plus insulin-white ""-acetylsalicylic acid-asian-insulin only-seated dbp , mean ( sd ) , mmhg-peripheral artery disease-aceis / arbs-daily insulin dose , mean ( sd ) , iu-diuretics-type nmbr diabetes duration , years-other-lipid - lowering medications-, nmbr years-loop diuretics-fpg , mean ( sd ) , mmol / l-$ nmbr years-. nmbr-bmi , mean ( sd ) , kg / mnmbr-hbanmbrc , mean ( sd ) , % [mmol / mol]"
1000,arms,"dapagliflozin nmbr mg group ( n = nmbr )-dapagliflozin nmbr mg group ( n = nmbr ) ""-placebo group ( n = nmbr )"
1002,arms,"aiirocumab ( n = nmbr )-aiirocumab ( n = nmbr ) """
1003,characteristic_name,"ethnicity-moderate ckd randomization-diabetes randomization-history ml ischemic stroke-age-gender-statin treatment-bmi-other llt randomization-race-bmi """
1004,characteristic_name,"antihypertensive-antiplatelet-qualifying hbanmbrc ( % )-antihyperglycemic-duration diabetes ( years ) ""-cigarette smoking-race / ethnicity-duration diabetes ( years ) t-urinary albumin : creatinine ratio ( mg / g )-lipid lowering"
1005,arms,"n = nmbr , nmbr-placebo n = nmbr-sitagliptin n = nmbr-sitagliptin n = nmbr """
1006,characteristic_name,"region-calcium channel blockers-diabetes duration subgroups-renal function subgroups-medications taken time randomization statins-aspirin-prior congestive heart failure-systolic blood pressure subgroups-insulin ""-sulfonylurea-metformin-history hypertension-ace inhibitors angiotensin receptor blockers-thiazolidinedione ( includes pioglitazone )-cigarette smoking status-hbanmbrc subgroups-sex-diuretics-age subgroups-race-insulin-beta blockers-diastolic blood pressure subgroups"
1007,measures,"hazard ratio ""-interaction p - value-nmbr % cl-n / n-hazard ratio"
1008,outcomes,"rec . ischemia requiring revasc-ml-rec . ischemia leading hasp-rec . ischemia due worsening angina-primary ep ( cvd / mi / ri )-rec . ischemia due ecg changes-rec . ischemia requiring revasc "" ; na-cv death-recurrent ischemia"
1009,characteristic_level,"pci-pci-no pci ""-no pa-no po-pa"
1010,characteristic_name,"medication , n ( % ) ""-cat score category-copd exacerbation history , n ( % )-gold nmbr groups-medication , n ( % )-mmrc grade-race , n ( % )-copd severity , n ( % )"
1011,characteristic_level,"postbronchodilator fevnmbr , l-nmbr-bdi focal score-nmbr - nmbr ( moderate )-nmbr - nmbr ( severe )-sgrq total score-age , years-nmbr - nmbr ( severe )-> nmbr-caucasian-gold d-moderate-postbronchodilator fevnmbr / fvc , %-asian-duration copd , years-postbronchodilator fevnmbr reversibility , %-missing-ics users baseline , n ( % ) ""-current smokers , n ( % )-severe-other-postbronchodilator fevnmbr , % predicted-patients prior copd - related-nmbr - nmbr ( mild )-ics users baseline , n ( % )-cat score-sex , male , n ( % )-mild-gold b"
1012,arms,"sfc nmbr / nmbr | ig bid n = nmbr-sfc nmbr / nmbr | ig bid n = nmbr ""-qvanmbr nmbr / nmbr | ig od n = nmbr"
1013,characteristic_name,"copd severity : severe / severe-overall-age ( years ) : nmbr - < nmbr-age ( years ) : > nmbr-smoking history : current smoker-baseline ics use : yes-smoking history : current smoker ""-smoking history : ex - smoker-age ( years ) : < nmbr-copd exacerbation : yes-copd severity : mild / moderate-copd exacerbation : no-baseline ics use :"
1015,characteristic_level,"white-other *-asian-black / african american-black / african american """
1016,characteristic_name,"body weight , mean = sd , kg-sbp , mean = sd , mmhg-egfr , mean = sd , ml / min / nmbr . nmbr mnmbr-hbanmbrc , mean = sd , %-female , n ( % ) ""-race , n ( % )-age , mean = sd , years-male , n ( % )-female , n ( % )"
1017,arms,"total ( n = nmbr )-cana nmbr mg ( n = nmbr )-placebo ( n = nmbr )-cana nmbrmg ( n = nmbr )-total ( n = nmbr ) """
1018,outcomes,"ldl - cz-ldl - c / hdl - cx-non - hdl - c *-hdl - cy-ldl - c / hdl - cx ""-triglycerides * *"
1019,measures,"baseline . mean _ sd . mg / mg-ls mean % change baseline _ se-baseline . mean _ sd , mg / dl-baseline . mean _ sd . mg / mg ""-baseline . mean _ sd . mg / dl"
1020,characteristic_level,"white-asian ""-other *-asian-black / african american"
1021,arms,"cana nmbr mg ""-pbo-cana nmbr mg"
1022,arms,"placebo ( n = nmbr ) ""-liraglutide ( n = nmbr )-placebo ( n = nmbr )"
1023,characteristic_level,"bmi ( nmbr . nmbr ; nmbr . nmbr )-pooled analysis-bmi > = nmbr-bmi ( nmbr . nmbr ; nmbr . nmbr ) """
1024,measures,"pooled analysis-pooled analysis ""-estimated means difference"
1026,characteristic_level,"bmi ( nmbr . nmbr ; nmbr . nmbr )-pooled analysis-bmi > nmbr-bmi ( nmbr . nmbr ; nmbr . nmbr ) """
1027,measures,"pooled analysis-pooled analysis ""-estimated response rate odds ratio"
1028,arms,"estimated odds ratio-estimated odds ratio ""-placebo mean ( n )-liraglutide nmbr . nmbr mg mean ( n )"
1029,characteristic_level,"bmi ( nmbr . nmbr ; nmbr . nmbr )-bmi > nmbr-bmi ( nmbr . nmbr ; nmbr . nmbr ) """
1030,measures,"nmbr . nmbr ""-nmbr . nmbr-nmbr . nmbr % ( nmbr )"
1031,arms,"nmbr . nmbr ""-nmbr . nmbr-nmbr . nmbr % ( nmbr )"
1032,characteristic_name,"number previous anti - tnf treatments psoriatic arthritis-patients specific disease characteristics ""-baseline disease quality - - life scores-patients specific disease characteristics-ethnic origin"
1033,characteristic_level,"unknown-pain ( vas )-dactylitis count-pasi < nmbr *-systemic glucocorticoid use randomisation-nmbr-age ( years )-pasi *-white-women-nmbr nmbr-dactylitis-methotrexate use randomisation-enthesitis ""-weight ( kg )-tender joint count ( nmbr joints )-enthesitis-psoriasis body surface area > nmbr %-asian-physician ' global assessment ( vas )-black-sfnmbr - pcs-dasnmbr - crp-enthesitis count-pasi score > nmbr *-other-haq - di-patient ' global assessment ( vas )-swollen joint count ( nmbr joints )"
1034,arms,"secukinumab nmbr mg ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1035,characteristic_level,"anti - tnf - naive patients-anti - tnf - naive patients ""-anti - tnf - ir patients"
1036,outcomes,"acrnmbr response ""-acrnmbr response-pasinmbr response }"
1037,arms,"secukinumab nmbr mg-secukinumab nmbr mg ""-placebo"
1038,measures,"value *-p value versus placebo-odds ratio versus placebo ( nmbr % ci )-value * """
1039,characteristic_name,"< nmbr months , n ( % )-bmi ( kg / mnmbr )-negative ( < nmbr . nmbr ) , n ( % )-steroid use baseline , n ( % )-age ( years )-ptgada ( mm )-joint space narrowing score-phgada ( mm )-haq - di score-average weekly mtx dose ( mg / week )-dasnmbr ( esr )-erosion score-weight ( kg )-sdai-erosion score ""-female , n ( % )-bone erosion ( judged physician ) , n ( % )-nmbr - < nmbr months , n ( % )-mtss-esr ( mm / h )-mmp - nmbr ( ng / ml ) *-tjc ( / nmbr joints )-high titre ( > nmbr times uln ) , n ( % )-titre ( u / ml ) t-ra duration ( months ) *-anti - ccp antibody positive , n ( % )-previous dmards use , n ( % )-rf positive , n ( % )-nmbr - nmbr months , n ( % )-crp ( mg / dl )-sjc ( / nmbr joints )"
1040,arms,"pbo + mtx n = nmbr-pbo + mtx n = nmbr ""-czp + mtx n = nmbr"
1041,characteristic_level,"nmbr - < nmbr-> nmbr . nmbr - < nmbr . nmbr-> nmbr - nmbr-< nmbr . nmbr ""-< nmbr-nmbr - nmbr-nmbr . nmbr - nmbr . nmbr-> nmbr . nmbr-> nmbr-< nmbr . nmbr"
1042,arms,"pbo + mtx-pbo + mtx ""-czp + mtx"
1043,characteristic_name,"method used diagnose incident pulmonary embolism , . ( % )-accp bleeding risk inclusion , . ( % ) f-characteristics pulmonary embolism inclusion-medical conditions , . ( % )-treatmentofpulmonary embolismpriorto randomization-main concomitant treatments , . ( % )-characteristics pulmonary embolism inclusion ""-thrombophilia , . ( % ) e-creatinine clearance category , ml / min , . ( % ) b"
1044,characteristic_level,"> nmbry , . ( % )-< nmbr-> nmbr , . ( % )-residual perfusion defect > nmbr % lung scan , . ( % ) ""-d - dimer level , mean ( sd ) , ng / mld-body mass index , mean ( sd )-moderate ( nmbr risk factor )-associatedproximaldeep - veinthrombosisatdiagnosis , . ( % )-age , mean ( sd ) , y-previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis-fluindione , . ( % )-chronic respiratory failure-acecoumarol , . ( % )-residual perfusion defect > nmbr % lung scan , . ( % )-high - probability ventilation / perfusion lung scanning-> nmbr-systolic pulmonary arterial pressure , mean ( sd ) , mm hg-minor-statins-spiralcomputedtomographyangiography-antiplatelet agent-residual deep - vein thrombosis , . ( % )-> nmbr - < nmbr-use compression stockings , . ( % )-high ( > nmbr risk factor )-duration initial anticoagulation , mean ( sd ) , mo-previous cancerc-low ( risk factor )-chronic heart failure-percentage time therapeutic inr range , mean ( sd )-major-women , . ( % )-warfarin , . ( % )"
1045,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-warfarin ( n = nmbr )"
1046,characteristic_name,"accp score-age-previous cancer-right ventriculardysfunction atinclusion-thrombophilia-bmi-time therapeutic range inclusion-sex-d - dimer levelsatinclusion-perfusion defectsatinclusion-accp score ""-compression stockings-pe associated dvt diagnosis"
1047,characteristic_level,"overall-> nmbr years-> nmbr %-> nmbr kg / mnmbr-> nmbr microg / l-< nmbr kg / nmbr-< nmbr-male-female-no-< nmbr microg / l-< nmbr ""-nmbr - nmbr years-< nmbr %-yes-> nmbr-< nmbr years"
1049,measures,". patients-no . events-no . patients """
1050,arms,"placebo ( n = nmbr ) ""-liraglutide nmbr . nmbr mg / day ( n = nmbr )-placebo ( n = nmbr )"
1051,characteristic_level,"baseline hbanmbrc < nmbr . nmbr %-baseline hbanmbrc > nmbr . nmbr % ""-baseline hbanmbrc > nmbr . nmbr %"
1052,arms,"placebo ( n = nmbr )-liraglutide nmbr . nmbr mg ( n = nmbr ) ""-liraglutide nmbr . nmbr mg ( n = nmbr )"
1053,measures,"r-e-n ( % )-n %-e """
1054,outcomes,"acr response , %-mean change radiographic end points ""-mean change radiographic end points"
1055,other,"dasnmbr - esr remission , %-acrnmbr-jsn score , mean nmbr sd ""-shs , mean nmbr sd-jsn score , mean nmbr sd-change baseline dasnmbr - esr , meannmbr sd-erosion score , mean nmbr sd-lda , %"
1056,arms,"czp nmbr mg ( n nmbr nmbr ) ""-pbo ( nnmbr )-czp nmbr mg ( n nmbr )-czp nmbr mg ( n nmbr nmbr )-pbo ( nnmbr nmbr )-czp nmbr mg ( nnmbr )"
1057,outcomes,"death ""-death-mi-ischemic stroke-timi major bleeding-stent thrombosis-cv death , mi , ischemic stroke-cv death-timi major minor bleeding"
1058,characteristic_level,"aspirin only-aspirin ""-aspirin nmbr clopidogrel"
1060,measures,"rate * ( n )-hr ( nmbr % ci )-rate * ( n ) """
1061,characteristic_level,"bdmard - naive-bdmard - naive ""-bdmard - ir"
1062,arms,"tofacitinib nmbr mg twice daily n = nmbr-tofacitinib nmbr mg twice daily n = nmbr ""-placebo n = nmbr"
1063,outcomes,"cdai < nmbr . nmbr * ""-haq - di improvement > nmbr . nmbr-dasnmbr - nmbr ( esr ) < nmbr . nmbrt-dasnmbr - nmbr ( esr ) < nmbr . nmbr *-cdai < nmbr . nmbr *-sdai < nmbr t-cdai < nmbrt-sdai < nmbr . nmbr *"
1064,characteristic_level,"bdmard - naive-bdmard - naive ""-bdmard - ir"
1065,arms,"tofacitinib nmbr mg twice daily n = nmbr-tofacitinib nmbr mg twice daily n = nmbr ""-placebo n = nmbr"
1066,arms,"control ( n = nmbr )-cyclosporine ( n = nmbr ) ""-cyclosporine ( n = nmbr )"
1067,characteristic_name,"rentrop score-dyslipidemia-age-ejection fraction-killip baseline ""-hypertension-diabetes-killip baseline-symptom onset-thrombus aspiration-final timi flow-initial timi flow-lad"
1068,characteristic_level,"< nmbr-no-nmbr-> nmbrh-< nmbr %-nmbr - nmbrh-< nmbrh-overall-> nmbr-nmbr ""-female-yes-= nmbr-proximal - mainleft-< nmbr yr-> nmbr %-nmbr yr-male-medial - distal - diag"
1070,measures,". events / total-no . events / total """
1071,characteristic_level,"race , white , n ( % )-type nmbr diabetes , n ( % ) d-ezetimibe use-statin use , n ( % )-genotyping-body mass index , kg / mnmbr , mean + sd-body mass index , kg / mnmbr , mean + sd ""-hypertension , n ( % )-coronary heart disease risk equivalents , n ( % ) c-clinical criterianmbr-diagnosis heterozygous familial hypercholester-age , years , mean + sd-coronary heart disease , n ( % ) b-current smoker , n ( % )-high - dose statin use , n ( % ) e-male , n ( % )"
1072,other,"fh ii-fh nmbr ""-fh nmbr"
1073,arms,"alirocumab ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1074,characteristic_name,"ethnicity-dose atorvastatin-region-age-dose rosuvastatin-gender-moderate ckd-statin treatment-bmi-llt statin randomization-age ""-prior history ml ischemic stroke-race-diabetes mellitus"
1075,arms,"placebo ""-alirocumab-placebo"
1076,characteristic_name,"age , y-vascular history , %-concomitant drugs , %-risk factors , %-vascular history , % """
1077,characteristic_level,"hyperlipidemia-previous stenting ( % previous pci )-australia / new zealand-hypertension-nmbr - nmbr mo-current smoker-europe i-< nmbr mo-any coronary revascularization-aspirin-lipid - lowering agents-diabetes mellitus-crcl < nmbr ml / min-white race , %-des ( % previous stenting )-previous cabg ( % total )-> nmbr mo-p - blockers-> nmbr y-europe ii-mean ( sd )-ace inhibitor arb-asia-europe ""-weight < nmbr kg-region , %-time qualifying mi , %-north america-latin america-female sex , %-previous pci ( % total )"
1080,outcomes,"ml-ischemic stroke-ucr-cv death / mi / stroke-stroke-ml ""-cv death / mi / stroke / ucr-cv death"
1081,characteristic_level,"thienopyridine-thienopyridine-no thienopyridine """
1082,measures,"n ( nmbryr km event rate , % )-n ( nmbryr km event rate , % ) """
1083,characteristic_name,"baseline cv medications , n ( % )-baseline cv medications , n ( % ) ""-baseline antihyperglycemic medications , n ( % )-baseline measurements-albumin - - creatinine ratio ,-race-demographic characteristics"
1084,characteristic_level,"fasting serum glucose , median ( sd ) , mg / dl-hbanmbrc , median ( sd ) , %-aspirin-median ( sd ) , mg / mmol-sulfonylurea-all others , n ( % )-metformin-diabetes duration , median ( iqr ) , years-female sex , n ( % )-aspirin ""-tzd-prior myocardial infarction , n ( % )-hypertension , n ( % )-egfr , median ( sd ) , ml / min-statins-weight , median ( sd ) , kg-bmi , median ( sd ) , kg / mnmbr-prior heart failure , n ( % )-hispanic / latino ethnicity , n ( % )-ace inhibitors-age , median ( iqr ) , years-b - blockers-diuretics-dyslipidemia , n ( % )-caucasian , n ( % )-current smoker , n ( % )-prior coronary revascularization , n ( % )-insulin"
1085,outcomes,"yes ( n = nmbr )-no ( n = nmbr , nmbr ) ""-no ( n = nmbr , nmbr )"
1087,arms,"saxagliptin-saxagliptin ""-placebo"
1088,measures,"total-total ""-hr-cl nmbr %-event"
1089,arms,"pooled empagliflozin ( n = nmbr ) ""-pooled empagliflozin ( n = nmbr )-empagliflozin nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
1090,characteristic_name,"estimated glomerular filtration rate-region-angiotensin - converting enzyme inhibitors / angiotensin receptor blockers-calcium channel blockers-glycated hemoglobin-body mass index-ethnicity-blood pressure control-age-sulfonylurea-metformin-age ""-sex-statins / ezetimibe-thiazolidinediones-diuretics-dpp - nmbr inhibitor-urine albumin - - creatinine ratio-antihypertensives-race-insulin-beta blockers-cardiovascular risk-acetylsalicylic acid"
1091,characteristic_level,"> nmbr years-hispanic / latino-only peripheral artery disease-europe-no-not hispanic / latino-> nmbr mg / g-only cerebrovascular disease-white-nmbr nmbr mg / g-< nmbr years-< nmbr ml / min / nmbr . nmbrmnmbr-< nmbr kg / mnmbr-sbp < nmbr mmhg dbp < nmbr mmhg-> nmbr ml / min / nmbr . nmbrmnmbr-asia-sbp > nmbr mmhg / dbp > nmbr mmhg-female-asian-black / african - american-< nmbr years ""-all patients-yes-> nmbr . nmbr %-africa-> nmbr kg / mnmbr-north america-latin america-only coronary artery disease-male-nmbr < nmbr ml / min / nmbr . nmbrmnmbr-nmbr nmbr high cardiovascular risk categories-< nmbr . nmbr %-< nmbr mg / g"
1093,arms,"placebo ""-placebo"
1094,characteristic_name,"estimated glomerular filtration rate-region-angiotensin - converting enzyme inhibitors / angiotensin receptor blockers-calcium channel blockers-glycated hemoglobin-body mass index-region ""-ethnicity-blood pressure control-age-sulfonylurea-metformin-sex-statins / ezetimibe-diuretics-urine albumin - - creatinine ratio-antihypertensives-insulin-beta blockers-cardiovascular risk-acetylsalicylic acid"
1095,characteristic_level,"> nmbr nmbr mg / g-> nmbr years-hispanic / latino-only peripheral artery disease-europe-no-not hispanic / latino-> nmbr mg / g-only cerebrovascular disease-white-< nmbr years-< nmbr ml / min / nmbr . nmbrmnmbr-< nmbr kg / mnmbr-sbp < nmbr mmhg dbp < nmbr mmhg-> nmbr ml / min / nmbr . nmbrmnmbr-europe ""-asia-sbp > nmbr mmhg / dbp > nmbr mmhg-female-asian-black / african - american-all patients-north america plus australia new zealand-yes-> nmbr . nmbr %-africa-> nmbr kg / mnmbr-latin america-only coronary artery disease-male-nmbr < nmbr ml / min / nmbr . nmbrmnmbr-nmbr nmbr high cardiovascular risk categories-< nmbr . nmbr %-< nmbr mg / g"
1097,arms,"placebo ""-empagliflozin-placebo"
1098,characteristic_name,"weight , kg-age , years-medical history , n ( % )-demographic-medical history , n ( % ) """
1099,characteristic_level,"heart failure-heart failure ""-n-median-prior myocardial infarction-cabg-hypertension-hyperlipidaemia-female sex , n ( % )-current smoker-prior stroke tia-interquartile range-prior ptca pci-peripheral artery disease-diabetes mellitus"
1100,other,"radial ""-radial"
1101,outcomes,"ischemia driven revascularization-death-ml-primary endpoint death / mi / idr / st-stent thrombosis-ischemia driven revascularization "" ; na"
1102,characteristic_level,"overall-femoral-radial-femoral """
1104,arms,"secukinumab , nmbr mg ( n = nmbr ) ""-secukinumab , nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
1105,characteristic_name,"anti - tnf - experienced patients ""-anti - tnf - naive patientsnmbr-anti - tnf - experienced patients"
1106,arms,"secukinumab-secukinumab ""-placebo"
1107,characteristic_name,"region , n ( % )-number prior aeds , n ( % ) ""-number concomitant aeds , n ( % )-concomitant aedsa-number prior aeds , n ( % )-lev status , n ( % )"
1108,characteristic_level,"itt population-europe ( non - eu )-nmbr-duration epilepsy , years , mean ( sd )-weight , kg , mean ( sd )-oxcarbazepine-topiramate-valproate-never used lev-baseline pos frequency per nmbr days , median ( min , max )-> nmbr-age , years , mean ( sd )-race , white , n ( % )-nmbr - nmbr ""-asia / pacific / other-europe ( eu )-north america-latin america-bmi , kg / mnmbr , mean ( sd )-prior lev use-lacosamide-gender , female , n ( % )-age first seizure , years , mean ( sd )-nmbr - nmbr-carbamazepine-lamotrigine"
1110,characteristic_name,"clinical characteristics-region-demographics-qualifying event-region """
1111,characteristic_name,"time end - - study ivus , median ( iqr ) , days-men , n ( % )-age , mean ( sd ) , yrs-history myocardial infarction-statin-anti - platelet therapy-ace inhibitor-active smoking-beta - blocker-hypertension-arb-body - mass index , mean ( sd )-arb ""-history pci"
1112,characteristic_level,"diabetes mellitus-diabetes mellitus ""-diabetes mellitus"
1113,outcomes,"first mace-death-elevated creatinine ( > nmbr pmol / l )-hyperkalemia ( > nmbr . nmbr meq / l )-non - fatal myocardial infarction-elevated bun ( > nmbr . nmbr meq / l )-non - fatal stroke-hospitalization heart failure-elevated bun ( > nmbr . nmbr meq / l ) ""-hospitalization acs-arterial revascularization"
1114,characteristic_level,"diabetes mellitus-diabetes mellitus ""-diabetes mellitus"
1115,arms,"dm - ( aliskiren vs . placebo ) ""-aliskiren ( dm - vs . dm + )-dm + ( aliskiren vs . placebo )-placebo ( dm - vs . dm + )-dm - ( aliskiren vs . placebo )"
1117,characteristic_name,"urine albumin / creatinine ratio ( mg / g ) ""-duration diabetes-urine albumin / creatinine ratio ( mg / g )"
1118,characteristic_level,"statin-ace inhibitor-< nmbr-duration diabetes ( )-b - blocker-aspirin-age ( )-white-egfr > nmbr ml / min-> = nmbr-nmbr - < nmbr-sulfonylurea-metformin-< nmbr y-body mass index ( kg / mnmbr )-nmbr - < nmbr y-thiazolidinedione-> = nmbr y-adp antagonist-ace inhibitor ""-established cardiovascular disease-male-insulin"
1119,characteristic_level,"hbanmbrc nmbr % - < nmbr % ( n - nmbr )-hbalc > = nmbr % ( n - nmbr )-hbanmbrc < nmbr % ( n - nmbr )-hbanmbrc < nmbr % ( n - nmbr ) ""-p value"
1120,characteristic_level,"overall-hbanmbrc nmbr - < = nmbr % ""-hbanmbrc > = nmbr %-hbanmbrc < nmbr %-hbanmbrc nmbr - < = nmbr %"
1122,characteristic_level,"overall-hbanmbrc nmbr - < = nmbr % ""-hbanmbrc > = nmbr %-hbanmbrc < nmbr %-hbanmbrc nmbr - < = nmbr %"
1124,characteristic_name,"region-region ""-nyha functional class"
1125,characteristic_level,"central europe-cardiac resynchronization therapy-western europe other-asia - pacific ""-hypertension-hospitalization heart failure-nmbr-myocardial infarction-atrial fibrillation-oral anticoagulant agent-percutaneous coronary intervention-digoxin-implantable cardioverter - defibrillator-iv-coronary artery bypass surgery-asia - pacific-beta - blocker-diabetes-asian-black-diuretic agent-antiplatelet agent-ii-iii-mineralocorticoid receptor antagonist-lipid - lowering agent-other-north america-latin america-stroke"
1126,measures,"risk score category ( points ) ""-p value trend-risk score category ( points )"
1127,characteristic_level,"nmbr - nmbr ( n = nmbr , nmbr ) ""-nmbr - nmbr ( n = nmbr , nmbr )"
1128,measures,"ratet ( nmbr % cl )-hr ( nmbr % cl ) ""-hr ( nmbr % cl )"
1129,outcomes,"- cause death n ""-all - cause death n-cv death hf hospitalization n-hf hospitalization n-cv death n"
1130,characteristic_name,"risk category ( points )-risk category ( points ) """
1131,characteristic_level,"nmbr ( n = nmbr ) ""-nmbr ( n = nmbr )-nmbr - nmbr ( n = nmbr )-nmbr - nmbr ( n = nmbr , nmbr )-nmbr ( n = nmbr , nmbr )"
1132,arms,"enalapril lcznmbr ( n = nmbr ) ( n = nmbr )-lcznmbr ( n = nmbr ) ""-lcznmbr ( n = nmbr )-enalapril ( n = nmbr )"
1133,arms,"adalimumab ( n = nmbr )-adalimumab ( n = nmbr ) ""-placebo ( n = nmbr )"
1134,characteristic_name,"race , n ( % ) ""-race , n ( % )-sex , n ( % )"
1135,arms,"total ( n = nmbr )-total ( n = nmbr ) ""-cana nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
1136,characteristic_level,"egfr < nmbr ml / min / nmbr . nmbr mz-< nmbr years age-duration tnmbrdm < nmbr years-duration tnmbrdm < nmbr years ""-fracture history-female-male-> nmbr years age-no fracture history-egfr > nmbr ml / min / nmbr . nmbr mz-duration tnmbrdm > nmbr years"
1137,arms,"pbo-all cana ""-all cana"
1138,characteristic_name,"thienopyridine randomization-type stent index procedure-indication index pci-patients-patients """
1139,characteristic_level,"hypertension-stroke tia-clopidogrel-prasugrel-age ( years )-bare metal-diabetes mellitus-non - white raceb-weight ( kg )-female sex-cigarette smoker-hispanic latino ethnic groupb ""-nstemi-drug eluting-stemi-prior cancer-unstable anginad-stable angina-prior myocardial infarction-peripheral arterial disease-other-hispanic latino ethnic groupb-congestive heart failure-renal insufficiency / failure-body mass indexc"
1140,arms,"continued thienopyridine ( n nmbr nmbr )-placebo ( n nmbr nmbr ) ""-placebo ( n nmbr nmbr )"
1141,characteristic_name,"aspirin dose randomization-thienopyridine randomization-stent type-age-region-body mass index-aspirin dose randomization ""-sex-race-indication pci"
1142,characteristic_level,"< nmbr-australia / new zealand-clopidogrel-current tobacco use-no prior mi-no prior cabg-prasugrel-bare metal stent-< nmbr mg-drug eluting stent-> nmbr mg-white-prior mi-no prior pci-non - white-> nmbr-history cancer-european union-mi-no mi-female-diabetes-prior pci-< median-no current tobacco use-no diabetes-prior cabg-> median-no history cancer-north america-male-> nmbr mg """
1144,characteristic_name,"age , yrs-chanmbrdsnmbr - vasc $ nmbr-modified - bled-chanmbrdsnmbr - vasc $ nmbr ""-previous myocardial infarction-male-hypertension-chanmbrdsnmbr - vasc-previous major bleeding-chadsnmbr-previous stroke-age > nmbr yrs-diabetes mellitus"
1146,arms,"long - term warfarin ( n - nmbr ) ""-long - term warfarin ( n - nmbr )-laa closure ( n - nmbr )"
1147,characteristic_level,"history tia / stroke-modified - bled < nmbr-modified - bled $ nmbr-history tia / stroke-female-chanmbrdsnmbr - vasc # nmbr-male-chanmbrdsnmbr - vasc > nmbr-age > nmbr yrs ""-age # nmbr yrs-age > nmbr yrs"
1149,characteristic_name,"b-b "" ; na"
1155,outcomes,"first co - primary outcome-cardiovascular death-cardiovascular death ""-second co - primary outcome"
1156,characteristic_level,"alc > = nmbr . nmbr %-new om-neither ace - arb use-prior dm-age < nmbr-placebo allocation-heart rate < nmbr bpm-new dm-triglycerides nmbrnd third-overall-alc < nmbr . nmbr %-bmi < = nmbr-omega - nmbr fa intake nmbrst third-omega - nmbr fa intake nmbrnd third-heart rate > nmbr bpm-omega - nmbr fa intake nmbr , third-no betablocker use-age > = nmbr-ace - arb use-no metformin use-ifg / igt-triglycerides nmbr , third-female-statin use-prior cv event-omega - nmbr fa intake nmbrst third ""-prior om-insulin glargine allocation-betablocker use-standard care allocation-omega nmbr allocation-male-bmi > nmbr-triglycerides nmbrst third-metformin use-no statin use-age > : nmbr-no prior cv event"
1159,characteristic_name,"demographic characteristics-screening-baseline-screening """
1160,characteristic_name,"japan n = nmbr-not - japan n = nmbr , nmbr-not - japan n = nmbr , nmbr ""-overall n = nmbr , nmbr"
1161,characteristic_level,"japan-overall-not - japan-not - japan "" ; na"
1162,arms,"ff / vi nmbr / nmbr pg od-ff nmbr pgod-ff / vi nmbr / nmbr pg od ""-placebo"
1163,characteristic_name,"n =-pulse ( beats / min ) cholesterol ( mmol / l )-dyslipidaemia , n ( % )-body weight ( kg )-diastolic bp ( mmhg )-triglycerides ( mmol / l )-total-wc ( cm )-duration tnmbrdm ( years )-systolic bp ( mmhg )-prediabetes , n ( % )-insulin ( pmol / l )-n = nmbr-hscrp ( nmol / l )-body mass index ( kg / mnmbr )-insulin ( pmol / l ) vital signs-vldl-hypertension , n ( % )-hdl-female-age , ( years ) ""-hbaic ( % )-age , ( years )-dyslipidaemia hypertension , n ( % )-male-fpg ( mmol / l )-ldl-hbanmbrc ( % )-ffa ( mmol / l )"
1164,characteristic_level,"( nmbr . nmbr % ) t-asian ( nmbr . nmbr % )-other ( nmbr . nmbr % ) ""-white ( nmbr . nmbr % )-black / african - american ( nmbr . nmbr % )"
1165,arms,"liraglutide nmbr . nmbr mg n = nmbr-placebo n = nmbr-placebo n = nmbr """
1166,characteristic_level,"white-asian ""-other-asian-black / african - american"
1169,characteristic_name,"p - blocker ( % )-creatinine clearance ( ml / min ) ""-exercise times per week , ( minimum-creatinine clearance ( ml / min )-systolic blood pressure ( mm hg )-hdl cholesterol ( mmol / l )-heart rate ( bpm )-age ( years )-ace / arb medication ( % )-current weekly alcohol use ( % )-triglycerides ( mmol / l )-history stroke ( % )-total cholesterol ( mmol / l )-number individuals-aspirin thienopyridines ( % )-history macrovascular disease ( % )-ldl cholesterol ( mmol / l )-body mass index ( kg / mnmbr )-lipid - lowering medication ( % )-history microvascular disease ( % )-duration diabetes ( years )-hbanmbrc ( % )-age completion highest level of-diastolic blood pressure ( mm hg )-any blood pressure medications ( % )"
1170,characteristic_level,"men ""-men-women"
1171,characteristic_level,"daily ""-never-daily-former"
1172,outcomes,"primary outcomes "" ; na-primary outcomes-secondary ' outcomes"
1174,outcomes,"secondary outcomes-primary outcomes-primary outcomes "" ; na"
1175,outcomes,"major cardiovascular-major cerebrovascular-all cardiovascular ""-major coronary-all cause mortality-nephropathy-all cardiovascular-all cancer"
1177,characteristic_name,"type mi ( % ) ""-medical history ( % )-type mi ( % )"
1178,characteristic_level,"killip class > ii ( % )-nstemi ""-symptom onset hospital arrival , hours-nstemi-creatinine clearance < nmbr ml / min ( % )-stemi-anemia ( % )-age , years-diabetes-hypertension-crusade bleeding score-previous mi-current smoker-body mass , kg-previous pci-previous stroke-body mass index ( kg / mnmbr )-> nmbr"
1179,arms,"control ( n = nmbr )-bivalirudin ( n = nmbr )-control ( n = nmbr ) """
1180,characteristic_name,"hyperlipidemia-nsteacs-lmwh-clopidogrel , nmbr mg *-radial-hypertension-ufh-previous mi-brachial-weight ( kg ) , median ( iqr )-current smoker-previous stroke tia-previous heart failure-previous pci-age ( ) , median ( iqr )-aspirin-bivalirudin-diabetes mellitus-other countries-drug - eluting stent , n ( % )-dx presentation , n ( % )-fondaparinux-white race , n ( % )-baseline hematocrit , median ( iqr )-united states-periprocedural medications , n ( % ) clopidogrel , nmbr mg *-stemi-duration pci ( min ) , median n ( iqr )-bare metal stent , n ( % )-nsteacs ""-baseline hemoglobin , median ( iqr , g / dl )-poba , n ( % )-stable angina-femoral-peripheral arterial disease-previous cabg-abnormal-age > nmbr , n ( % )-normal"
1182,arms,"cangrelor ( n = nmbr )-clopidogrel ( n = nmbr )-clopidogrel ( n = nmbr ) """
1183,arms,"placebo ""-pioglitazone-placebo"
1184,measures,"( n = nmbr )-( n = nmbr ) """
1185,arms,"baricitinib , nmbr mg daily ( n = nmbr )-baricitinib , nmbr mg daily ( n = nmbr ) ""-placebo ( n = nmbr )"
1186,characteristic_name,"# prior bdmards-# prior non - tnfi bdmards * ""-overall population-# prior tnfi among non - tnfi naive-# prior non - tnfi bdmards *"
1187,characteristic_level,"nmbr-> nmbr-nmbr ""-< nmbr"
1188,arms,"baricitinib nmbr mg-baricitinib nmbr mg """
1189,characteristic_name,"age , y-white-other ""-other-baseline nmbr - h ppg ,-hdl - c , mg / dl-current smoker ,-asian-bmi , kg / mnmbr-black-tnmbrdm duration , y-baseline fpg ,-baseline hbanmbrc , %-women , n ( % )-sbp , mmhg"
1190,characteristic_level,"ukpds nmbr - year risk score > nmbr % ""-ukpds nmbr - year risk score > nmbr %-ukpds nmbr - year risk score < nmbr %"
1191,arms,"saxagliptin nmbrmg ( n z nmbr )-saxagliptin nmbrmg ( n z nmbr ) ""-saxagliptin nmbr . nmbr mg ( n z nmbr )-placebo ( n z nmbr )"
1192,characteristic_name,"baseline laboratory values , median ( iqr ) d-qualifying myocardial infarction ""-pciperformed qualifying event-time study drug administration coronary revascularization , median ( iqr ) , h-region-medical history-demographics-race-catheterization performed qualifying event-useofmedical therapyathospitaldischarge-qualifying myocardial infarction"
1193,characteristic_level,"hyperlipidemia-baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc-prior coronary artery bypass graft surgery-statin-prior ischemic stroke-age , median ( iqr ) , y-hypertension-nmbr-current smoker-western europe-high - sensitivityc - reactive protein , mg / l-non - st - elevation myocardial infarction-aspirin-st - elevation myocardial infarction ""-n - terminal pro - brain natriuretic peptide , pg / ml-diabetes mellitus-st - elevation myocardial infarction-white-p - blocker-prior peripheralarterialdisease-body mass index , median ( iqr ) b-asia - pacific-ace inhibitor angiotensin receptor blocker-female-asian-black-prior pci-fibrinolytic qualifying event-prior myocardial infarction-other-eastern europe-north america-south america-prior heart failure-pnmbrynmbr inhibitor"
1194,arms,"placebo ( n = nmbr ) ""-losmapimod ( n = nmbr )-placebo ( n = nmbr )"
1195,characteristic_name,"planned treatment strategy-age , y-no . predictors cardiovascular risk-prior mi-time randomization pci ( non - st - elevation mi ) , h-chronic kidney disease-prior pci cabg surgery-actual treatment strategy-prior mi ""-time randomization pci ( st - elevation mi ) , min-prior heart failure-sex-qualifying diagnosis-diabetes mellitus"
1196,characteristic_level,"invasive-overall-pci-nmbr < nmbr-medical management only-conservative-< nmbr-non - st - elevation mi-male-female-no-nmbr-yes ""-st - elevation mi-cabg surgery-yes-> nmbr"
1198,arms,"losmapimod-losmapimod ""-placebo"
1199,characteristic_name,"indication index procedure-demographics ""-treatment-medical history-demographics"
1200,characteristic_level,"weight , kg-hypertension-previous mi-atrial fibrillation-stroke / tia-unstable anginat-diabetes mellitus-history major bleeding-age , yrs-oral medications-acute coronary syndrome-female ""-race nonwhitet-history cancer-cigarette smoker-nstemi-stemi-female-prior pci-peripheral artery disease-prior cabg-stable angina-other-diet controlled no-bmi , kg / mnmbr-hispanic latino-insulin-congestive heart failure"
1202,characteristic_name,"age $ nmbr yrs-unknown-body mass index , kg / mnmbr-statin-nonwhite race-current smoker-history chf-systolic blood pressure , mm hg-history stroke transient ischemic attack-history hypercholesterolemia-non - end - stage renal dysfunction-age , yrs-egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd )-ace - angiotensin receptor blocker-oral hypoglycemic-history hypertension-type nmbr diabetes-body mass index , kg / mnmbr ""-nstemi-qualifying mi < nmbr yrs prior-stemi-history peripheral artery disease-beta - blocker-prior angina-qualifying mi type-history atrial fibrillation-prior coronary artery bypass grafting-multivessel coronary artery disease-history percutaneous coronary intervention-male-history diabetes requiring drugs-insulin-history second prior mi"
1204,characteristic_name,"region-qualifying mi type-qualifying mi type """
1205,characteristic_level,"age $ nmbr yrs-unknown-western europe ( including south africa )-body mass index , kg / mnmbr-history pci stenting-beta - blocker use baseline-current smoker-history chf-history hypercholesterolemia-qualifying mi $ nmbr yrs prior ""-age , yrs-history claudication-history stroke tia-egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd )-history hypertension-ace - arb use baseline-history copd-aspirin use baseline-caucasian-nstemi-stemi-female-qualifying mi $ nmbr yrs prior-prior angina-prior cabg-peripheral revascularization-time qualifying mi , yrs-eastern europe-north america-statin use baseline-multivessel coronary artery disease-abi # nmbr . nmbr-south america-time last dose pnmbrynmbr inhibitor , days-history second prior mi-history diabetes-asia / australia / new zealand"
1207,characteristic_name,"body - mass index-age-previous ml-ldl cholesterol-lvef-duration assigned regimen surgery post - randomisation characteristic *-lvef """
1208,characteristic_level,"< nmbr yr-> nmbr , < nmbr mg / dl-> nmbr %-> nmbr kg / mnmbr-nmbr - nmbr days-> nmbr % ""-< nmbr mg / dl-> nmbr mg / dl-no-< nmbr days-nmbr - nmbr yr-> nmbr yr-< nmbr %-yes-all patients-< nmbr kg / mnmbr"
1210,characteristic_name,"postoperative glucocorticoid use post - randomisation characteristic * *-previous statin use-troponin nmbr baseline *-age-duration assigned regimen surgery post - randomisation characteristic * *-procedure * *-postoperative nsaid glucocorticoid use post - randomisation characteristic * *-sex ""-sex-surgical technique post - randomisation characteristic * *"
1211,characteristic_level,"< nmbr yr-cabg-off pump-on pump-male-female-no-< nmbr . nmbr ng / ml-> nmbr yr-< nmbr days-> nmbr days-avr-male ""-all patients-> nmbr . nmbr ng / ml-yes"
1213,characteristic_name,"body - mass index-age-previous ml-ldl cholesterol-lvef-duration assigned regimen surgery post - randomisation characteristic *-lvef """
1214,characteristic_level,"< nmbr yr-> nmbr , < nmbr mg / dl-> nmbr %-> nmbr kg / mnmbr-nmbr - nmbr days-> nmbr % ""-< nmbr mg / dl-> nmbr mg / dl-no-< nmbr days-nmbr - nmbr yr-> nmbr yr-< nmbr %-yes-all patients-< nmbr kg / mnmbr"
1216,characteristic_name,"region , n ( % )-region , n ( % ) ""-bmi ( kg / mnmbr )"
1217,characteristic_level,"< nmbr months , median ( min , max )-esr ( mm / h ) , median ( min , max )-months since ra first diagnosed , mean ( sd )-sdai , mean ( sd )-erosion score , median ( min , max )-> nmbr months , mean ( sd )-jsn , median ( min , max )-n-> nmbr months , median ( min , max )-systemic corticosteroids , n ( % ) a-acpa positive ( > nmbr iu / ml ) , n ( % )-mean age , years ( sd )-mtss , median ( min , max )-crp ( mg / l ) , median ( min , max )-female , n ( % )-sjc ( nmbr joints ) , mean ( sd )-mean ( sd )-high disease activity : > nmbr . nmbr , n ( % )-rf positive ( > nmbr iu / ml ) , n ( % )-cdai , mean ( sd )-tjc ( nmbr joints ) , mean ( sd )-haq - di , mean ( sd )-dasnmbr ( esr ) , mean ( sd )-presence erosions , n ( % ) ""-europe australia-< nmbr months , mean ( sd )-months since first ra symptom , mean ( sd ) f-moderate disease activity : > nmbr . nmbr < nmbr . nmbr , n ( % )-latin north america-presence erosions , n ( % )"
1219,arms,"patients ( n = nmbr )-indacaterol - glycopyrronium group ( n = nmbr )-salmeterol - fluticasone group ( n = nmbr ) ""-salmeterol - fluticasone group ( n = nmbr )"
1220,characteristic_name,"severity copd-inhaled glucocorticoid use screening-laba use screening-smoking status screening-inhaled glucocorticoid use screening ""-severity airflow limitation-sex-race-copd exacerbations previous year-laba - inhaled glucocorticoid use screening-lama use screening"
1221,characteristic_level,"overall-white-no use-severe-other-moderate-nmbr exacerbation-asian-female-male-use ""-former smoker-> nmbr exacerbations-current smoker-group d-use-very severe-group b"
1223,characteristic_name,"severity copd , airflow limitation , n ( % )-severity copd , combined assessment , n ( % )-smoking history , n ( % )-copd exacerbation history , n ( % )-cardiovascular risk factors-severity copd , combined assessment , n ( % ) ""-mmrc dyspnea scale , n ( % )-race , n ( % )"
1224,characteristic_level,"post - bronchodilator fevnmbr , % predicted-hyperlipidemia-very severe ( gold nmbr )-group c-post - bronchodilator fevnmbr reversibility , % a-hypertension-nmbr-pre - bronchodilator fevnmbr ( l )-atrial fibrillation / flutter-copd assessment test ( cat ) score-current smoker-age ( years )-duration copd ( years )-group b-diabetes mellitus-grade nmbr-number pack - years-ccv history / condition-> nmbr-female , n ( % )-caucasian-ex - smoker-black-group d-missing-ics use baseline , n ( % )-moderate ( gold nmbr )-others-missing ""-severe ( gold nmbr )-post - bronchodilator fevnmbr ( l )-male , n ( % )"
1225,arms,"ind nmbr mg q . . n = nmbr-gly nmbr . nmbr mg b . . . n = nmbr-ind nmbr mg q . . n = nmbr """
1226,characteristic_name,"history atrial fibrillation / flutter-history cardiac arrhythmia-ccv history / condition baseline-long - acting bronchodilator use screening-age ( years )-age ( years ) ""-race-severity airflow obstruction-ics use baseline"
1227,characteristic_level,"caucasian-nmbr < nmbr ""-nmbr < nmbr-< nmbr-female-male-no-severe severe copd-black-mild moderate copd-yes-> nmbr"
1228,arms,"gly nmbr . nmbr gg b . . n / n ( % )-ind nmbr gg q . . n / n ( % ) ""-ind nmbr gg q . . n / n ( % )"
1229,characteristic_name,"renal function-geographic region ""-geographic region"
1230,characteristic_level,"normal ( egfr > nmbr )-chronic kidney diseased ""-> nmbr % stenosis coronary , carotid , lower extremity arteries-cvd risk factors ( age > nmbr )-europe-body weight , kg-established cvd ( age > nmbr )-diastolic blood pressure , mm hg-systolic blood pressure , mm hg-heart failurea-prior revascularization-age , years-rest world-chronic kidney diseased-male sex-severe impairment ( egfr < nmbr )-prior stroke transient ischemic attack-asia-diabetes duration , years-hypertension left ventricular hypertrophy-left ventricular systolic diastolic dysfunction-moderate impairment ( egfr nmbr - nmbr )-ankle - brachial index < nmbr . nmbr-prior myocardial infarction-north america-documented asymptomatic cardiac ischemiac-bmi , kg / mnmbr-microalbuminuria proteinuria-mild impairment ( egfr nmbr - nmbr )-heart failure nyha ii - iii-glycated hemoglobin , %-documented symptomatic chdb"
1231,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-liraglutide ( n = nmbr , nmbr )"
1232,characteristic_level,"egfr < nmbr ml / min / nmbr . nmbr mnmbr-egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr-egfr > nmbr ml / min / nmbr . nmbr mnmbr-egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr """
1234,characteristic_name,"age , y-duration pci , min-periprocedural medications-medical history-weight-periprocedural medications """
1236,outcomes,"gusto - defined bleeding-death / mi / idr / st / gusto - defined moderate severe bleeding-primary safety end point : severe / life - threatening-key secondary end point : st-death / st-primary end point : death / mi / idr / st-any blood transfusion-mi-minor-acuity - defined bleeding-moderate-efficacy-idr-death cardiovascular causes-q - wave mi-timi - defined bleeding-severe moderate-death cause-death / q - wave mi / idr-mild-minor ""-safety : non - cabg - related bleeding-major-efficacy safety : net adverse clinical events *"
1239,characteristic_name,"baseline pulmonary medication , n ( % )-mean ( sd ) pre - bronchodilator ""-mean ( sd ) pre - bronchodilator-smoking status , n ( % )-mean ( sd ) post - bronchodilator"
1240,characteristic_level,"fevnmbr , l-fevnmbr , l ""-ics-any-ex - smoker-lama-laba-saba-mean ( sd ) age , years-current smoker-fevnmbr / fvc ratio , % ( sd )-sama-patients , n-male , n ( % )-fevnmbr % predicted"
1241,characteristic_level,"ics : no-overall-gold nmbr-gold d-naive : yes-ics : yes-gold a-gold c-naive : no-gold b-naive : yes """
1242,characteristic_name,"common concomitant aeds , n ( % )-lev status , n ( % ) ""-seizure types reported baseline , b n ( % )-racial group , n ( % )-no . prior aeds , c n ( % )-lev status , n ( % )"
1243,characteristic_level,"partial evolving secondarily generalized ( ic )-weight , kg , mean ( sd )-oxcarbazepine-mean age , ( sd )-topiramate-valproate-complex partial ( ib )-> nmbr-female , n ( % )-lev - naive ""-prior lev treatment-asian-black-whitea-simple partial ( ia )-baseline focal seizure frequency / nmbr days , median ( qnmbr - qnmbr )-lev - naive-nmbr - nmbr-carbamazepine-lamotrigine"
1244,arms,"brv dosage , mg / ""-brv dosage , mg /"
1245,arms,"nmbr ( n nmbr nmbr )-nmbr ( n nmbr nmbr ) """
1246,characteristic_name,"medical history , n ( % ) "" ; na-medical history , n ( % )"
1247,characteristic_level,"ckd ( egfr < nmbrb )-nt - probnp pg / mla ( iqr )-bmi ( kg / mnmbr )-hypertension-atrial fibrillation-age ( years )-ischaemic aetiology-number patients-egfr ( ml / min / nmbr . nmbr mnmbr )-kccq score-female sex , n ( % )-iv-hf hospitalization-diabetes-syst . bp ( mmhg )-ii-iii-caucasian , n ( % )-lvef-nyha class , n ( % ) i-age ( years ) ""-heart rate ( b . p . . )"
1248,outcomes,"hf hospitalization-hf hospitalization ""-all - cause mortality-significant worsening kccq clinical score ( > nmbr ) nmbr monthsnmbr-hf hospitalization cardiovascular death-cardiovascular death"
1250,characteristic_name,"diuretics-sbp , mm hg-age , yrs-ace-other-ischemic cardiomyopathy-icd-nt - probnp , pg / ml-history af ""-diabetes-lvef-nmbr-history stroke-arb-history af-mra-bnp , pg / ml-crt"
1252,characteristic_level,"prior hf hospitalization-nmbr - nmbr months-p value interaction-> nmbr months-< nmbr months "" ; na-< nmbr months"
1253,arms,"sacubitril / valsartan ""-sacubitril / valsartan-enalapril"
1254,outcomes,"dose reduction-drug discontinuation due death-average daily dose ( % target ) *-average daily dose ( % target ) * ""-elevated serum potassium , > nmbr . nmbr mmol / l"
1255,characteristic_name,"age-time randomization-sex ""-history ischemic stroke-history hypertension-sex-history hypercholesterolemia-lipid - lowering agents-history diabetes"
1256,characteristic_level,"hospital factor # nmbr-> nmbr beds-no-< nmbr beds-non - cortical-lesion location-overall-> nmbr enroll-vascular territory # nmbr-mca-female-male ""-< nmbr enroll-time treatment-yes-< nmbr yr-others-anterior circulation-cortical only-male-> nmbr yr-> nmbr hr-posterior circulation-< nmbr hr"
1258,arms,"placebo plus aspirin-placebo plus aspirin ""-clopidogrel plus aspirin"
1259,characteristic_name,"bloodpressure , mean ( sd ) , hg-priorvascular disease , %-cigarettesmoking , % ""-antihyperglycemictherapies , %-baseline heart failure severity amongthose priorheartfailure , %-glycatedhemoglobin category , %-cardiovascular medications , %-region , %-race / ethnicity , %-cigarettesmoking , %"
1260,characteristic_level,"diuretic-peripheral artery-nmbr . nmbr %-statin-coronary artery disease-glycated hemoglobin , mean ( sd ) , %-myocardial infarction-former-western europe-< nmbr %-never-aspirin-asia pacific other-egfr , mean ( sd ) , ml / min / nmbr . nmbr mnmbr-age , mean ( sd ) , y-white-p - blocker-nyha class iv-metformin-sulfonylurea-current ""-cerebrovascular-insulin-diastolic-systolic-not hispanic latino-ace inhibitor angiotensin receptor blocker-nyha class reported-thiazolidinedione-asian-black-nyha class ii-nyha class iii-diabetesduration , mean ( sd ) , y-priorheartfailure , %-other-body massindex , mean ( sd ) a-eastern europe-north america-latin america-hispanic latino-nyha class i-nonaspirin antiplatelet agent-calcium channel blocker-weight , mean ( sd ) , kg-female sex , %-nmbr < nmbr . nmbr %-current"
1261,characteristic_level,"without ( n = nmbr nmbr )-with ( n = nmbr )-without ( n = nmbr nmbr ) """
1264,characteristic_name,"number ( ) features present-who / idf ifg-number ( ) features present ""-laboratory data , mean ( sd )-antihypertensive medication or-ada ifg"
1265,characteristic_level,"fasting glucose ( mg / dl )-hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol )-triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l )-sbp / dbp $ nmbr / $ nmbr mmhg-insulin ( mu / ml )-nmbr-abdominal obesity *-nmbr ""-hbanmbrc ( % )-homa - ir-hbanmbrc nmbr . nmbr < nmbr . nmbr % ( nmbr - nmbr mmol / mol )-( $ nmbr mg / dl [nmbr . nmbr mmol / l] )-nmbr more-hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) men / women"
1266,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-pioglitazone ( n = nmbr , nmbr )"
1267,characteristic_name,"homa-abdominal obesity-aerobic activity-race-medication adherence-age-coronary artery disease history-ada impaired fasting glucose-hdl-glycated hemoglobin-body mass index-triglycerides-metabolic syndrome-hypertension history-sex-hispanic ethnicity-homa ""-who / idf impaired fasting glucose"
1269,characteristic_name,"race ( % )-previous oad ( % )-homa - ir ( % ) b-duration tnmbrdm ( % )-bmi category ( % )-homa - ir ( % ) b """
1270,characteristic_level,"> nmbr years-bmi ( kg / mnmbr )-> nmbr . nmbr mu / l $ mmol / l-nmbr-nmbr < nmbr kg / mnmbr-age ( years )-white-< nmbr . nmbr mu / l $ mmol / l ""-> nmbr-nmbr enmbr years-> nmbr . nmbr < nmbr . nmbr mu / l $ mmol / l-< nmbr kg / mnmbr-homa - ir , mean ( sd ) ( mu / l $ mmol / l ) b-asian-male ( % )-black-none-< nmbr year-> nmbr kg / mnmbr-presence mets ( % ) a-< nmbr . nmbr mu / l $ mmol / l-hbanmbrc ( % )-fasting c - peptide ( nmol / l ) c"
1271,arms,"linagliptin ( n z nmbr )-placebo ( n z nmbr ) ""-placebo ( n z nmbr )"
1272,characteristic_name,"disease characteristics * ""-disease characteristics *-demographics"
1273,characteristic_level,"mean disease duration , years-sjc-acpa positive , %-haq - di-dasnmbr - nmbr ( esr )-mean age , years-caucasian , n ( % )-tjc-vdhmtss-hscrp , mg / dl-rf positive , %-erosion score-rf positive , % ""-female , n ( % )"
1274,arms,"tofacitinib nmbr mg two times day-mtx-tofacitinib nmbr mg two times day """
1275,measures,"early ( n = nmbr )-established ( n = nmbr )-established ( n = nmbr ) """
1276,characteristic_name,"hbanmbrc ( % ) ""-on sulfonylurea-hbanmbrc ( % )-hbanmbrc distribution"
1277,arms,"placebo ( n = nmbr ) ""-sitagliptin ( n = nmbr )-placebo ( n = nmbr )"
1278,outcomes,"nmbr - h pmg ( mg / dl ) ""-hbanmbrc ( % )-fpg ( mg / dl )-nmbr - h pmg ( mg / dl )"
1279,characteristic_level,"subset patients metformin-subset patients metformin ""-subset patients metformin-entire cohort"
1280,measures,"ls mean change baselinenmbr ""-difference ls means ( nmbr % ci ) nmbr-ls mean change baselinenmbr"
1281,arms,"placebo ( n = nmbr ) ""-sitagliptin ( n = nmbr )-placebo ( n = nmbr )"
1282,characteristic_name,"ara functional class-duration ra ( years )-gender-age ( years )-ara functional class ""-race"
1283,characteristic_level,"white-mean ( sd )-min - max age-other-dmard corticosteroid-methotrexate user-asian-female-multi - racial-black-class ii-class iii-biologics user-low - dose corticosteroid user-dmard user-low - dose corticosteroid user ""-class"
1284,arms,"total n = nmbr n ( % )-etoricoxib nmbr mg n = nmbr n ( % )-placebo n = nmbr n ( % )-total n = nmbr n ( % ) """
1285,outcomes,"macce-mi-gusto moderate severe bleeding ""-gusto moderate severe bleeding"
1286,characteristic_level,"omt ""-on omt-off omt"
1287,characteristic_name,"cardiovascular history-comorbidities ""-comorbidities-medical therapies"
1288,characteristic_level,"history atrial fibrillation , n ( % )-white , n ( % )-history tia , n ( % )-ace inhibitor , n ( % )-diabetes mellitus , n ( % )-history pci , n ( % )-history stroke , n ( % )-history cabg , n ( % )-history hypertension , n ( % )-age , median ( iqr )-egfr < nmbr , n ( % )-statin , n ( % )-qualifying nstemi , n ( % )-history chf , n ( % )-female , n ( % )-dbp ( mm hg ) , median ( iqr )-history second prior mi , n ( % )-current smoking , n ( % ) ""-current smoking , n ( % )-bmi , median ( iqr )-weight kg , median ( iqr )-aspirin , n ( % )-arb , n ( % )-multivessel cad , n ( % )-hypercholesterolemia , n ( % )-sbp ( mm hg ) , median ( iqr )"
1289,characteristic_level,"stroke n = nmbr nmbr-stroke n = nmbr-stroke n = nmbr ""-p value"
1290,characteristic_level,"renal dysfunction-no prior stroke / tia-prior stroke / tia-diabetes-renal dysfunction-history chf-no history chf-history af-no diabetes-no history af ""-no history af"
1292,characteristic_name,"medical history risk factors-killip class-previous cardiovascular events-medical history risk factors ""-coronary angiography intervention-sex-age ( years )-stented vessels-concomitant medication randomisation"
1293,characteristic_level,"unstable angina-statin-proton - pump inhibitor-two - vessel disease-hypertension-coronary bypass graft-left main-myocardial infarction-current smoker-stent implanted-aspirin-left circumflex coronary artery-percutaneous coronary intervention-left anterior descending coronary artery-drug - eluting stent implanted ( least one )-chronic respiratory failure-creatinine clearance < nmbr ml / min-iv-> nmbr-coronary artery bypass grafting-heart failure-peripheral vascular disease-dyslipidaemia ""-dyslipidaemia-ace inhibitor arb-nstemi-inflammatory disease-stemi-three - vessel disease-number stents implanted-female-diabetes-( blocker-mra ( spironolactone eplerenone )-calcium - channel blocker-left main artery-multivessel ( two vessel , three vessel , left main )-i-right coronary artery-ii-iii-primary pci-radial access-one - vessel disease-bodyweight ( kg )-left ventricular ejection fraction-previous cancer-male-median ( iqr )-body - mass index ( kg / ' )-secondary pci-creatinine clearance admission ( ml / min )-haemoglobin ( g / dl )"
1294,arms,"monitoring group ( n = nmbr ) ""-control group ( n = nmbr )-monitoring group ( n = nmbr )"
1295,characteristic_level,"men-age > nmbr-st --no prior cancer-age < nmbr-hypertension-no prior ml-no prior heart failure-women-bms-length stent > median-full population-prior ml-no hypertension-women ""-diabetes-weight > nmbr kg-weight < nmbr kg-one vessel-no diabetes-no current smoking-prior cancer-length stent < median-st +-multi vessel ( left main )-des-current smoking-prior heart failure-number stent > nmbr-number stent = l nmbr nmbr-creat clearance < nmbr ml / min-creat clearance > nmbr ml / min"
1297,measures,"n ""-n"
1298,characteristic_name,"age group ( years )-ethnic group ""-ethnic group-smoking history-sex-race"
1299,characteristic_level,"diagnosis allergic rhinitis-time since asthma diagnosis ( years )-prebronchodilator fevnmbr ( % predicted normal ) t-missing data ""-reversibility ( % ) t-patients > nmbr exacerbations resulting hospital admission-former-age ( years )-total asthma symptom score :-acq - nmbr score *-never-prebronchodilator fevnmbr ( l ) t-number resulting hospital admission-white-number resulting emergency department visit-missing data-atopic ( based phadiatop test )-body - mass index ( kg / mnmbr ) t-> nmbr < nmbr-number exacerbations past nmbr months-history omalizumab treatment-not hispanic latino-current-female-asian-central eosinophil count ( cells per pl ) t-nasal polyps-black african american-> nmbr nmbr-other *-male-hispanic latino-smoking pack year ( years ) fl-patients > nmbr exacerbations resulting emergency department visit-aqlq ( ) + nmbr scorets-local eosinophil count ( cells per pl ) t-fevnmbr / fvc prebronchodilatort"
1300,characteristic_level,"high - dosage ics plus laba baseline blood eosinophils < nmbr cells per pl ( n = nmbr )-high - dosage ics plus laba baseline blood eosinophils anmbr cells per pl ( n = nmbr ) ""-high - dosage ics plus laba baseline blood eosinophils anmbr cells per pl ( n = nmbr )-all patients ( n = nmbr )"
1301,arms,"benralizumab nmbr mg qnmbrw ( n = nmbr )-benralizumab nmbr mg qnmbrw ( n = nmbr ) ""-placebo ( n = nmbr )"
1302,characteristic_name,"age group ( years )-ethnic group ""-ethnic group-sex-race"
1303,characteristic_level,"diagnosis allergic rhinitis-time since asthma diagnosis ( years )-acq - nmbr scoret-patients > nmbr exacerbations resulting ed visit-number resulting ed visit-patients > nmbr exacerbations resulting hospital admission-eosinophil count ( cells per pl )-age ( years )-prebronchodilator fevnmbr / fvc-central eosinophil count ( cells per pl )-number resulting hospital admission-white-smoker-nicotine pack - years-missing data-total asthma symptom score-atopic ( based phadiatop test )-> nmbr < nmbr-number exacerbations past nmbr months-history omalizumab treatment-not hispanic latino-predicted normal ( % )-reversibility ( % )-female-asian-aqlq ( ) + nmbr scored-nasal polyps-black african american-prebronchodilator fevnmbr ( l ) ""-> nmbr nmbr-other *-male-hispanic latino-prebronchodilator fevnmbr ( l )-body - mass index ( kg / ' )"
1304,characteristic_level,"high - dosage ics plus laba baseline blood eosinophils < nmbr cells per pl ( n = nmbr )-high - dosage ics plus laba baseline blood eosinophils > nmbr cells per pl ( n = nmbr )-high - dosage ics plus laba baseline blood eosinophils > nmbr cells per pl ( n = nmbr ) ""-all patients ( n = nmbr )"
1305,arms,"benralizumab nmbr mg qnmbrw ( n = nmbr )-benralizumab nmbr mg qnmbrw ( n = nmbr ) ""-placebo ( n = nmbr )"
1306,characteristic_name,"ncep risk category study entry , n ( % )-ncep risk category study entry , n ( % ) """
1307,characteristic_level,"apolipoprotein b , mean ( sd ) , g / l-triglycerides , median ( ql , qnmbr ) , mmol / l-current cigarette use , n ( % )-c - peptide , median ( ql , qnmbr ) , nmol / l-sbp , mean ( sd ) , mm hg-white-statin use study entry , n ( % )-waist circumference , mean ( sd ) , cm-insulin , median ( ql , qnmbr ) , pmol / l-low risk ""-coronary artery disease , n ( % )-low risk-moderate risk-moderately high risk-homa . ir , median ( ql , qnmbr ) , % / nmbr-lipoprotein ( ) , median ( ql , qnmbr ) , nmol / l-hypertension , n ( % )-demographics age , years , mean ( sd )-high risk-dbp , mean ( sd ) , mm hg glycaemic parameters-fpg , median ( ql , qnmbr ) , mmol / l-other lipid - modifying drug use study entry , n ( % )-black african american-hbalc , median ( ql , qnmbr ) , %-low - density lipoprotein cholesterol , mean ( sd ) , mmol / l-homa . % b , median ( ql , qnmbr ) , %-other-cerebrovascular peripheral arterial disease , n ( % )-female sex , n ( % ) race , n ( % )-high - density lipoprotein cholesterol , mean ( sd ) , mmol / l-bmi , mean ( sd ) , kg / mnmbr-weight , mean ( sd ) , kg"
1308,characteristic_level,"mets-type nmbr diabetes-ifg-no dysglycaemia mets-no dysglycaemia mets """
1309,arms,"evomab ( n = nmbr ) ""-pbo ( n = nmbr )-evomab ( n = nmbr )"
1310,outcomes,"homajr tx difference vs pbo , median change baseline ( se ) nmbr lipid parameters-hbalc tx difference vs pbo , median change baseline ( se ) nmbr-hbalc tx difference vs pbo , median change baseline ( se ) nmbr ""-insulin tx difference vs pbo , median change baseline ( se ) nmbr-triglycerides tx difference vs pbo , ls mean % change baseline ( se )-apolipoprotein b tx difference vs pbo , ls mean % change baseline ( se )-parameter-low - density lipoprotein cholesterol tx difference vs pbo , ls mean % change baseline ( se )-lipoprotein ( ) tx difference vs pbo , ls mean % change baseline ( se )-high - density lipoprotein cholesterol tx difference vs pbo , ls mean % change baseline ( se )-homa_ % b tx difference vs pbo , median change baseline ( se ) nmbr-c - peptide tx difference vs pbo , median change baseline ( se ) nmbr-fpg tx difference vs pbo , median change baseline ( se ) nmbr"
1311,characteristic_level,"mets-type nmbr diabetes-ifg-no dysglycaemia mets-no dysglycaemia mets """
1312,arms,"pbo ( n = nmbr ) vs-pbo ( n = nmbr ) vs """
1313,characteristic_name,"age , y-total cholesterol-core laboratory percent stenosis-egfr-hdl-bmi-race-hdl ""-systolic blood pressure , mm hg-albumin creatinine ratio"
1314,characteristic_level,"uacr available-cohort nmbr ( uacr > nmbr . nmbr mg / g ) ""-cohort nmbr ( uacr < nmbr . nmbr mg / g )-cohort nmbr ( uacr > nmbr . nmbr mg / g )"
1315,arms,"medical therapy ( n = nmbr )-stent ( n = nmbr )-medical therapy ( n = nmbr ) """
1316,characteristic_name,"acr deciles-acr deciles """
1317,characteristic_level,"overall-> = nmbr . nmbr-nmbr , nmbr - < nmbr . nmbr ""-nmbr - < nmbr . nmbr-nmbr , nmbr - < nmbr . nmbr-nmbr . nmbr - < nmbr . nmbr-nmbr . nmbr - < nmbr-< nmbr . nmbr"
1319,characteristic_name,"congestive heart failure-age , yrs-u . . site-previous cabg-weight , kg-prior stroke tia-white race-male-prior stroke tia ""-previous mi-peripheral artery disease-previous pci-smokers-diabetes mellitus"
1321,outcomes,"death "" ; na-d / mi / idr / st-death-ml-idr-st-qmi"
1322,characteristic_level,"sa-acs-acs """
1323,characteristic_name,"diabetes duration , n ( % )-number antidiabetes drugs screening , n ( % )-hbanmbrc , % , n ( % ) b ""-age , n ( % )-race , n ( % )-hbanmbrc , % , n ( % ) b-renal function ( egfr , ml / min / nmbr . nmbr mnmbr , according mdrd ) , n ( % )-ethnicity , n ( % )"
1324,characteristic_level,"nmbr < nmbr years-concomitant medication , n ( % )-> nmbr years-coronary artery disease-hispanic / latino-hypertension-nmbr-aspirin-age , years ( sd )-fasting plasma glucose , mg / dl , mean ( sd ) b-white-microvascular disease , n ( % )-neuropathy-< nmbr years-retinopathy-lipid - lowering drugs-cerebrovascular disease-asian-black-hbanmbrc , % , mean ( sd ) b-native american / alaskan-nephropathy-peripheral artery disease-> nmbr . nmbr % ""-< nmbr year-severe impairment ( < nmbr )-> nmbr . nmbr %-mild impairment ( nmbr < nmbr )-macrovascular disease , n ( % )-normal ( > nmbr )-antihypertensive drugs-bmi , kg / mnmbr , mean ( sd )-< nmbr . nmbr %-non - hispanic / latino-male , n ( % )-moderate impairment ( nmbr < nmbr )"
1325,arms,"linagliptin-linagliptin ""-linagliptin / metformin"
1326,characteristic_name,"ethnicity-bmi ( kg / mnmbr )-creatinine clearance ( ml / min )-race ""-age ( years )-race"
1327,measures,"difference ( nmbr % cl )-difference ( nmbr % cl ) ""-number patients"
1328,arms,"baricitinib nmbr mg qd ( n = nmbr )-baricitinib nmbr mg qd ( n = nmbr ) ""-placebo ( n = nmbr )"
1329,characteristic_name,"cardiovascular risk factors , n ( % )-sex , n ( % )-medical history , n ( % )-cardiovascular risk factors , n ( % ) """
1330,characteristic_level,"mean age , years ( sd )-chronic renal failure-smoker ( current / former )-mean % predicted dlco * ( sd )-mean ucsd - sobq score * ( sd )-male-hypertension-diabetes-hypercholesterolaemia-cardiovascular disease-copd-obesity t-smoker ( current / former ) ""-mean % predicted fvc ( sd )-mean nmbrmwd * , ( sd )"
1332,outcomes,"nmbrmwd decrease > nmbr m-absolute decrease > nmbr %-ipf - related-all - cause ""-all - cause-all - cause mortality-relative decrease > nmbr %-death absolute fvc decrease > nmbr %-respiratory - related^-disease - progression composite outcome !-absolute fvc decrease > nmbr %-death nmbrmwd decrease > nmbr"
1333,measures,"bivariate frailty model ( statin users vs non - users )-crude analysis , n ( % )-crude analysis , n ( % ) """
1335,characteristic_name,"mmrc grade , n ( % )-copd exacerbation history , n ( % )-catscorecategory , n ( % )-gold nmbr groups , n ( % )-mmrc grade , n ( % ) ""-copd severity , n ( % ) *"
1336,characteristic_level,"no-nmbr-nmbr - nmbr ( moderate )-nmbr - nmbr ( severe )-post - bronchodilator fevnmbr reversibility , %-post - bronchodilator fevnmbr , l-age , years-nmbr - nmbr ( severe )-icsusers atbaseline , n ( % )-nmbr ""-gold d-moderate-duration copd , years-yes-post - bronchodilator fevnmbr / fvc , %-current smokers , n ( % )-severe-post - bronchodilator fev , , % predicted-nmbr - nmbr ( mild )-sex , male , n ( % )-mild-gold b"
1337,arms,"sfcnmbr / nmbr pg b . . . n = nmbr ""-ind / glynmbr / nmbr pg . . n = nmbr-sfcnmbr / nmbr pg b . . . n = nmbr"
1338,characteristic_name,"cigarette smoking-glucose - lowering therapies-cigarette smoking ""-cardiovascular medications"
1339,characteristic_level,"diuretic-bmi ( kg / mnmbr )-coronary artery disease-statin-uacr ( mg / g )-myocardial infarction-former-age ( years )-acei / arb-never-aspirin-hbanmbrc ( mmol / mol )-beta blocker-women-sulfonylurea-metformin-current ""-egfr ( ml / min / nmbr . nmbrmnmbr )-heart failure-ldl - cholesterol ( mg / dl )-systolic blood pressure ( mmhg )-diabetes duration ( years )-total cholesterol ( mg / dl )-cerebrovascular disease-thiazolidinedione-diastolic blood pressure ( mmhg )-thienopyridine-peripheral arterial disease-white race-hbanmbrc ( % )-calcium channel blocker-insulin-previous vascular disease-current"
1340,characteristic_name,"stage nmbra-stage nmbrb ""-stage nmbrb-stage nmbr"
1341,characteristic_level,"egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ) ""-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % )"
1342,outcomes,"hospitalization unstable angina-nmbr - point mace ""-all - cause death-nmbr - point mace-stroke-hospitalization heart failure-myocardial infarction-cv death"
1343,characteristic_name,"stage nmbr ""-stage nmbr-stage nmbra-stage nmbrb-treatment egfr stage"
1344,characteristic_level,"egfr > nmbr ml / min / nmbr . nmbrmnmbr-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr-egfr > nmbr ml / min / nmbr . nmbrmnmbr """
1345,characteristic_name,"il - nmbr ( pg / ml )-serum creatinine ( mmol / l )-haemoglobin ( g / l )-nt - probnp ( pg / ml )-age-disease duration ( years )-dasnmbr-c - reactive protein ( mg / dl )-troponin ( pg / ml )-number previous dmards-swollen joint count ( n / nmbr )-white ethnicity-white ethnicity ""-tender joint count ( n / nmbr )-current smoker-female sex-baseline diabetes"
1346,characteristic_name,"clinical characteristics-clinical characteristics ""-demographics-baseline medical therapy-peripheral artery disease details"
1347,characteristic_level,"hyperlipidemia-history atrial fibrillation fl utter-hypertension-current smoker-smoking status-aspirin-abi-diabetes mellitus-age , yrs-history stroke tia-prior amputation-abi > nmbr . nmbr-any coronary artery disease-prior carotid intervention-abi < nmbr . nmbr-peripheral artery revascularization without amputation-hypertension ""-ace inhibitor arb-egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr-female-never smoker-weight < nmbr kg-former smoker-thienopyridine-claudication ( fontaine class > nmbr )-no antiplatelet therapy-aspirin thienopyridine therapy-white race-bmi , kg / mnmbr-statin therapy-cilostazol"
1349,characteristic_name,"clinical features hf-nyha class-race / ethnicity-treatment randomization-medical history-medical history """
1350,characteristic_level,"cardiac resynchronization therapy-ischemic cardiomyopathy-bnp , median ( iqr ) , pg / ml-hypertension-nmbr-myocardial infarction-atrial fibrillation-left ventricular ef , mean ( sd ) , %-sbp , mean ( sd ) , mm hg-heart rate , mean ( sd ) , beats / min-age , mean ( sd ) , y-white-p - blocker-implantable cardioverter - defibrillator-bmi , mean ( sd )-digitalis-iv-atrial fibrillation ""-potassium , mean ( sd ) , meq / l-female sex-asian-diabetes-black-potassium supplement-creatinine , mean ( sd ) , mg / dl-nt - probnp , median ( iqr ) , pg / ml-diuretics-ii-iii-other-hospitalization hf-stroke"
1351,measures,"p value mra vs mra-no . ( % ) participants ""-no . ( % ) participants"
1352,arms,"mra baseline-mra baseline-mra baseline """
1353,arms,"sacubitril / valsartan ( n = nmbr )-enalapril ( n = nmbr )-enalapril ( n = nmbr ) """
1354,outcomes,"hyperkalemiab ""-severe hyperkalemiac-hyperkalemiab"
1355,characteristic_level,"mra baseline-mra baseline-mra baseline """
1357,characteristic_name,"baseline medications-lntensityd-lntensityd ""-race / ethnicity"
1358,characteristic_level,"baseline ezetimibe usec-men-baseline statin usec-ace inhibitor-previous ml-hypertension-previous pci-antiplatelet therapy-age , mean ( sd ) , y-white-p - blocker-smoking-american indian alaska native-moderate-low ""-asian-diabetes-arb-bmi , mean ( sd ) b-black african american-native hawaiian pacific islander-high-other-multiple-low"
1359,arms,". ( % )-no . ( % ) """
1360,characteristic_name,"baseline tav - < median ( n = nmbr , nmbr )-non - smoker ( n = nmbr , nmbr )-non high dose statin ( n = nmbr , nmbr )-family history chd ( n = nmbr , nmbr )-baseline tav - > = median ( n = nmbr , nmbr )-proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr , nmbr )-prior statin ( n = nmbr , nmbr )-race - white ( n = nmbr , nmbr )-current smoker ( n = nmbr , nmbr )-non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr , nmbr )-type nmbr diabetes ( n = nmbr , nmbr )-high dose statin ( n = nmbr , nmbr )-age ( years ) - < median ( n = nmbr , nmbr )-proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr , nmbr )-no family history chd ( n = nmbr , nmbr )-race - non - white ( n = nmbr , nmbr )-baseline pav - > = median ( n = nmbr , nmbr )-no history mi ( n = nmbr , nmbr )-female ( n = nmbr , nmbr ) ""-age ( years ) - > = median ( n = nmbr , nmbr )-baseline pav - < median ( n = nmbr , nmbr )-female ( n = nmbr , nmbr )-no type nmbr diabetes ( n = nmbr , nmbr )-no prior statin ( n = nmbr , nmbr )-history mi ( n = nmbr , nmbr )-male ( n = nmbr , nmbr )-non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr , nmbr )"
1361,measures,"pav , mean ( nmbr % ci )-pav , mean ( nmbr % ci ) """
1362,arms,"evolocumab ( nmbr mg )-evolocumab ( nmbr mg ) ""-placebo"
1363,measures,"baseline-on - treatment-on - treatment """
1364,characteristic_name,"race - . ( % )-baseline lipid / lipoprotein values-chd risk - . ( % )-prior diagnosis - . ( % )-type concomitant statin daily dose - . ( % )-use concomitant lipid - lowering therapy - . ( % )-at ldl - c ( bq ) goal * baseline - . ( % )-type concomitant statin daily dose - . ( % ) """
1365,arms,"anacetrapib nmbr mg ( n - nmbr ) ""-anacetrapib nmbr mg ( n - nmbr )-placebo ( n = nmbr )"
1366,characteristic_name,"medication use baseline , n ( % ) ""-medication use baseline , n ( % )"
1367,characteristic_level,"basmi ( linear ) , mean ( sd )-elevated hscrp > nmbr mg / l , n ( % )-patient ' global assessment disease activity , mean ( sd )-total basdai , mean ( sd )-methotrexate ""-hla - bnmbr positive , n ( % )-basfi , mean ( sd )-sulfasalazine-age , mean ( sd ) years-msasss , mean ( sd )-syndesmophyte present , n ( % )-glucocorticoids-time since diagnosis , mean ( sd ) years-hscrp , median ( min , max ) , mg / l-total back pain , mean ( sd )-methotrexate-weight , mean ( sd ) kg-current smoker , n ( % )-anti - tnf - naive , n ( % )-male gender , n ( % )"
1368,arms,"secukinumab intravenous nmbr mg ( n = nmbr ) ""-secukinumab intravenous nmbr mg ( n = nmbr )"
1369,characteristic_level,"patients syndesmophytes baseline-elevated hscrp-patients without syndesmophytes baseline-male-female-male ""-smokers ( baseline )-overall population-non - smokers ( baseline )-normal hscrp"
1370,measures,"baseline-patients ( n )-change week nmbr-baseline """
1371,arms,"placebo secukinumab nmbr mg-placebo secukinumab pooled-placebo secukinumab nmbr mg """
1372,characteristic_name,"baseline pulmonary medication , n ( % ) ""-gold , n ( % )-baseline pulmonary medication , n ( % )-smoking status , n ( % )"
1373,characteristic_level,"laba-nmbr ( < nmbr % )-b - blocker-mean ( sd ) age , years-current smoker-sama-ics ""-diabetes mellitus-vascular disordersb-nmbr ( nmbre < nmbr % )-cardiac history-lama-cardiac rhythm disorders-saba-co - morbidities , n ( % )-ischaemic heart disease-mean ( sd ) extent exposure , days-nmbr ( > nmbr % )-baseline cardiovascular medication , c n ( % )-ex - smoker-xanthines-ics-male , n ( % )"
1374,arms,"tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr )-tiotropium nmbr mg ( n = nmbr )-tiotropium nmbr mg ( n = nmbr ) ""-olodaterol nmbr mg ( n = nmbr )"
1375,outcomes,"cardiac failure , n ( % )-total patients , n-supraventricular tachyarrhythmias ( incl . atrial-hypertension , n ( % )-any aes , n ( % )-cerebrovascular disorders , n ( % ) ""-ventricular tachyarrhythmias-other ischaemic heart disease ( non - infarction )-tachyarrhythmias , n ( % )-myocardial infarction-haemorrhagic-cerebrovascular disorders , n ( % )-ischaemic-ischaemic heart disease , n ( % )"
1376,characteristic_level,"cardiac rhythm disorder baseline yes-cardiac rhythm disorder baseline yes """
1377,arms,"tiotropium nmbr g ""-tiotropium nmbr g-tiotropium / olodaterol nmbr / nmbr mg-olodaterol nmbr g"
1378,characteristic_name,"age-racea-copd disease severity-cardiac history-age ""-cardiac rhythm disorders-sex-ics use baseline-diabetes mellitus"
1379,arms,"tiotropium nmbr mg-olodaterol nmbr mg-total-tiotropium nmbr . nmbr mg-tiotropium / olodaterol nmbr / nmbr mg-tiotropium / olodaterol nmbr . nmbr / nmbr mg-tiotropium / olodaterol nmbr . nmbr / nmbr mg """
1380,measures,"n-n ( % ) ""-n ( % )"
1381,characteristic_name,"nationality ""-ethnicity-nationality-race"
1382,characteristic_level,"sex , male-india-body weighta , kg-white-malaysia-age , years-asian-bmi , kg / mnmbr-korea , republic of-malaysia ""-china-duration tnmbrdm , years-philippines-romania-not hispanic latino"
1383,characteristic_level,"chinese subgroup-chinese subgroup ""-full analysis set"
1384,arms,"sitagliptin nmbr mg n = nmbr-sitagliptin nmbr mg n = nmbr ""-placebo n = nmbr"
1385,outcomes,"hbanmbrc , %-fpg , mmol / l ""-fpg , mmol / l"
1386,characteristic_level,"chinese subgroup-chinese subgroup ""-full analysis set"
1387,arms,"sitagliptin nmbr mg n = nmbr-sitagliptin nmbr mg n = nmbr ""-sitagliptin nmbrmg n = nmbr-placebo n = nmbr"
1388,characteristic_name,"organ system involvement , . ( % )-disease hare . . ( % ) i-race / ethnicity-( nmbr - nmbr - cm vas )-medications . . ( % )-enrollment region , . ( % )-selena - sledai ( range u - nmbrunmbr ) t-enrollment region , . ( % ) ""-immunosuppressants"
1389,characteristic_level,"female , . ( % )-hematologic-age , mean nmbr sd years-mycophenolate mofetil-americas , excluding us-renal-mean nmbr sd-vascular-cardiovascular respiratory-mucocutaneous-immunosuppressants only-score # nmbr , . ( % )-physician ' global assessment . mean nmbr sd-score $ nmbr , . ( % )-disease duration , median ( range ) years-facit - fatigue . mean nmbrsd ( range nmbr - nmbr )-at least nmbr flare-not hispanic latino-corticosteroids immunosuppressants only-asia-us-azathioprine-constitutional-methotrexate-at least nmbr severe flare-weight , mean nmbr sd kg-eastern europe-immunosuppressants antimalarials only-immunologic-corticosteroids . immunosuppressants . antimalarials-central nervous system-hispanic latino-western europe / australia / israel-corticosteroids only-antimalarials only-corticosteroids antimalarials only-us ""-median ( range )-musculoskeletal"
1390,arms,"placebo ( n nmbr )-belimumab nmbr mg sc ( n nmbr )-belimumab nmbr mg sc ( n nmbr ) """
1391,characteristic_name,"ss baseline-race ss baseline-baseline body weight quartile-steroid use baseline-race-steroid use baseline """
1392,characteristic_name,"bmi ( kg / mnmbr )-age ( years )-esr ( mm / hour )-haq - di score-dasnmbr ( esr )-sjc ( / nmbr joints )-erosion score-weight ( kg )-sdai-female , n ( % )-mmp - nmbr ( ng / ml )-bone erosion ( judged physician ) , n ( % )-mtss-average weekly mtx dose ( mg / week ) t-tjc ( / nmbr joints )-sjc ( / nmbr joints ) ""-ra duration ( months ) *-anti - ccp antibody positive , n ( % )-rf positive , n ( % )-crp ( mg / dl )-joint space narrowing score"
1393,arms,"pbo + mtx^mtx-czp + mtx^mtx-czp + mtx^mtx """
1394,measures,"total patients n = nmbr-patients entering pt period n = nmbr ""-patients entering pt period n = nmbr"
1395,measures,"db baseline ( week nmbr ) ""-pt baseline ( week nmbr )-db baseline ( week nmbr )"
1396,characteristic_name,"mmp - nmbr ( ng / ml )-il - nmbr ( pg / ml )-ra duration ( months ) *-haq - di-mtss-dasnmbr-il - nmbr ( pg / ml ) "" ; na-tnf - alpha ( pg / ml )-baseline steroids-rf ( iu / ml )-mtx exposure ( mg / week )-crp ( mg / dl )-baseline erosion"
1397,characteristic_level,"nmbr - < nmbr-> nmbr . nmbr - < nmbr . nmbr-nmbr < - nmbr-< nmbr-no-yes-nmbr - nmbr-> nmbr . nmbr-> nmbr - < nmbr-> nmbr-> nmbr . nmbr - < nmbr . nmbr ""-< nmbr . nmbr"
1398,arms,"czp + mtx mtx ""-pbo + mtx mtx-czp + mtx mtx"
1399,other,"mtss cfb ""-mtss cfb"
1400,measures,"sd-n-mean-mean """
1401,characteristic_name,"ethnic origin ""-methotrexate dose baseline-sex-age range ( years )-ethnic origin"
1402,characteristic_level,"tender joint count ( nmbr - nmbr )-unknown-bmi ( kg / mnmbr )-< nmbr-age ( years )-swollen joint count ( nmbr - nmbr )-white-stiffness ( min )-haq - di score ( nmbr - nmbr )-anti - ccp antibody positive-> nmbr < nmbr-clinical disease activity index score ( nmbr - nmbr )-conventional synthetic dmard use baseline-> nmbr-dasnmbr ( c - reactive protein )-> nmbr < nmbr - nmbr mg / week-bmi ( kg / mnmbr ) ""-female-asian-c - reactive protein ( mg / l )-black-none-duration morning-other-male-simplified disease activity index score ( nmbr - nmbr )-rheumatoid factor - positive-> nmbr - nmbr mg / week-duration rheumatoid arthritis ( years )"
1404,characteristic_name,"overall-prior anti - tnf therapy-prior biologic therapy ( including anti - tnfs ) ""-prior biologic therapy ( including anti - tnfs )"
1405,measures,"acrnmbr response week nmbr , n ( % ) ""-acrnmbr response week nmbr , n ( % )"
1406,characteristic_level,"received nmbr prior biologic therapies , n ""-received > nmbr prior anti - tnf therapies , n-received nmbr prior biologic therapy , n-received nmbr prior biologic therapies , n-received nmbr prior anti - tnf therapy , n-evaluable acrnmbr week nmbr , n"
1407,arms,"placeboa-sirukumab nmbr mg qnmbrw-sirukumab nmbr mg qnmbrw """
1408,characteristic_name,"coexisting conditions-type event-laboratory findings-demographics-medications-coexisting conditions ""-at randomization"
1409,characteristic_level,"unstable angina-hs - crp , mg / l-statin-beta - blocker !-time acs randomization-peripheral artery disease *-egfr < nmbr ml / min / nmbr . nmbr mnmbr *-acei / arb-aspirin-previous stroke *-age , yrs-egfr , ml / min / nmbr . nmbr mnmbr-previous cabg ( index acs ) *-previous pci ( index acs )-caucasian-age > nmbr yrs *-non - hdl - c , mg / dl-female-ml st - segment elevation-ldl - c , mg / dl-thienopyridine-ml without st - segment elevation !-current smoking *-lipid - lowering agent-total cholesterol , mg / dl-hypertension *-previous ml ( index acs )-heart failure *-bmi , kg / mnmbr-pre - randomization pci-diabetes *-diabetes * """
1410,characteristic_level,"intermediate ( nmbr ) ( n = nmbr , nmbr ; nmbr % )-high ( > nmbr ) ( n = nmbr , nmbr ; nmbr % ) ""-low ( nmbr - nmbr ) ( n = nmbr , nmbr ; nmbr % )-overall ( n = nmbr , nmbr )-high ( > nmbr ) ( n = nmbr , nmbr ; nmbr % )"
1411,characteristic_name,"non - hdl - c-total cholesterol-hs - crp-ldl - c-tg-hdl - c-total cholesterol ""-apo - b"
1412,characteristic_level,"overall-low risk ( ri = nmbr - nmbr )-intermediate risk ( ri = nmbr ) ""-intermediate risk ( ri = nmbr )-high risk ( ri = nmbr )"
1413,measures,"baseline-nmbryr-nmbryr """
1414,arms,"simva ""-ez / simva-pooled-simva"
1415,measures,"n = nmbr ""-n = nmbr"
1416,characteristic_name,"race *-blood pressure ( mm hg )-waist circumference ( cm )-hdl cholesterol-cholesterol ( mmol / l )-race * ""-sex-bmi category"
1417,characteristic_level,"men-bmi ( kg / mnmbr )-black african - american-ldl cholesterol-nmbr-age ( years )-overall-free fatty acids ( mmol / l )-white-total-vldl cholesterol-fasting glucose ( mmol / l )-women-triglycerides ( mmol / l )-dyslipidaemiat-women ( n = nmbr vs nmbr )-nmbr - nmbr - nmbr , overweight-nmbr - h plasma glucose ogtt ( mmol / l )-weight ( kg )-hispanic latino ethnic group *-diastolic-men ( n = nmbr vs nmbr )-systolic-dyslipidaemia hypertensiont-other ""-american indian alaska native-fasting insulin ( pmol / l )-nmbr - nmbr - nmbr , obesity class nmbr-non - hdl cholesterol-asian-hypertensiont-native hawaiian pacific islander-other-glycated haemoglobin ( % )-> nmbr , obesity class nmbr-male"
1418,arms,"liraglutide nmbr - nmbr mg ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1419,characteristic_name,"concomitant medications , n ( % )-physical examination-demographic features-laboratory data-concomitant medications , n ( % ) ""-clinical history , n ( % )"
1420,arms,"placebo ""-pioglitazone-placebo"
1421,measures,"( n = nmbr )-( n = nmbr ) """
1422,characteristic_name,"body mass index ""-statin-age-ada impaired fasting glucose-coronary artery disease history-gender-glycated hemoglobin-body mass index-triglycerides-atrial fibrillation-hypertension history-race-arb / ace-aspirin-homa > median"
1423,characteristic_level,"> nmbr years-absent ( < nmbr mg / dl )-< nmbr-present ( > nmbr mg / dl )-no-> nmbr mg / dl-nmbr . nmbr % - nmbr . nmbr %-all participants-> nmbr-< nmbr years-nmbr . nmbr - nmbr . nmbr % t-fema le-white / other-< nmbr mg / dl-< nmbr ""-yes-black african american-male-< nmbr . nmbr %"
1425,characteristic_name,"clinical characteristics-ecg-physical examination-medical history-medications ""-medications"
1426,characteristic_level,"dilatative , n ( % )-beta - blockers ( ) , n ( % )-previous cabg , n ( % )-bmi ( kg / mnmbr )-mitral regurgitation , n ( % )-peripheral vascular disease , n ( % )-age ( yrs )-pathologic q waves , n ( % )-previous pci , n ( % )-former / current smoker , n ( % )-rales , n ( % )-nyha iv , n ( % )-ischaemic , n ( % )-symptoms-oral anticoagulant , n ( % )-diuretics , n ( % )-heart failure cause-amiodarone , n ( % )-previous myocardial infarction , n ( % )-digoxin , n ( % )-pm , n ( % )-nyha iii , n ( % )-non - detectable / unknown , n ( % )-calcium channel blockers , n ( % )-other cause , n ( % )-snmbr gallop , n ( % )-systolic blood pressure ( mmhg )-total cholesterol ( mg / dl )-hypertension , n ( % )-previous cancer , n ( % )-ace inhibitors / arbs , n ( % )-diastolic blood pressure ( mmhg )-heart rate ( beats / min )-icd , n ( % )-spironolactone , n ( % )-other antiplatelet agents , n ( % )-previous stroke , n ( % )-diabetes , n ( % )-nyha ii , n ( % )-aortic stenosis , n ( % )-previous hf hospitalization , n ( % )-aspirin , n ( % )-history atrial arrhythmia , n ( % )-qrs duration > nmbr ms , n ( % )-other antiplatelet agents , n ( % ) ""-lv hypertrophy , n ( % )-atrial fibrillation / flutter , n ( % )-hypertensive , n ( % )-nitrates , n ( % )-women , n ( % )"
1428,outcomes,"- cause hospitalization-cv mortality-non cv mortality "" ; na-all - cause mortality-non cv mortality"
1430,measures,"p-hr ( nmbr % cl )-p """
1431,characteristic_name,"blood eosinophils count-blood eosinophils count """
1432,characteristic_level,"> nmbr cells / pl-> nmbr %-< nmbr cells / pl-nmbr < nmbr cells-< nmbr %-> nmbr cells / pl """
1433,measures,". patients ind / gly sfc ""-rate ratio ( nmbr % ci )-no . patients ind / gly sfc-annualized rate ind / gly sfc"
1434,measures,"age , mean ( sd ) , years-age , mean ( sd ) , years ""-baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )-nmbr - nmbr-> nmbr-female , n ( % )"
1435,arms,"levetiracetam-topiramate-lamotrigine ""-carbamazepine-lamotrigine"
1436,characteristic_name,"naive ( n = nmbr )-naive ( n = nmbr ) ""-exposed ( n = nmbr )"
1437,arms,"rivaroxaban-rivaroxaban ""-aspirin nmbr mg ( n = nmbr )"
1438,characteristic_name,"known thrombophilia-history recurrent venous thromboembolism-presentation index event-extent index event-active cancer-age-risk factor profile index event-duration pre - randomization anticoagulant therapy-body mass index-fragile-body weight-sex-creatinine clearance-active cancer """
1439,arms,"aspirin nmbr mg-rivaroxaban nmbr mg-aspirin nmbr mg """
1440,characteristic_name,"race-race ""-copd medication study entry-sex-smoking status"
1441,characteristic_level,"coronary artery osteochondrosis-> nmbr % < nmbr %-coronary artery disease-cholecystitis chronic-myocardial ischaemia-hypertension-chronic bronchitis !-myocardial infarction-fvc ( l ) *-current smoker-age ( years )-< nmbr %-diabetes mellitus-white-body - mass index ( kg / - )-arteriosclerosis-cardiac failure-blood leucocyte concentration ( nmbr cells per l )-laba / lama-lama-ischaemic heart disease-black / african american-spacer use study-patients least one concomitant disease *-inspiratory capacity ( l )-reversibility ( % )-ex - smoker-female-% predicted normal value *-blood eosinophil concentration , nmbr cells per l-ics / laba-exacerbation rate previous year ( range )-time since first copd diagnosis ( years )-ischaemic cardiomyopathy-body - mass index ( kg / - ) ""-ics / lama-other-obesity-fevnmbr , l *-blood eosinophil proportion ( % )-male-cat total score-angina pectoris-fevnmbr / fvc ratio *"
1442,arms,"tiotropium ( n = nmbr )-tiotropium ( n = nmbr ) ""-open triple ( n = nmbr )-fixed triple ( n = nmbr )"
1443,outcomes,"fpg ( mmol / l )-nmbr - h ppg ( mmol / l )-daily iglar dose week nmbr ( u )-hbanmbrc ( % ) "" ; na-hbanmbrc ( % )-tnmbrdm duration ( years )"
1444,arms,"iglarlixi ( fixed - ratio combination )-iglar ( insulin glargine lnmbr u )-iglar ( insulin glargine lnmbr u ) """
1445,characteristic_level,"> lnmbr years ""-< lnmbr years-< nmbr years-> lnmbr years"
1446,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-ularitide ( n = nmbr )"
1447,characteristic_name,"coronary artery disease-age screening-ejection fraction-region-gender-diabetes-baseline systolic bp-time first eval-gfr assessed mdrd-nt - pro bnp-race-troponin t-history chronic hf-gender """
1448,characteristic_name,"european quality life - nmbr dimensions - nmbr level ( eq - nmbrd )-number concomitant csdmards , n ( % )-disease activity ""-patient characteristics-( haq - di , nmbr - nmbr )-disease activity-activity ( nmbr - nmbr vas )-number prior csdmards , n ( % )-short form nmbr ( sf - nmbr )-patient - reported outcome measures"
1449,characteristic_level,"female patients , n ( % )-mtx + non - mtx-duration ra ( time symptom onset ) , years-nmbr-esr , mm / hour-mtx-dasnmbr - hscrp-health state index score , uk algorithm-health assessment questionnaire - disability index-tender joint count , nmbr ""-age , years-mental component score ( mcs )-cdai-> nmbr-sdai-swollen joint count , nmbr-vas ( nmbr - nmbr )-physical component score ( pcs )-concomitant mtx use , n ( % )-patient ' assessment pain ( nmbr - nmbr vas )-functional assessment chronic illness-nmbr non - mtx-hscrp , mg / l-non - mtx-tender joint count , nmbr-concomitant corticosteroid use , n ( % )-mean ( sd ) mtx dose , mg / week-patient ' global assessment disease"
1450,arms,"baricitinib nmbr mg ( n = nmbr ) ""-baricitinib nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
1451,characteristic_name,"cardiovascular inclusion criteriat-high risk ( receiving treatment ) :-high risk ( receiving treatment ) : ""-race-concomitant cardiovascular therapy ( taken > nmbr days )"
1452,arms,"placebo , n = nmbr-combination therapy , n = nmbr-fluticasone furoate , n = nmbr-placebo , n = nmbr ""-vilanterol , n = nmbr-total , n = nmbr nmbr"
1453,characteristic_name,"ethnicity-african - american / african heritage ( n = nmbr )-race-ischemic heart disease indicator ( n = nmbrl )-region-gender-vascular disease indicator ( n = nmbr )-african - american / african heritage ( n = nmbr ) ""-cv entry criteria-nmbr - nmbr cv risk disease ( n = nmbr )-smoking status-age group"
1454,characteristic_level,"asian ( n = nmbr ) "" ; na-> nmbr years < nmbr years ( n = nmbr )-former smoker ( n = nmbr )-nmbr - nmbr cv disease ( n = nmbr )-current smoker ( n = nmbr )-white ( n = nmbr )-< nmbr years ( n = nmbr )-usa ( n = nmbr )-female ( n = nmbr )-hispanic latino ( n = nmbr )-rest - - world ( n = nmbr )-yes ( n = nmbr )-asian ( n = nmbr )-other ( n = nmbr )-europe nmbr ( n = nmbr )-male ( n = nmbr )-not hispanic latino ( n = nmbr )-asia ( n = nmbr )-> nmbr years ( n = nmbr )"
1455,measures,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )-hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr ) """
1456,other,"octave induction nmbr-octave sustain-octave induction nmbr """
1457,arms,"tofacitinib , nmbr mg ( n = nmbr ) ""-tofacitinib , nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
1458,characteristic_name,"demographic characteristics-disease characteristics ""-medication use-disease characteristics"
1459,arms,"abatacept ( n = nmbr * )-placebo ( n = nmbr * ) ""-placebo ( n = nmbr * )"
1460,characteristic_level,"tnfi naive ""-tnfi naive-total population-tnfi exposed"
1461,measures,"acrnmbr-acrnmbr """
1462,other,"week nmbr ""-week nmbr"
1464,characteristic_name,"copd severity ""-copd severity"
1465,characteristic_level,"moderate , n ( % ) a-white , n ( % )-mean age , years-mean fevnmbr , l ( sd )-baseline ics use , n ( % ) ""-mean sgrq total score ( sd )-current smoker , n ( % )-post - bronchodilator percent predicted fevnmbr , % ( sd )-severe , n ( % ) b-previous treatment laba / lama , n ( % ) c-baseline ics use , n ( % )-mean bdi focal score ( sd )-cigarette smoking , mean pack - years ( sd )-male , n ( % )-mean number exacerbations previous nmbr months ( sd )"
1466,arms,"placebo ( n = nmbr ""-ab / ff nmbr / nmbr pg ( n = nmbr )-ab nmbr pg ( n = nmbr )-placebo ( n = nmbr-ff nmbr pg ( n = nmbr )"
1467,characteristic_name,"history amputation-history heart failure-region-glycated hemoglobin-bmi-blood pressure control ""-egfr-blood pressure control-history peripheral vascular disease-age-insulin use-beta - blocker use-race-statin use-sex-diuretic use-antithrombotic use-study-duration diabetes-raas inhibitor use-history cardiovascular disease"
1468,characteristic_level,"europe-central america south america-< nmbr-no-< nmbr %-systolic blood pressure < nmbr mm hg diastolic blood pressure < nmbr mm hg-white-nmbr < nmbr ml / min / nmbr . nmbr mnmbr-rest world-> nmbr-systolic blood pressure > nmbr mm hg diastolic blood pressure > nmbr mm hg-> nmbr ml / min / nmbr . nmbr mnmbr-female-asian-black-all patients-canvas - r-yes-< nmbr yr-> nmbr %-other-north america-canvas-systolic blood pressure < nmbr mm hg diastolic blood pressure < nmbr mm hg ""-male-> nmbr yr"
1470,measures,". participants per nmbr patient - yr ""-no . participants per nmbr patient - yr"
1471,characteristic_name,"time since diagnosis diabetesa , n ( % )-egfr ( ckd - epi , cystatinc ) , ml / min / nmbr . nmbr mnmbr , n ( % )-time since diagnosis diabetesa , n ( % ) ""-uacra , mg / g , n ( % )-race , n ( % )"
1472,characteristic_level,"> nmbr years-diastolic blood pressurea , mmhg-^ - blockers-uacra , mg / g , gmean = gcv-weight , kg-< nmbr-hbanmbrca , % ( mmol / mol )-< nmbr year ""-white-> nmbr nmbr years-metformin-age , years-oral antidiabetes combination therapy without insulina , n ( % )-insulina , n ( % )-calcium antagonists-> nmbr-egfr ( mdrd ) , ml / min / nmbr . nmbr mnmbr-oral antidiabetes monotherapya , n ( % )-hawaiian / pacific islander-antihypertensive therapy , n ( % )-statins-black / african - american-asian-arbs-ace inhibitors-< nmbr year-diuretics-egfr ( ckd - epi , cystatin c ) , ml / min / nmbr . nmbr mnmbr-other-bmi , kg / mnmbr-nmbr < nmbr-systolic blood pressurea , mm hg-male , n ( % )"
1473,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-linagliptin ( n = nmbr )"
1474,characteristic_level,"europe ""-asia-north america-europe-baseline uacr > nmbr mg / g-all participants-baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr-baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr-baseline uacr < nmbr mg / g"
1476,characteristic_name,"time since diagnosis type nmbr diabetes-triglycerides *-hdl cholesterol *-hbanmbrc-sex-race-egfr - ""-ldl cholesterolt-egfr --total cholesterol *"
1477,characteristic_level,"normoalbuminuria baseline ( nmbr % patients treated ) ""-microalbuminuria baseline ( nmbr % patients treated )-macroalbuminuria baseline ( nmbr % patients treated )-normoalbuminuria baseline ( nmbr % patients treated )"
1478,arms,"empagliflozin ( n = nmbr )-empagliflozin ( n = nmbr ) ""-placebo ( n = nmbr )"
1479,characteristic_level,"uric acid tertile nmbr ( < nmbr . nmbr mg / dl )-uric acid tertile nmbr ( > nmbr . nmbr mg / dl )-uric acid tertile nmbr ( nmbr . nmbr < nmbr . nmbr mg / dl )-uric acid fertile nmbr ( > nmbr . nmbr mg / dl )-uric acid tertile nmbr ( > nmbr . nmbr mg / dl ) """
1480,measures,"n analysed-change baseline *-difference vs placebo '-difference vs placebo * *-change baseline * """
1481,characteristic_level,"patients normoalbuminuria baseline-patients macroalbuminuria baseline ""-patients microalbuminuria baseline-patients macroalbuminuria baseline"
1482,arms,"placebo ""-empagliflozin-placebo"
1483,characteristic_name,"dyspnoea - mmrc grade , n ( % )-number exacerbation previous nmbr months , n ( % )-baseline treatments , n ( % ) a-baseline treatments , n ( % ) "" ; na"
1484,characteristic_level,"laba + ics ( free fixed - dose combination )-lama ( monotherapy )-othersc "" ; na-nmbr-laba ( monotherapy )-othersc-> nmbr"
1485,arms,"ind / gly n = nmbr-ind / glyb n = nmbr-ind / glyb n = nmbr ""-laba + ics n = nmbr-laba lamab n = nmbr"
1486,characteristic_name,"reversibility-smoking status "" ; na-age , years-baseline therapy-mmrc baseline-exacerbations previous year-sex-smoking status-fevnmbr baseline"
1487,characteristic_level,"= nmbr-> nmbr %-ex - smokers-other-ex - smokers ""-= nmbr %-form / bud-< nmbr-male-female-nmbr-< nmbr %-sfc-current"
1488,measures,"number patients ""-laba + ics versus indzgly lsm difference ( nmbr % cl )-number patients"
1489,arms,"indzgly-laba + ics-indzgly """
1490,characteristic_name,"reversibility-age , years-fev , baseline-mmrc baseline-baseline therapy-age , years "" ; na-exacerbations previous year-sex-smoking status"
1491,characteristic_level,"snmbr %-nmbr ""-nmbr % nmbr-snmbr-others-< nmbr-male-female-laba-nmbr-lama-nmbr nmbr-ex - smokers nmbr-> nmbr % nmbr-< nmbr %-current"
1492,outcomes,"st ( arc definite )-death-mi-gusto severe-acuity major-ipst-death , mi , idr , st , gusto moderate / severe bleeding-gusto moderate / severe-timi major-idr-gusto severe ""-gusto moderate-death , mi , idr , st , timi bleeding-st-death , mi , idr , st gusto severe bleeding-timi minor-timi major / minor-death , mi , idr , st"
1493,characteristic_level,"age < nmbr ( n = nmbr )-age > nmbr ( n = nmbr )-age < nmbr ( n = nmbr ) """
1495,arms,"aspirin alone ( n = nmbr )-rivaroxaban alone ( n = nmbr )-rivaroxaban plus aspirin ( n = nmbr )-rivaroxaban alone ( n = nmbr ) """
1496,characteristic_name,"baseline dyslipidemia-geographic region-race-coronary artery disease-age-peripheral arterial disease-sex ""-history hypertension-estimated gfr-baseline tobacco use-body weight-sex-baseline diabetes"
1498,other,". events / total . ( % ) ""-no . events / total . ( % )"
1499,characteristic_name,"killip class-infarct location ""-timi risk score-infarct location"
1500,characteristic_level,"low risk ( nmbr - nmbr )-men-body mass index , kg / mnmbr-weight , kg-hypertension-high risk ( nmbr - nmbr )-glucose , mmol / l-scr , gmol / l-hemorrhagic stroke-diabetes mellitus-ischemic stroke-ldl - c , mmol / l-diastolic blood pressure-hypercholesterolemia-anterior ""-systolic blood pressure-crp , mg / l-hemoglobin , g / l-age , y-heart rate , beats / min-anterior-family history coronary disease-hdl - c , mmol / l-not anterior-ii - iv-peripheral artery disease-previous angina pectoris-red blood cell counting , nmbr / l-i-moderate risk ( nmbr - nmbr )-mean platelet volume , fl-previous coronary intervention-platelet , nmbr / l-total cholesterol , mmol / l-triglyceride , mmol / l"
1502,characteristic_level,"< nmbr hr-men-nmbr < nmbrmmhg-women-iiiv-nmbrlnmbrmmhg-no-< nmbrkg-nmbr < nmbrkg-nmbr < nmbrmmhg ""-nmbr - nmbr hr-nmbrto < nmbrmmhg-yes-i"
1503,characteristic_name,"killip class-time randomization-hypertension-diabetes-weight-systolic blood pressure ""-sex-systolic blood pressure"
1505,measures,". panents . total . nmbr % )-no . panents . total . nmbr % ) """
1506,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-all patients ( n = nmbr , nmbr )-anacetrapib ( n = nmbr , nmbr )"
1507,characteristic_name,"region-prior disease-hdl cholesterol ( mg / dl )-alcohol intake-medication-gender-urinary albumimcreatinine ratio-body mass index ( kg / mnmbr )-lipoprotein ( ) ( nmol / l )-systolic blood pressure ( mmhg )-total cholesterol ( mg / dl )-apolipoprotein anmbr ( mg / dl )-diastolic blood pressure ( mmhg )-time since qualifying event-waisthip ratio ""-apolipoprotein b ( mg / dl )-triglycerides ( mg / dl )-atorvastatin dose-cigarette smoking-waisthip ratio-non - hdl cholesterol ( mg / dl )-glomerular filtration rate ( ml / min / nmbr . nmbrma ,-age randomization ( years )-ldl cholesterol ( mg / dl )"
1508,characteristic_level,"diuretic-medium-coronary heart disease-former / non - drinker-all-< nmbr-europe-> nmbr < nmbr-current smoker-peripheral - artery disease-non - smoker-china-< nmbr months-> nmbr-heart failure-micro - albuminuria-macro - albuminuria-ace inhibitor arb-> nmbr , < nmbr-cerebrovascular disease-beta - blocker-female-diabetes-former smoker-high ""-high-current drinker-north america-male-normal-> nmbr months-calcium channel blocker-low-anti platelet therapy"
1509,measures,"lipid difference ( mg / dl ) ""-no . participants events ( % )-lipid difference ( mg / dl )"
1511,characteristic_name,"renal function ( egfr , ml / min / nmbr . nmbr mnmbr )-renal function ( egfr , ml / min / nmbr . nmbr mnmbr ) """
1512,characteristic_level,"normal ( egfr > nmbr )-systolic blood pressure , mmhg-not treated ""-insulin - na ' ive-calcium channel blockers-insulin + oad-hba , % nmbrc-nmbr bmi , kg / m-ace inhibitors arb-diastolic blood pressure , mmhg-egfr ( ml / min / nmbr . nmbr mnmbr )-age , years-male sex , n ( % )-insulin treated-severe impairment ( egfr < nmbr )-macroalbuminuria-lipid - lowering drugs-statins-diabetes duration , years-insulin only-microalbuminuria-moderate impairment ( egfr nmbr - nmbr )-diuretics-antihypertensive therapy-others-not treated-loop diuretics-oad only-mild impairment ( egfr nmbr - nmbr )-beta blockers"
1513,arms,"placebo ( n = nmbr ) ""-liraglutide ( n = nmbr )-placebo ( n = nmbr )"
1514,outcomes,"post - bronchodilation fevnmbr-pre - bronchodilation fevnmbr-pre - bronchodilation fvc ""-pre - bronchodilation fvc-post - bronchodilation fvc"
1516,characteristic_level,"cat > nmbr-cat > nmbr ""-cat < nmbr"
1518,measures,"mean ( se )-n-mean ( se ) """
1519,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-mepolizumab , nmbr mg ( n = nmbr )"
1520,characteristic_name,"< nmbr historical count > nmbr-> nmbr < nmbr-< nmbr historical count > nmbr ""-< nmbr regardless historical count-< nmbr historical count > nmbr-> nmbr"
1522,other,"randomization groups nmbr nmbr ""-randomization groups nmbr nmbr"
1523,characteristic_level,"pfo closure group ( n = nmbr )-anticoagulant group ( n = nmbr )-antiplatelet - onl group ( n = nmbr ) ""-antiplatelet - onl group ( n = nmbr )-antiplatelet - group ( n = nmbr )"
1524,characteristic_name,"comorbidities ""-comorbidities-asthma control test score baseline-number exacerbations nmbr months randomisation"
1525,characteristic_level,"vascular-diabetes ""-any-cardiac-< nmbr-diabetes-nmbr-nmbr - nmbr-> nmbr"
1526,arms,"fluticasone furoate vilanterol ( n = nmbr )-fluticasone furoate vilanterol ( n = nmbr ) ""-usual care ( n = nmbr )"
1527,characteristic_name,"region ,-ethnicity ,-cv risk factor-time since diagnosis type nmbr diabetes-anti - coagulants-urine albumin - - creatinine ratio-lipid - lowering therapy-medication taken alone combination-region , ""-race-anti - hypertensive therapy"
1528,characteristic_level,"patients without prevalent kidney disease baseline ""-patients without prevalent kidney disease baseline-patients prevalent kidney disease baseline"
1529,arms,"empagliflozin ( n = nmbr )-empagliflozin ( n = nmbr ) ""-placebo ( n = nmbr )"
1530,outcomes,"ldl - cholesterol ( mg / dl )-hdl - cholesterol ( mg / dl )-systolic blood pressure ( mmhg )-hdl - cholesterol ( mg / dl ) ""-hemoglobin ( g / dl )-hbanmbrc ( % )-serum uric acid ( mg / dl )-weight ( kg )"
1531,measures,"baseline-week nmbr-change baseline week nmbr-change baseline week nmbr ""-difference vs placebo"
1532,characteristic_level,"patients egfr > nmbr ml / min / nmbr . nmbrmnmbr baseline ""-patients egfr < nmbr ml / min / nmbr . nmbrmnmbr baseline-patients egfr > nmbr ml / min / nmbr . nmbrmnmbr baseline"
1533,arms,"empagliflozin nmbr mg ( n = nmbr ) ""-empagliflozin nmbr mg ( n = nmbr )-placebo ( n = nmbr )"
1534,characteristic_name,"statin intensitynmbr * nmbr-mean ( . . ) calculated ldl cholesterol-mean ( . . ) fpg-mean ( . . ) measured ldl cholesterol-total cholesterol-median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol-race , n ( % ) ""-concomitant lipid - lowering therapy , n ( % )-median ( qnmbr : qnmbr ) total daily insulin dosenmbr-mean ( . . ) hdl cholesterol-median ( qnmbr : qnmbr ) tgs-mean ( . . ) non - hdl cholesterol-age group , n ( % )-concomitant antihyperglycaemic drugs , n ( % )-race , n ( % )-ethnicity , n ( % )"
1535,characteristic_level,"tnmbrdm-tnmbrdm """
1536,arms,"alirocumab ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1537,outcomes,"baseline-% change baseline , mean ( . e . )-week nmbr-baseline """
1539,characteristic_level,"tnmbrd-tnmbrd """
1540,arms,"alirocumab ( n = nmbr )-placebo ( n = nmbr ) ""-difference vs placebo , % [nmbr % cl] , p-placebo ( n = nmbr )"
1541,arms,"pbo-pbo "" ; na-ali"
1542,characteristic_name,"ethnicity-region-other medication usage-cigarette smoking status-cardiovascular medication usage-antihyperglycemic medication usage ""-race-antihyperglycemic medication usage-history cardiovascular disease-european subcategories"
1543,characteristic_level,"coronary artery disease-calcium channel blockers-never-aspirin-renin inhibitor ( e . g . aliskerin )-asia pacific-body mass index ( kg / mnmbr )-nitrates-thiazide-sitagliptin-cerebrovascular disease-thiazolidinedione-native hawaiian pacific islander-> nmbr %-factor xa inhibitor-allogliptin-nmbr - nmbr-age randomization ( years )-beta blockers-aldosterone antagonists ( e . g . spironolactone )-ranolazine-alpha - glucosidase inhibitors ""-alpha nmbr blockers-< nmbr-former-alpha - glucosidase inhibitors-other anti - platelet agents-hormone replacement therapy-clopidogrel / ticlopidine-biguanides-fish oil-hispanic-dual therapy-monotherapy-sglt - nmbr inhibitors^-none-low molecular weight heparin-latin america-statini-hispanic latino-hbanmbrc ( % )-indian ( american ) alaska native-diuretic-> nmbr years-pramlintide-ace inhibitor-europe-western europe-digoxin / digitalis glycoside-chronic coxnmbr inhibitors-sulfonylurea-glp - nmbr receptor agonist ( study drug )-lipid - lowering medications^-insulin alone-other antihypertensive-< nmbr years-history congestive heart failure-not hispanic latino-oral agents use-dapagliflozint-angiotensin receptor blockers-diabetes duration ( years )-niacini-egfr via mdrd ( ml / min / nmbr . nmbrmnmbr )-insulin plus > nmbr oral agent-fibrate-proton pump inhibitors-saxagliptin-min , max-north america-vitamin k antagonist ( e . g . warfarin / coumarol )-antithrombotic anticoagulant medications-ezetimibe-non - sulfonylurea secretagogues-other glp - nmbr receptor agonist-linagliptin-< nmbr %-dpp - nmbr inhibitor therapy-white-> nmbr - < nmbr years-chronic non - steroidal antiinflammatory drugs-> nmbr-female-asian-exenatide lar-black-other sglt - nmbr inhibitor-vildagliptin-exenatide-prior cv event randomization !-antihypertensive , antianginal , cardiovascular medications-peripheral arterial disease-eastern europe-insulin plus nmbr oral agent-liraglutide-direct thrombin inhibitors-> nmbr oral agents-hydralazine-insulin-other antihyperglycemic agents , listed-current"
1544,arms,"placebo n = nmbr ""-exenatide n = nmbr-placebo n = nmbr"
1545,characteristic_name,"background aha therapy screening , n ( % ) ""-region , n ( % )-background aha therapy screening , n ( % )-race / ethnicity , n ( % )"
1546,characteristic_level,"three agents-sbp , mm hg-fpg , mg / dl-hbanmbrc , %-europe-calcium channel blockers-body weight , kg-dpp - nmbr inhibitors-white-sulphonylureas-egfr , ml / min / nmbr . nmbr mnmbr-ras agents-two agents-age , years-biguanides-one blood pressure medications , n ( % )-hbanmbrc , mmol / mol-other anti - hypertensives-american indian alaska native-asia-dbp , mm hg-c - peptide-asian-fpg , mmol / l-duration tnmbrdm , years-black african american-diuretics-egfr , ml / min / nmbr . nmbr mnmbr ""-north america-bmi , kg / mnmbr-hispanic latino-south america-multiple-beta blockers-male , n ( % )"
1548,characteristic_name,"hbanmbrc distribution baseline , n ( % ) ""-hbanmbrc distribution baseline , n ( % )"
1549,characteristic_level,"= nmbr . nmbr % ( = nmbr mmol / mol )-< nmbr . nmbr % ( nmbr mmol / mol )-nmbr . nmbr < nmbr . nmbr % ( nmbr < nmbr mmol / mol ) ""-nmbr . nmbr < nmbr . nmbr % ( nmbr < nmbr mmol / mol )"
1550,arms,"ertugliflozin nmbr mg-ertugliflozin nmbr mg ""-placebo"
1551,characteristic_name,"racenmbr-region-nyha functional class screening-racenmbr ""-laboratory measures-time since diagnosis heart failure-medical history-lv ejection fraction ( % )-medications randomization-physiological measures-cause heart failure-devices heart failure screening visit"
1552,characteristic_level,"diuretic-central europe-nt - probnp ( pg / ml ) ( qnmbr - qnmbr )-> nmbr years-non - ischaemic cardiomyopathy-hypertension-hospitalization heart failure-myocardial infarction-atrial fibrillation-beta - adrenergic blocker-western europe-< nmbr %-egfr ( ml / min / nmbr . nmbr mnmbr )-percutaneous coronary intervention-digitalis-other / missing-iv-coronary artery bypass surgery-> nmbr - nmbr years-mineralocorticoid receptor antagonists-caucasian-asia-systolic blood pressure ( mmhg )-icd-crt - d-crt - p-asian-black-< nmbr year-ischaemic cardiomyopathy-ii-iii-lipid - lowering agent-> nmbr %-north america-latin america-stroke-other / missing ""-antiplatelet drug-oral anticoagulant-heart rate ( b . p . . )"
1553,outcomes,"diabetes ""-no diabetes-diabetes"
1554,arms,"aliskiren ( n = nmbr )-enalapril + aliskiren ( n = nmbr )-enalapril ( n = nmbr )-aliskiren ( n = nmbr ) """
1556,characteristic_level,"diabetes ""-diabetes-non - diabetes"
1557,characteristic_level,"unstable angina-statin-hypertension-triglycerides ( median , iqr ) , mg / dl-atrial fibrillation-acei / arb-aspirin-diabetes mellitus-white-prior cabg ( index acs )-hdl - c ( median , iqr ) , mg / dl-score nmbr - nmbr-prior stroke-heart failure-nstemi-age ( median , iqr ) , y-stemi-hs - crp ( median , iqr ) , mg / l-egfr < nmbr ml / min / nmbr . nmbrmnmbr-female-prior ml ( index acs )-bmi ( median , iqr ) , kg / mnmbr-peripheral artery disease-egfr ( median , iqr ) , ml / min / nmbr , nmbrmnmbr-total cholesterol ( median , iqr ) , mg / dl-thienopyridine-age > nmbr , y-lipid - lowering agent-p blocker-ldl - c ( median , iqr ) , mg / dl ""-current smoking-chanmbrdsnmbr - vasc score ( median , iqr )-ldl - c ( median , iqr ) , mg / dl-time acs randomization ( median , iqr )"
1558,characteristic_name,"labs index acs event ""-labs index acs event-coexisting conditions-at index acs event-demographics-before index acs event"
1560,characteristic_level,"smoking-age > nmbr-age < nmbr-males-crci > nmbr-overall-ldl - csmedian ""-females-prior stroke-ldl - csmedian-caucasian-crcl < nmbr-non - caucasian-stemi-diabetes-htn-no htn-ldl - c > median-crci > nmbr - < nmbr-no diabetes-no prior stroke-prior llt-no prior llt-current smoking-nste - acs"
1562,outcomes,"unstable angina-ischemic stroke-ml-cv death , ml , stroke ""-primary trial end point-coronary heart disease death-coronary revascularization-cv death , ml , stroke-urgent coronary revascularization-all - cause mortality-hemorrhagic stroke-stroke etiology-cv death"
1565,characteristic_name,"modified rankin scale score-modified rankin scale score ""-index event subtype"
1566,characteristic_level,"coronary artery disease-stroke ( vs tia )-nmbr-lacunar-atrial fibrillation-current smoker-age , mean ( sd ) , y-other defined-aphasia-motor weakness-male sex-atrial fibrillation ""-prior stroke-hemoglobin anmbrc , mean ( sd ) , % b-hypertension history-peripheral artery disease-cardioembolic-uncertain-systolic blood pressure , mean ( sd ) , mm hga-large vessel atherosclerosis"
1567,measures,"patients , . / total . ( % )-patients , . / total . ( % ) """
1568,arms,"placebo ( n = nmbr ) ""-pioglitazone ( n = nmbr )-placebo ( n = nmbr )"
1569,characteristic_name,"aphasia-age-cad-current smoker ""-htn hx-current smoker-prior stroke"
1570,characteristic_level,"nmbr +-< nmbr-no-yes ""-nmbr - nmbr-yes"
1572,measures,"risk *-events / n-risk * """
1573,characteristic_name,"years [range]-ibdq domain scores , mean [sd]-sf - nmbrvnmbr domain scores , mean [sd]-ibdq domain scores , mean [sd] """
1574,characteristic_level,"previous anti - tnf therapy , n [ % ]-gender , n [ % ] male-sf - nmbrvnmbr pcs , mean [sd] ""-physical function-duration disease , median-ibdq total score , mean [sd]-role emotional-emotional status-concomitant aminosalicylates , n [ % ] concomitant corticosteroids , n [ % ] mayo score , mean [sd]-systemic symptoms-sf - nmbrvnmbr pcs , mean [sd]-social function-mental health-role physical-general health-sf - nmbrvnmbr mcs , mean [sd]-age , mean years , [sd]-social functioning-vitality-bodily pain-bowel function"
1575,other,"octave induction nmbr-octave sustain-octave induction nmbr """
1576,arms,"tofacitinib nmbr mg bid [n = nmbr | ""-tofacitinib nmbr mg bid [n = nmbr |-placebo [n = nmbr]-placebo [n = nmbr |"
1577,characteristic_level,"male-female-no-male "" ; na-yes"
1578,characteristic_name,"prior anti - tnf therapy-gender-gender ""-corticosteroid use baseline"
1579,other,"octave induction nmbr nmbr-octave induction nmbr nmbr """
1580,arms,"placebo ""-tofacitinib nmbr mg bid-placebo"
1581,characteristic_name,"prior anti - tnf therapy-gender-corticosteroid use baseline-prior anti - tnf therapy """
1582,characteristic_level,"""-male-female-no-yes"
1583,other,"octave sustain-octave sustain """
1584,arms,"tofacitinib nmbr mg bid-tofacitinib nmbr mg bid ""-placebo"
1585,outcomes,"ibdq total score week nmbr , mean [se]-in ibdq total score week nmbr , mean [se] """
1586,characteristic_level,"body mass index , kg / mnmbr-sirolimus - eluting-bifurcation lesion side branch $ nmbr . nmbr mm stented-paclitaxel - eluting-hypertension-nmbr-nonwhite race-lesion length $ nmbr mm-previous mi-atrial fibrillation-unstable angina *-prasugrel-clopidogrel-coronary artery bypass graft-diabetes mellitus-vein bypass graft stented-unprotected left main stented-age , yrs-previous percutaneous coronary intervention-thrombus - containing lesion-number stents ( per patient )-everolimus - eluting-stroke / transient ischemic attack-> nmbr des type-history cancer-stent diameter < nmbr mm-stent type-left ventricular ejection fraction < nmbr %-stemi-prior brachytherapy-> nmbr lesions per vessel-non - stemi-stent diameter $ nmbr mm-stable angina-current cigarette smoker within past year-peripheral arterial disease-other-number treated vessels ( per patient )-hispanic latino ""-male-hispanic latino-congestive heart failure-renal insufficiency / failure-zotarolimus - eluting"
1587,characteristic_name,"anatomic complexity characteristics "" ; na-anatomic complexity characteristics"
1589,characteristic_name,"index event subtype-demographic features-physical examination-laboratory data-concomitant medications-clinical history-concomitant medications ""-index event"
1590,characteristic_level,"unknown-body mass index , kg / mnmbr-statin-coronary artery disease-hbanmbrc , %-black race-hypertension-lacunar-prior stroke ( index event )-atrial fibrillation-hispanic ethnicity-systolic blood pressure , mm hg-diastolic blood pressure , mm hg-large vessel-other defined-anticoagulant-modified rankin scale screening , nmbr - nmbr-male sex-nihss randomization , nmbr - nmbr-age , y-current cigarette smoking-ischemic stroke ( vs . tia )-carotid artery intervention *-cardioembolic-ldl cholesterol , mmol / l-uncertain-statin ""-triglycerides , mmol / l-c - reactive protein-homa - ir-antiplatelet"
1591,arms,"placebo ( n = nmbr ) ""-pioglitazone ( n = nmbr )-placebo ( n = nmbr )"
1592,characteristic_name,"carotid stenosis-age-ldl - cholesterol-gender-glycated hemoglobin-body mass index-race ""-atrial fibrillation-hypertension history-race-prior stroke-homa > median"
1593,characteristic_level,"white / ""-> nmbr years-> nmbr kg / mnmbr-white / other-nmbr . nmbr % - nmbr . nmbr %-> nmbr . nmbr mmol / l-female-male-yes-no-< nmbr . nmbr mmol / l-nmbr . nmbr - nmbr . nmbr % f-< nmbr . nmbr %-black african american-< nmbr years-< nmbr kg / mnmbr"
1595,measures,"risk ""-risk-events / n"
1596,characteristic_name,"race , n ( % ) ""-race , n ( % )-sex , n ( % )-egfr category , n ( % )"
1597,characteristic_level,"white-bmi , mean ( sd ) ""-other-> nmbr ml / min / nmbr . nmbr mnmbr-asian-female-male-bmi , mean ( sd )-nmbr nmbr ml / min / nmbr . nmbr mnmbr-nmbr onmbr ml / min / nmbr . nmbr mnmbr-black african american"
1598,arms,"canagliflozin dose-canagliflozin dose """
1599,arms,"total ( n = nmbr )-nmbr mg ( n = nmbr )-nmbr mg ( n = nmbr ) """
1600,characteristic_name,"smokinq status-previous treatment ""-reqion-sex-previous treatment"
1601,characteristic_level,"> nmbr years-previous myocardial infarction-hypertension-( e - blocker-current smoker-western european includinq australia , israel , south africa-north american-asia , pacific other-ace inhibitor arb-diabetes-female-former smoker-peripheral artery disease-lipid - lowerinq druq-< nmbr year-calcium channel blocker ""-male-nmbr - nmbr years-calcium channel blocker-south american-eastern european"
1602,arms,"aspirin alone ( n = nmbr )-rivaroxaban alone ( n = nmbr )-rivaroxaban alone ( n = nmbr ) ""-low - dose rivaroxaban plus aspirin ( n = nmbr )"
1603,characteristic_name,"history myocardial infarction-baseline diabetes ""-region-timi risk score !-non - smokers receiving lipid - lowering drugs , p blockers ,-history cabg-history pci / ptca-sex-age ( years )-baseline total cholesterol-myocardial infarction / cabg / pci < nmbr years-ethnic origin-baseline diabetes-peripheral artery disease"
1604,characteristic_level,"> nmbr mmol / l-> nmbr years-< nmbr-asia pacific other-no-nmbr-overall-white-n o-< nmbr years-y es-w est europe-< nmbr mmol / l-asian-black-n ""-yes-f emale-other-north america-no previous myocardial infarction-male-east europe-south america-nmbr - nmbr-nmbr - nmbr years"
1606,characteristic_name,"blood pressure-history pad-medications-smoking status-medications ""-risk factors pad-sex-abi"
1607,arms,"aspirin alone ( n = nmbr )-rivaroxaban alone ( n = nmbr )-rivaroxaban alone ( n = nmbr ) ""-low - dose rivaroxaban plus aspirin ( n = nmbr )"
1608,characteristic_name,"diabetes ""-egfr-symptomatic pad-diabetes-cad-smoking status-pad lower extremities-abi"
1609,characteristic_level,"overall pad-< nmbr - nmbr-> nmbr - nmbr-no ""-< nmbr-no-former never-yes-> nmbr-current"
1611,characteristic_name,"screening bmi ( kg / mnmbr )-basal insulin dose run - ( u / day )-iglar dose randomization ( u / day )-baseline hbanmbrc ( % )-duration tnmbrd ( years )-screening hbanmbrc ( % )-female ( % )-age ( years )-duration tnmbrd ( years ) """
1612,arms,"iglar-iglar ""-iglarlixi"
1613,characteristic_name,"completers ( n nmbr nmbr )-hbanmbrc > nmbr % ( n nmbr nmbr )-hbanmbrc < = nmbr % ( n nmbr nmbr )-nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr )-hbanmbrc > nmbr % ( n nmbr nmbr ) """
1614,arms,"iglar-iglar ""-iglarlixi"
1615,characteristic_name,"completers-hbanmbrc > nmbr %-hbanmbrc > nmbr % ""-hbanmbrc < = nmbr %-nmbr % < hbanmbrc < = nmbr %"
1616,outcomes,"sbp , mm hg-hbanmbrc , %-dbp , mm hg-iwqol - lite total score ( arbitrary units ) #-iwqol - lite physical score ( arbitrary units )-fpg , mmol / l-body weight , kg-iwqol - lite physical score ( arbitrary units ) ""-waist circumference , cm-body weight , %"
1617,characteristic_name,"individuals without diabetes , n = nmbr , nmbr-individuals without diabetes , n = nmbr , nmbr """
1619,outcomes,"sbp , mm hg-hbanmbrc , %-dbp , mm hg-iwqol - lite total score ( arbitrary units ) #-iwqol - lite physical score ( arbitrary units )-fpg , mmol / l-body weight , kg-iwqol - lite physical score ( arbitrary units ) ""-waist circumference , cm-body weight , %"
1620,characteristic_name,"individuals diabetes , n = nmbr-individuals diabetes , n = nmbr """
1622,characteristic_name,"qualifying myocardial infarction-qualifying myocardial infarction ""-sex"
1623,characteristic_level,"hypertension-hdl cholesterol ( mmol / l )-age ( years )-history pci-hscrp ( mg / l )-triglycerides ( mmol / l )-total cholesterol ( mmol / l )-history cabg-unknown missing-triglycerides ( mmol / l ) ""-egfr ( ml / min per nmbr - nmbr ' )-ldl cholesterol ( mmol / l )-history congestive heart failure-renin - angiotensin inhibitors-waist circumference ( cm )-stemi-female-diabetes-lipid - lowering therapy-non - stemi-current smoking-male-anti - ischaemia agents *-body - mass index ( kg / ' )-interleukin - nmbr ( ng / l )-randomised canakinumab nmbr mg"
1624,arms,"canakinumab , hscrp > nmbr - nmbr mg / l nmbr months ( n = nmbr ) ""-canakinumab , hscrp > nmbr - nmbr mg / l nmbr months ( n = nmbr )-canakinumab , hscrp < nmbr - nmbr mg / l nmbr months ( n = nmbr )-placebo ( n = nmbr )"
1625,characteristic_name,"hdl cholesterol < nmbr - nmbr mmol / l-men-overall-age < nmbr years-non - smoker-smoker-women-no diabetes ""-ldl cholesterol < nmbr - nmbr mmol / l-triglycerides > nmbr - nmbr mmol / l-hscrp > nmbr mg / l-diabetes-bmi < nmbr kg / mnmbr-no diabetes-ldl cholesterol > nmbr - nmbr mmol / l-bmi > nmbr kg / mnmbr-triglycerides < nmbr - nmbr mmol / l-hscrp > nmbr < nmbr mg / l-age > nmbr years-hdl cholesterol > nmbr - nmbr mmol / l"
1626,measures,"incidence rate per nmbr person - years-incidence rate per nmbr person - years ""-hr ( nmbr % ci )"
1627,arms,"placebo ""-canakinumab-placebo"
1628,characteristic_name,"qualifying event-at randomization "" ; na-at randomization"
1629,characteristic_level,"prior lipid - lowering agent use-unstable angina-cabg-statin-hypertension-history chf ""-current smoker-history chf-aspirin-diabetes mellitus-history stroke tia-age , y-nstemi-stemi-ldl - c < nmbr mg / dl-age > nmbr y-thienopyridine-history coronary revascularization-peripheral arterial disease-egfr < nmbr ml / min / nmbr . nmbr mnmbr-prior statin use-bmi , kg / mnmbr-dual antiplatelet"
1630,characteristic_name,"men ( n = nmbr nmbr ) ""-men ( n = nmbr nmbr )-women ( n = nmbr )"
1631,characteristic_level,"women ""-men-women"
1632,characteristic_name,"hospitalization unstable angina-stroke-cardiovascular death / myocardial infarction / stroke-myocardial infarction-any death-chd death-coronary revascularization nmbr days randomization-cardiovascular death-cardiovascular death / myocardial infarction / stroke ""-primary endpoint"
1634,outcomes,"gallbladder - related aes-cancer-permanently stopped study drug adverse events-rhabdomyolysis myopathy-rhabdomyolysis-alt , ast , > nmbrx uln-rhabdomyolysis , myopathy , myalgia ck elevation > nmbrx uln-cancer """
1635,characteristic_level,"women ""-men-women"
1637,outcomes,"gallbladder - related aes-rhabdomyolysis , myopathy , myalgia ck elevation > nmbrx uln ""-cancer-rhabdomyolysis-alt , ast , > nmbrx uln-rhabdomyolysis , myopathy , myalgia ck elevation > nmbrx uln-myopathy"
1638,characteristic_level,"women ""-men-women"
1640,characteristic_name,"index event-medications randomization ""-laboratory values admission ( median iqr )-medical history-laboratory values randomization ( median iqr )-medications randomization-medications admission"
1641,characteristic_level,"hyperlipidemia-statin-statin admission-hypertension-myocardial infarction-low - density lipoprotein cholesterol , mg / dl-aspirin-angiotensin - converting enzyme inhibitor angiotensin receptor blocker-white-p - blocker-percutaneous coronary intervention-aspirin ""-median body mass index , kg / mnmbr ( iqr )-coronary artery bypass grafting-triglycerides , mg / l-female-no prior statin use-median weight , kg ( iqr )-peripheral arterial disease-no statin admission-current smoking-prior statin use-mean age ( sd ) , y-diagnostic angiography-high - density lipoprotein cholesterol , mg / l-c - reactive protein , * mg / l-st - segment elevation myocardial infarction-congestive heart failure-creatine clearance , ml / min"
1643,outcomes,"cholecystectomy ( n = nmbr )-cancer ( n = nmbr )-alanine aminotransferase aspartate aminotransferase > nmbrx upper limit normal ( n = nmbr )-rhabdomyolysis ( n = nmbr )-gall bladder adverse event ( n = nmbr )-cancer ( n = nmbr ) ""-hemorrhagic stroke ( n = nmbr )"
1644,characteristic_name,"dm present-dm absent-dm present """
1646,characteristic_name,"age ( years ) , mean ( sd )-van der heijde mtss , mean ( sd )-time since psa diagnosis ( years ) , mean ( sd )-tender joint count ( nmbr joints ) , mean ( sd )-swollen joint count ( nmbr joints ) , mean ( sd )-time since psa diagnosis ( years ) , mean ( sd ) ""-weight ( kg ) , mean ( sd )-haq - di total score , mean ( sd )-male , n ( % )"
1647,characteristic_name,"none ( cdmard - naive past use baseline ) ""-mtx-cdmard-none ( cdmard - naive past use baseline )"
1648,arms,"ixeqnmbrw , n = nmbr-ixeqnmbrw , n = nmbr ""-pbo , n = nmbr"
1649,characteristic_name,"exposure-pah classification-exposure "" ; na-congenital shunts-geographical region"
1650,characteristic_level,"idiopathic-associated drug / toxin-asia-eastern europe-latin america-north america-heritable-associated ctd-female sex ""-nmbr - min walk distance ( )-age ( years )-associated hiv infection-western europe / australia-associated corrected-female sex-time since pah diagnosisc ( years )"
1651,characteristic_name,"fc ii symptoms baseline-who fc iii symptoms baseline-overallb-overallb """
1652,arms,"selexipag ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1653,characteristic_name,"jsn score ( nmbr - nmbr )-ptga , nmbr - nmbr-radiographic characteristics baseline randomization-dasnmbr-total haq , nmbr - nmbr-erosion score ( nmbr - nmbr )-general health vas , nmbr - nmbr mm-age , years-cdai-disease duration , years-pain vas , nmbr - nmbr mm-sjc , nmbr - nmbr-clinical patient - reported characteristics baseline randomization-sdai-crp , mg / l-tjc , nmbr - nmbr-female , n ( % )-prior tobacco use , n ( % )-crp , mg / l ""-pga , nmbr - nmbr-rf positive , n ( % )-mtss ( nmbr - nmbr )-esr , nmbr - nmbr mm / hour-acpa positive , n ( % )"
1654,arms,"mtx n = nmbr-etn nmbr mg + mtx n = nmbr ""-etn nmbr mg + mtx n = nmbr"
1655,characteristic_name,"hyperlipidemia-pad ""-caucasian-pad-age , yrs-chf-hypertension-male-smoking-egfr < nmbr ml / min / nmbr . nmbr mnmbr *-prior pci-qualifying mi : stemi-prior cabg-diabetes mellitus"
1657,characteristic_name,"pre - bronchodilator fevnmbr ""-race , n ( % )-pre - bronchodilator fevnmbr-sex"
1658,characteristic_level,"body mass index , kg / mnmbr-% predicted-aqlq ( ) score-biomarker low ( periostin < nmbr ng / ml blood eosinophils < nmbr cells per pl ) , na-white-median serum periostin , ng / mla-age , years-american indian-former smoker , n ( % )-female , n ( % )-saba puffs per day baseline-median blood eosinophil count , cells per pla-asian-median feno , ppba-biomarker low ( periostin < nmbr ng / ml blood eosinophils < nmbr cells per pl ) , na ""-black african american-biomarker high ( periostin > nmbrng / ml blood eosinophils > nmbrcells per pl ) , na-absolute , litres-reversibility , %-multiple-male , n ( % )"
1659,arms,"montelukast ( n = nmbr )-lebrikizumab ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1660,characteristic_name,"corticosteroid use-region ( pooled )-seropositivity-age , years-overall population-disease duration , years-baseline weight , kg-disease duration , years """
1661,arms,"baricitinib nmbr mg-placebo ""-placebo"
1662,characteristic_name,". prior bdmards-no . prior tnfi-prior tnfi treatment-no . non - tnfi-overall population-no . tnfi among non - tnfi naive-overall population """
1663,characteristic_level,"ada , no-etn , no-inflix , yes-snmbr-nmbr mg-inflix , no-< nmbr-nmbr-ada , yes-nmbr mg ""-etn , yes"
1664,arms,"baricitinib nmbr mg-placebo ""-placebo"
1665,characteristic_name,"race *-clinical copd phenotype^-clinical copd phenotype^ ""-sex-smoking status"
1666,arms,"bdp / ff / g ( n = nmbr )-ind / gly ( n = nmbr ) ""-ind / gly ( n = nmbr )"
1667,characteristic_name,"nyha class ""-nyha class-race"
1668,characteristic_level,"diuretic-cabg-ace inhibitor-candesartan-hypertension-anti arrhythmic-current smoker-ischaemic-aspirin-european-sbp , mmhg-hypertensive-cancer-creatinine , mg / dl_-other vasodilator-ef , %-age , years-digitalis-spironolactone-iv-idiopathic-physical exam oedema-ml-af-pacemaker-icd-calcium antagonist-beta - blocker-black-dbp , mmhg-dm-ii-iii-pci-bmi , kg / mnmbr ""-other-stroke-bmi , kg / mnmbr-female gender-lipid - lowering-angina pectoris-oral anticoagulant-previous hf-other antiplatelet"
1670,outcomes,"hf hospitalization-all - cause hospitalization-cv death + hf hospitalization-all - cause death-all - cause death ""-cv death-recurrent hf hospitalization"
1671,measures,"unadjusted hr .-incidence rate "" ; na-incidence rate-unadjusted irr-unadjusted hr"
1673,arms,"candesartan ""-candesartan-placebo"
1674,characteristic_name,"anthropometry : mean ( sd )-medication enrolment-m / f-mean ( sd ) age years-medication within nmbr days enrolment-risk factors-medication enrolment ""-number patients"
1675,characteristic_level,"cabg-aspirin-infarction nmbr - nmbr days-a ngina > nmbr day previously *-ptca-infarction > nmbr days previously-current smokers *-aspirin ""-calcium antagonists-nitrates-infarct ion w ithin previous nmbr day s-height ( cm )-ticlopidin-hypertension *-infarction , date reported-intravenous heparin-w eight ( k g )-( nmbr - blockers-diabetes *"
1676,arms,"abciximab ( n = nmbr ) ""-abciximab ( n = nmbr )-placebo ( n = nmbr )"
1677,arms,"pravastatin ( n = nmbr > ""-pravastatin ( n = nmbr >-placebo ( n = nmbr )"
1678,characteristic_name,"qualifying event ""-total cholesterol-hdl cholesterol-unstable angina age-ldl cholesterol-diabetes-smoking-hypertension !-triglycerides-sex-qualifying event"
1679,characteristic_level,"nonsmoker-< nmbr yr-nmbr yr-hospitalization ""-< nmbr mg / dl-nmbr - nmbr mg / dl-nmbr mg / dl-male-female-nmbr - nmbr yr-yes-no-former smoker-myocardial infarction-current smoker-nmbr nmbr mg / dl-hospitalization"
1680,arms,"placebo ""-pravastatin-placebo"
1681,measures,"event ( % )-reduction risk ( nmbr % ci ) %-n-n """
1682,characteristic_name,"plasma lipoproteins , mmol / l-concurrent medications-concurrent medications ""-concurrent illness-sex-race"
1683,characteristic_level,"diuretic-apoanmbr , mg / dl-weight , kg-hypertension-/ nmbr - blocker-cholesterol-plasma creatine , mg / dl-triglycerides-baseline abi , affected limb-white-n-ldl - c-hdl - c-baseline pfd , m-baseline mwd , m-oral hypoglycemic-age , y-female-diabetes-apob , mg / dl-hdlnmbr-prior myocardial infarction-diuretic ""-male-minority-angina pectoris-insulin-lpa , mg / dl"
1684,arms,"placebo ""-cilostazol-placebo"
